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Abstract 
Glaucoma is a major cause of visual impairment and the second leading cause of 
blindness worldwide. The most common form is adult-onset, primary open-angle 
glaucoma (POAG), which has a strong genetic component, with family history an 
established risk factor. This dissertation explores several different approaches to the 
analysis of extended POAG pedigrees to dissect the genetic aetiology of this 
phenotypically and genetically heterogeneous disease. The families were collected as 
part of the Glaucoma Inheritance Study in Tasmania (GIST), a study of glaucoma in 
Tasmania, representing almost complete population ascertainment of POAG patients. 
One aim of this study was to investigate linkage to the POAG loci known at the time in 
a selection of 10 extended pedigrees from the GIST. These pedigrees were genotyped 
at POAG loci GLC1A, GLC1B, GLC1C, GLC1D, GLC1E and GLC1F, at an average 
marker spacing of 4 cM within each locus. Initial Markov chain Monte Carlo based 
linkage analyses revealed several suggestive results, and two families were 
subsequently selected for fine-mapping and follow-up analyses. One of these, family 
GTas15, produced p-values of 0.01 or less at five markers flanked by D251897 and 
D2S2269 in the follow-up nonparametric linkage analysis, with a minimum p-value of 
0.005 at D2S1897. A 9 cM haplotype of interest was identified, overlapping the 
original GLC1B locus. These findings provided supportive evidence for the GLCIB 
locus on chromosome 2cen-q13, and verified the existence of a POAG susceptibility 
gene in this region. 
This study also aimed to identify genetic contributions to POAG by investigating 
quantitative components of the disease phenotype. Genome-wide multipoint variance-
components linkage analyses of maximum recorded intraocular pressure (lOP) and 
vi 
maximum vertical cup-to-disc ratio were conducted on data from a single, extended 
POAG pedigree from the GIST, previously found to segregate the myocilin Q368X 
mutation in some individuals. Multipoint linkage analysis of maximum recorded LOP 
produced a significant peak LOD score of 3.3 (p=0.00015) near marker D10S537 on 
chromosome 10q22, whereas maximum cup-to-disc ratio produced a suggestive peak 
LOD score of 2.3 (p=0.00056) near markers DIS197 to Dl S220 on chromosome 1p32. 
Inclusion of the myocilin Q368X mutation as a covariate provided evidence of an 
interaction between this mutation and the LOP and cup-to-disc ratio loci. Identification 
of genes contributing to the variance of the quantitative phenotype components of this 
disease will enhance understanding of the pathophysiology of POAG as a whole. 
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Chapter 1 — Introduction 
1.1 Introduction to glaucoma 
Glaucoma is a term used to describe a heterogeneous group of eye disorders involving 
damage to the optic nerve and loss of vision, resulting in irreversible blindness if left 
untreated. The varying types of glaucoma are classified according to aetiology (primary 
vs. secondary), anatomy of the anterior chamber (open angle vs. closed angle) and age 
of onset (congenital vs. juvenile vs. adult). There are three major types of glaucoma: 
primary open-angle glaucoma (POAG), primary angle closure glaucoma (PACG) and 
primary congenital glaucoma (PCG or Buphthalmos), as well as several secondary 
forms associated with a wide range of ocular pathologies and developmental 
abnormalities such as aniridia and Rieger syndrome. Adult-onset, primary open-angle 
glaucoma is the most common form of glaucoma and is the focus of this dissertation. 
1.2 Prevalence 
Glaucoma is a major cause of visual impairment and blindness in developed countries 
and is the second leading cause of blindness worldwide (Quigley 1996; Resnikoff et al. 
2004). Glaucoma was responsible for 12.3% of global blindness (4.5 million people) in 
2002 (Resnikoff et al. 2004). Primary open-angle glaucoma is the most common form, 
accounting for approximately 67-75% of glaucoma cases (Leske and Rosenthal 1979; 
Buhrmann et al. 2000; Bourne et al. 2003). Within Australia, POAG affects 2-3% of 
the population over the age of 40 (Mitchell et al. 1996), with up to half of those affected 
being undiagnosed (Coffey et al. 1993; Dielemans et al. 1994; Mitchell et al. 1996; 
Wensor etal. 1998; Leske etal. 2001; Weih et al. 2001b; Mukesh etal. 2002). Onset 
of POAG typically occurs after the fourth decade of life, and prevalence rises with age, 
reaching as high as 10% of those over 85 years of age (Mitchell et al. 1996; Weih etal. 
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2001b). The number of Australians affected by the disease is expected to double over 
the next 30 years as the population ages (Rochtchina and Mitchell 2000). 
Prevalence of POAG varies between ethnic groups. The prevalence of POAG in the 
urban population of Thailand appears to resemble Caucasian prevalence rates (Bourne 
et al. 2003). In the United States, POAG is three to six times more common in African 
Americans than Caucasians (Tielsch et al. 1991b). The higher prevalence and earlier 
age of onset of POAG in black populations has been confirmed in several studies 
including those based in the West Indies (Mason etal. 1989), Barbados (Leske etal. 
1994), Britain (Wormald et al. 1994), East Africa (Buhrmann et al. 2000) and West 
Africa (Ntim-Amponsah et al. 2004). The prevalence of POAG has been shown to be 
higher in Afro-Caribbean individuals than African Americans (Leske etal. 1994), while 
the prevalence of POAG in rural East Africa was shown to be less than in Afro-
Caribbean populations but similar to African American prevalence rates (Buhrmann et 
al. 2000). 
1.3 Primary open-angle glaucoma 
Primary open-angle glaucoma is the most common form of glaucoma, accounting for 
67-75% of glaucoma cases (Leske and Rosenthal 1979; Buhrmann et al. 2000; Bourne 
et al. 2003). It is divided into adult onset (after 40 years) and the juvenile onset form 
(JOAG) with age of onset between 3 and 40 years. The underlying pathogenesis of 
POAG is not fully understood, however the loss of vision in all subtypes is due to a 
final common pathway of retinal ganglion cell death by apoptosis, leading to atrophy of 
the optic nerve and a cupped appearance. 
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The adult-onset form of POAG has a milder presentation and more moderate elevation 
of intraocular pressure (lOP), compared with the juvenile-onset form. Current medical 
and surgical treatments can delay progression with a satisfactory outcome in the 
majority of cases, provided the disease is detected early. The greatest clinical issue for 
POAG is the painless progression of the disease, often resulting in late diagnosis by 
which time irreversible optic nerve damage may have occurred, which in some cases is 
advanced at the time of diagnosis. Glaucoma of all forms is treatable by lowering LOP. 
This is achieved by either topical therapy (eye-drops), laser treatment, or surgery in 
more severe cases. Glaucoma treatment has been shown to slow loss of vision in 
randomised control trials (Kass etal. 2002; Leske etal. 2003; Leske etal. 2004), and 
thus glaucoma blindness may be largely preventable if early diagnosis was achievable in 
all cases. 
Estimates suggest JOAG is far less common than typical adult onset POAG (Sarfarazi 
1997) and is in fact a rare presentation, with some prevalence estimates as low as 1 in 
50,000; however there are no reliable, published prevalence studies. JOAG also tends 
to be more severe than adult-onset POAG, involving higher IOP and a poor response to 
drug treatments, often requiring surgical intervention (Craig and Mackey 1999). JOAG 
is a useful sub-classification in which to search for genetic contributions to glaucoma as 
it often exhibits an autosomal dominant inheritance pattern, occurs at an early age, 
demonstrates a well defined phenotype and is likely to be found in multiple living 
generations of a pedigree. However, the rarity of the disease hinders attempts to collect 
large, informative datasets. Also, while one JOAG gene (MYOC) has been shown to 
also account for approximately 3% of adult-onset POAG (Stone et al. 1997; Alward et 
al. 2002), the wider relevance of other JOAG genes to adult-onset POAG is not yet 
clear. 
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1.4 Clinical definition of POAG 
There is no universally accepted definition of POAG, a phenotypically complex and 
subtle disease (Kahn and Milton 1980; Wolfs et al. 2000; Kroese and Burton 2003). 
The clinical diagnosis is based on a combination of several main characteristics: specific 
changes to the appearance of the optic nerve head, characteristic visual field loss and a 
slow and generally asymptomatic progression (Khaw et al. 2004). Diagnosis is made 
when all principal features are present, but is less certain when one or more of the key 
features are absent. POAG is usually bilateral, although sometimes asymmetric 
(American Academy of Ophthalmology 2003). Elevated intraocular pressure (lOP) is a 
major contributing factor to POAG, but this elevation is neither necessary nor sufficient 
for onset or progression of the disease, and is no longer typically included in the modern 
clinical definition of POAG (American Academy of Ophthalmology 2003; Ithaw etal. 
2004), although its monitoring and treatment remains a fundamental cornerstone of 
glaucoma management (European Glaucoma Society 1998; Van Veldhuisen etal. 2000; 
Goldberg et al. 2002). 
Diagnosis of POAG additionally relies on the absence of any secondary explanations for 
progressive glaucomatous optic nerve change, such as pseudoexfoliation or pigment 
dispersion syndrome, as well as evidence of open, normal-appearing anterior-chamber 
angles (American Academy of Ophthalmology 2003). Open and closed-angle glaucoma 
are differentiated by gonioscopy, a procedure involving examination of the width of the 
iridocorneal angle (between the iris and the cornea at their junction). The angle is the 
area of outflow of aqueous humor and contains the trabecular meshwork (Figure 1.1). 
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Figure 1.1 - Anatomy of the eye 
, 
This schematic representation of the eye shows all the major structures relevant to 
glaucoma. The anterior segment or front portion of the eye includes the angle of the 
eye; the point where the iris meets the cornea. The trabecular meshwork is located 
within the angle. 
Figure taken from Quigley HA (1993). Open-angle glaucoma. N Engl J Med 328( 15): 
1097-106. 
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There is still much debate over a suitable and universal clinical definition of POAG and 
a lack of consistency in the clinical definition of POAG in published studies (Bathija et 
al. 1998; Foster et al. 2002; Kroese and Burton 2003). Bathija et al. (1998) conducted a 
literature review of 182 papers between 1980 and 1990 to determine the criteria used to 
define glaucoma, revealing that the definition used was clearly reported in only 66% of 
papers, and even in these there was much variability, with raised IOP the only criterion 
in 20% of described definitions. 
1.4.1 Intraocular pressure 
Pressure within the eye is dependent on the production rate of fluid (aqueous humor) 
from the ciliary body and rate of fluid drainage through the trabecular meshwork and 
diffusion through the uvea and sclera (Figure 1.2). The consistent volume of the adult 
eye necessitates that aqueous humor production and outflow are almost equal. In most 
instances, elevated IOP is the result of impaired drainage of aqueous humor through the 
trabecular meshwork outflow pathways (Quigley 1993). Prolonged increased IOP may 
exert physical force on the structural framework of the lamina cribrosa in the optic 
nerve, leading to axonal injury, and this process has been suggested as one mechanism 
leading to neuronal damage in glaucoma. Diurnal (daily) variation in TOP has been well 
documented (Drance 1963; Asrani et al. 2000; Liu 2001; Hughes et al. 2003; Liu et al. 
2003), with a larger range of TOP fluctuation in untreated POAG cases than normal 
individuals (Sacca et al. 1998; Asrani et al. 2000; Hughes et al. 2003; Liu et al. 2003). 
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Figure 1.2 - The anterior segment of the eye, aqueous humor production, and outflow 
Panel A is a transverse section of the anterior segment or front portion of the eye. The major structures are labelled. The scleral spur is 
the posterior boundary of the trabecular meshwork and the point of attachment of the longitudinal muscle of the ciliary body. 
Contraction of the longitudinal muscle can open the trabecular meshwork and increase aqueous outflow. 
Panel B shows the flow of aqueous humor through the anterior segment. Aqueous humor is produced by the ciliary-body processes. It 
flows around the lens, then passes through the pupil and into the anterior chamber, where it nourishes the cornea before leaving the eye 
through the trabecular meshwork into the venous system. A small amount of aqueous humor exits by way of uveoscleral channels 
through the iris root and ciliary body. 
Figure taken from Alward WL, Fin gert JH, Coote MA, et al. (1998). Clinical features associated with mutations in the chromosome 1 
open- angle glaucoma gene (GLC1A). N Engl J Med 338(15): 1022 - 7. 
Elevated intraocular pressure is a major risk factor for POAG, but this elevation is 
neither necessary nor sufficient for onset or progression of the disease. POAG that 
includes optic nerve damage and visual field loss, but with IOP below 22mmHg (a 
somewhat arbitrary cut-off for normal IOP, approximately 2 standard deviations above 
the European population mean of 16mmHg) is sometimes referred to as normal-tension 
glaucoma (NTG). Initially thought to be a rare sub-form of POAG, NTG has now been 
shown to account for 20-50% of the disease (Tielsch et al. 1991a; Werner 1996). 
Whether NTG constitutes a pathological entity distinct from POAG is debated (Kamal 
and Hitchings 1998); it may simply be part of a spectrum of phenotypes extending from 
patients with ocular hypertension and no evidence of optic neuropathy, to those with 
optic nerve damage without significantly elevated IOP. The Baltimore Eye Study found 
no support for the distinction between low-tension' and 'high-tension' glaucoma 
(Sommer et al. 1991). Similarities have been found between the optic nerve heads of 
low and high tension glaucoma patients, suggesting both phenotypes may belong to a 
spectrum of the same disease (Tomita 2000). It is important to note that several studies 
have shown that glaucomatous optic nerve damage occurs even at low pressures as a 
result of abnormal pressure sensitivity in some individuals (Anderson et al. 1998; Van 
Veldhuisen et al. 2000). IOP is no longer included in most definitions of POAG 
(American Academy of Ophthalmology 2003; Khaw et al. 2004), yet it remains the 
primary target of POAG treatment and monitoring (European Glaucoma Society 1998; 
Van Veldhuisen et a/. 2000; Goldberg et al. 2002). It has been clearly shown in several 
prospective randomised control trials that lowering IOP reduces the progression of optic 
nerve damage, with an approximate 10% decrease in risk per mmHg decrease in IOP 
(Gordon et a/. 2002; Leske etal. 2003; Leske et a/. 2004), supporting 10P targeting as 
an effective treatment for many forms of POAG, including NTG. 
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Individuals with raised KM) (greater than or equal to 22mmHg) but no evidence of 
glaucomatous optic nerve damage or visual field loss are referred to as having ocular 
hypertension (OH). 
While not an essential component for a clinical diagnosis of POAG, 1OP still functions 
as an important risk factor for the disease. The Baltimore Eye Survey identified an 
increased prevalence of POAG associated with increasing LOP (Sommer et al. 1991), 
later confirmed in the Barbados Eye Study (Leske et al. 1995) and the Rotterdam Study 
in the Netherlands (Dielemans et al. 1994). Sommer (1996) suggests that, while the 
relationship between IOP and POAG is not strictly linear, it is nevertheless monotonic: 
the higher the IOP the greater the risk of POAG, similar to the relationship between 
blood pressure and stroke. In the Ocular Hypertension Treatment Study and the Early 
Manifest Glaucoma Trail the risk of POAG increased by 10% for each lmmHg increase 
in IOP (Gordon et al. 2002; Leske et al. 2003). The continuous nature of the glaucoma-
LOP relationship, originally described in the Baltimore Eye Survey (Sommer et al. 
1991), was confirmed in an Australian population (Mitchell et al. 1996), highlighting 
the arbitrary nature of using a single threshold IOP value to distinguish the commonly 
used categories of low and high tension glaucomas. This taxonomic dilemma has been 
further complicated by the recent widespread acceptance that Goldman applanation 
tonometry errors in IOP measurement based on inter-individual variation in corneal 
thickness would result in patients with borderline 10P values being potentially 
misclassified as NTG (see section 1.5). 
A relatively low proportion (25%) of POAG cases in the Blue Mountains Eye Study had 
elevated IOP, suggesting approximately 75% of cases had low IOP, however the 
measurements were taken in a cross-sectional study, giving no information about peak 
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or mean IOP or the duration of elevation (Mitchell et al. 1996). Prospective studies 
reveal lower rates of normal IOP; almost 40% of previously undiagnosed cases in the 
Rotterdam Study had pressure below 21mmHg (Dielemans etal. 1994), with similar 
results in the Baltimore Eye Survey (50%) (Sommer etal. 1991). 
The Blue Mountains Eye Study also found a modest but statistically significant 
association between increasing iris colour and IOP. After adjustment for variables 
associated with IOP the mean measurements were 15.92mmHg for blue iris colour, 
16.04mmHg for hazel or green, 16.11mmHg for tan-brown and 16.49mmHg for dark 
brown (p=0.001 for trend) suggesting iris colour may be associated with IOP (Mitchell 
et al. 2003). The Melbourne Visual Impairment Project identified a similar relationship 
between iris colour and IOP and determined that the association did not appear to be 
confounded by ethnicity (Weih etal. 2001a). 
1.4.2 Optic disc abnormalities 
The normal optic disc is the site of passage, from the eye, of more than 1 million axons 
that make up the optic nerve. Within the optic disc is the lamina cribrosa, composed of 
fenestrated connective tissue, through which the bundles of axons pass. The diameter of 
a normal optic disc, as well as the number of axons within the disc, varies from eye to 
eye (Jonas etal. 1988b; Jonas et al. 1990; Quigley etal. 1990). Generally the axons do 
not completely fill the disc, leaving a depression in its centre known as the cup (Figure 
1.3). 
The characteristic changes in the optic nerve head associated with POAG include 
increased cupping or excavation, notching or thinning of the neuroretinal rim, disc 
haemorrhages, asymmetry of cupping between the two eyes and loss of the retinal nerve 
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fibre layer (European Glaucoma Society 1998; American Academy of Ophthalmology 
2003). The optic nerve head is best examined using a slit lamp with a binocular view. 
A standard way to describe the appearance of the optic nerve head is by the vertical cup-
to-disc ratio, which expresses the size of the cup in relation to the optic nerve head size 
(Figure 1.3). The vertical cup-to-disc ratio is a simple, robust indicator of glaucomatous 
loss of the neuroretinal rim (Foster et al. 2002). A normal cup-to-disc ratio is 
approximately 0.3 (Jonas etal. 1988b), which may increase to between 0.7 and 1.0 
(Jonas etal. 1988a) with mild to end-stage glaucomatous injury. Eyes with a cup-to-
disc ratio greater than or equal to 0.55 are at increased risk of developing glaucomatous 
visual field loss compared with eyes having a cup-to-disc ratio less than 0.55 (Quigley 
et al. 1992). In the Ocular Hypertension Treatment Study the risk of POAG increased 
1.3 times for each 0.1 increase of horizontal or vertical cup-to-disc ratio (Gordon et al. 
2002). Accurate assessment of the cup-to-disc ratio remains one of the main indicators 
used in the clinical assessment of POAG (Jonas et al. 1999). 
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Figure 1.3 - Normal and glaucomatous optic discs 
Panel A shows a normal optic disc with a small cup-to-disc ratio, indicated by the tiny 
pale central area (cup) within the larger orange disc. 
Panel B shows a glaucomatous optic disc with a large cup-to-disc ratio. The cup is 
much larger than in Panel A and shows signs of excavation, indicated by the sharp and 
undermined edge of the cup. 
Panel C and Panel D are schematic diagrams of the features of normal and 
glaucomatous discs, respectively. The internal structure of the lamina cribrosa is 
compressed and rotates backward on its insertion into the sclera in patients with 
glaucoma. 
Figure adapted from Quigley HA (1993). Open-angle glaucoma. N Engl J Med 
328(15): 1097-106. 
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The Baltimore Eye Study confirmed that African American individuals have, on 
average, larger optic discs than white European Americans (Varna et al. 1994; Varma 
et al. 1995). They suggest the same number of optic nerve axons are splayed over a 
larger disc perimeter, resulting in African American individuals having larger cups but 
the same neuroretinal nerve area when compared with European American individuals 
(Varna et al. 1995). Similar results have also been obtained from the Australian 
Aboriginal population (Dr Jamie Craig 2005, personal communication) 
1.4.3 Visual field abnormalities 
Specific patterns of peripheral and central vision loss characteristic of POAG are the 
result of optic nerve fibre damage during the course of disease progression (Figure 1.4). 
Vision loss is first manifest in the mid-peripheral field, with central visual function 
involved much later in disease progression (Khaw et al. 2004). Computer assisted 
visual field testing is the most common way to estimate optic nerve function. The 
procedure assesses the ability of the eye to detect the brightness of small points of light 
both centrally and peripherally. Visual field loss characteristic of POAG includes nasal-
field loss, superior or inferior arcuate-field loss, generalised depression, and paracentral 
visual field loss (American Academy of Ophthalmology 2003). Eventually, in the end 
stages of POAG, all vision may be lost leading to total blindness. 
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Figure 1.4 - Loss of visual field in POAG 
Panel A depicts an optic disc with the neural tissue digested by enzymes to show the 
connective tissue alone. The larger pores and lower density of the supportive tissue at 
the top and bottom of the disc are clearly evident. 
Panel B is a cross-section of the optic nerve showing the hourglass pattern of the 
preferential loss of nerve fibres (seen as a decrease of the dark, myelinated tissue) in the 
polar regions of lower density supportive tissue. These selectively susceptible zones of 
the nerve serve the mid-peripheral visual field. 
Panel C shows the resulting characteristic loss of side vision, revealed by the automated 
visual-field test, shown as a dark area in the schematic diagram. 
V denotes vein, A artery, TEM temporal, NAS nasal, SUP superior, and INF inferior. 
Figure taken from Quigley HA (1993). Open-angle glaucoma. N Engl J Med 328(15): 
1097-106. 
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1.5 Risk factors for POAG 
Factors associated with increased risk of progression to glaucoma but more likely to be 
an early manifestation of POAG, such as nerve fibre layer defects, asymmetric cupping 
of the optic disc and raised IOP, are not specifically included as risk factors in this 
section and have been discussed previously. It is unclear whether IOP is a component 
of the POAG phenotype or a risk factor for POAG, however there is a clear link 
between increased IOP and risk of POAG, as described in section 1.4.1. 
Central corneal thickness (CCT) has been suggested as a risk factor for POAG. 
Applanation tomometry measurements of IOP are known to be influenced by CCT 
(Hansen and Ehlers 1971; Stodtmeister 1998): CCT has a positive and apparently linear 
correlation with IOP (Wolfs et al. 1997), thus thick corneas increase the measured IOP 
in contrast to the actual true 10P. CCT is now known to be strongly genetically 
determined (Toh et al. 2005), with familial thick corneas shown to segregate in a family 
with apparent ocular hypertension (Dohadwala and Damji 2000). In the Ocular 
Hypertension Treatment Study it was determined that thinner CCT measurements 
appeared to increase the risk of developing POAG, with a CCT of 55511m or less 
conferring a three-fold increase in risk compared with CCT measurements of 5881.tm or 
more (Gordon et al. 2002). Reanalysis of this data determined that a 40gm decrease in 
CCT produced a 1.8 times increase in the risk of developing POAG (Coleman et al. 
2004). The mean CCT measurement was 23.511m thinner in African Americans than 
other participants in the Ocular Hypertension Treatment Study (Gordon et al. 2002), 
possibly accounting for a component of their increased risk of POAG. 
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1.5.1 Demographic risk factors 
Family history, age, gender and ethnicity are the common demographic risk factors 
associated with POAG. 
Family history is an established risk factor for POAG (Rosenthal and Perkins 1985; 
Tielsch et al. 1994; Wolfs et al. 1998; Budde and Jonas 1999; Nemesure et al. 2001; 
Weih et al. 2001b; Le et al. 2003; Fan et al. 2004). Many of the population-based 
studies report a three to four-fold increase in risk of POAG for first degree relatives of 
affected cases (Tielsch et al. 1994; Leske et al. 1995; Nemesure etal. 1996; Mitchell et 
al. 2002). Moreover, results from the Rotterdam Eye Study, in the most carefully 
controlled study of its kind, suggest relatives of POAG patients have a ten-fold increase 
in risk of the disease (Wolfs et al. 1998). The variation in risk between various studies 
may be due to many factors, including the late age of onset of the disease and high rate 
of undiagnosed cases (up to 50% as described in section 1.2), as well as a lack of 
disclosure within families. Studies on the under-reporting of family history suggest the 
risk attributable to family history may be even greater than previously suggested; for 
example the Glaucoma Inheritance Study in Tasmania (GIST) determined that 27% of 
previously diagnosed POAG cases were unaware of their positive family history 
(McNaught et al. 2000). 
Several studies have shown an increase in risk of POAG with increasing age, including 
the Visual Impairment Project (Le et al. 2003), Barbados Eye Study (Leske etal. 2001), 
and many others (Dielemans et al. 1994; Leske et al. 1995; Mitchell et al. 1996; Voogd 
et al. 2005). The Visual Impairment Project found a significant increase in risk of 
POAG over 60 years of age, increasing rapidly with every additional decade of life (Le 
et-al. 2003). While older age appears to predispose individuals to POAG, it is not clear 
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whether older eyes are themselves more susceptible to damage, or if the increase in risk 
is the result of cumulative exposure to other risk factors, making the optic nerve head 
more vulnerable to damage. 
The relationship between gender and the risk of developing POAG is unclear. The 
Barbados Eye Study (Leske et al. 2001) and the Rotterdam Study (Dielemans etal. 
1994) showed a trend towards a higher risk of POAG in men than women, while the 
Dalby Sweden Study showed a higher incidence in women (Bengtsson 1989). Most 
other studies have shown little or no relationship between the risk of POAG and gender 
(Viggosson et al. 1986; Tielsch et al. 1991b; Klein et al. 1992; Mitchell etal. 1996; 
Weih etal. 2001b; Gordon etal. 2002; Landers etal. 2002; Le etal. 2003). 
As mentioned in Section 1.2, the prevalence of POAG varies between ethnic groups, 
suggesting an underlying genetic susceptibility to the disease. In the Baltimore Eye 
Survey, African Americans had a three to six-fold increase in risk of POAG compared 
with Caucasians (Tielsch et al. 1991b). A similar increase in risk has also been 
demonstrated in other populations of African descent (Mason etal. 1989; Leske et al. 
1994; Wormald etal. 1994). 
1.5.2 Cardiovascular risk factors 
Several cardiovascular-related risk factors have been postulated for POAG, including 
smoking, alcohol consumption, cardiovascular disease, hypertension and diabetes. 
While one small Chinese study has recently identified a strong (ten-fold) increase in risk 
of POAG associated with cigarette smoking (Fan et al. 2004), most large studies have 
shown little or no increase in risk associated with smoking (Klein et al. 1993; Leske et 
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al. 1995; Kang etal. 2003; Le et al. 2003). However, a weak correlation between 
smoking and increased IOP has been shown (Carel et al. 1984; Wu and Leske 1997), 
suggesting smoking may have an indirect link to POAG risk (Cheng et al. 2000). 
Cardiovascular disease has been associated with the senile sclerotic subgroup of 
glaucomatous optic disc appearance (Broadway and Drance 1998), but not necessarily 
with risk of POAG (Leske etal. 1995; Bonomi etal. 2000; Weih etal. 2001b; Le et al. 
2003). 
Hypertension has been shown to be associated with the risk of POAG in some studies 
(Dielemans et al. 1995; Tielsch et al. 1995b; Bonomi et al. 2000; Mitchell et al. 2004), 
but not in others (Leske et al. 1995; Weih etal. 2001b; Le etal. 2003). Ocular 
perfusion pressure (blood pressure minus IOP) has been shown to be associated with 
POAG (Leske etal. 1995; Tielsch etal. 1995b; Bonomi etal. 2000) and may be a more 
appropriate risk factor for optic nerve head ischemia and POAG than hypertension. The 
Baltimore Eye Survey, including 2500 African American and 2500 Caucasian 
individuals, identified an inverse relationship between perfusion pressure and risk of 
POAG (Tielsch etal. 1995b). 
There is no convincing association between diabetes and POAG (Leske et al. 1995; 
Tielsch etal. 1995a; Ellis etal. 2000; Landers etal. 2002; Le etal. 2003). The 
association between diabetes and POAG identified in some studies (Klein etal. 1994; 
Dielemans et al. 1996) may in part be the result of inherent selection bias. Individuals 
diagnosed with diabetes are more likely to have frequent ophthalmological 
investigations than individuals from the general population, decreasing their chances of 
having undiagnosed POAG. 
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1.6 Mode of transmission 
Primary open-angle glaucoma is thought to be a complex trait resulting from the 
interaction of multiple genes in conjunction with environmental influences. In general, 
most familial POAG appears to segregate as an autosomal dominant trait with 
somewhat reduced penetrance (Stoilova et al. 1996; Wirtz et al. 1997; Sarfarazi et al. 
1998; Trifan et al. 1998; Wirtz etal. 1999; Charlesworth etal. 2006), although on 
further investigation these inheritance patterns do not reflect a simple mode of 
inheritance or a single underlying genetic cause. While genetic susceptibility is clearly 
involved in the pathophysiology of POAG, the late age of onset and generally painless 
progression, coupled with variations in definition and clinical diagnosis and the 
potential for phenocopies, often make it difficult to discern the exact mode of 
inheritance from family data. 
1.7 Nomenclature of POAG loci 
The glaucoma loci have been named according to the Human Genome Organisation 
(HUGO) guidelines for human gene nomenclature (Wain etal. 2002). The first part of 
the locus name, GLC, indicates glaucoma. Following this is a number indicating the 
type of glaucoma; 1 for primary open-angle, 2 for angle closure and 3 for primary 
congenital glaucoma. A letter is then added to indicate each new locus. Thus, the first 
POAG locus is named GLC1A, and the first primary congenital glaucoma locus is 
GLC3A. 
1.8 Summary of POAG genetics 
The Rotterdam Study reported a ten fold increase in risk of POAG for first degree 
relatives of patients compared with the general population, suggesting a strong genetic 
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component to the disease (Wolfs etal. 1998), although, as mentioned in section 1.5.1, 
studies investigating the under-reporting of family history suggest that even this may be 
an underestimation (McNaught etal. 2000). Many extended POAG pedigrees have 
been reported (Morissette etal. 1995; Stoilova etal. 1996; Wirtz et al. 1997; Sarfarazi 
et al. 1998; Trifan etal. 1998; Baird et al. 2003; Charlesworth etal. 2006), consistent 
with a high disease heritability. The ethnic differences in the risk of POAG, described 
in section 1.5.1, also support an underlying genetic component to the disease. 
There have been few twin studies of POAG (Teikari 1987; Gottfredsdottir et al. 1999) 
and some reports of twin pairs within the context of wider family studies (Teikari et al. 
1987; Wiggs et al. 1995), yet while the results of these few studies are highly variable, 
they do suggest a strong genetic component to the disease. The heritability of POAG 
was estimated at 13% in one study of 29 monozygotic twins and 79 dizygotic pairs 
(Teikari 1987) and 98% in another study of 50 monozygotic twin pairs (Gottfredsdottir 
et al. 1999). However, as mentioned in section 1.4, the clinical diagnosis and 
stringency of the phenotype definition of POAG varies and is not defined according to 
strict guidelines, confounding the interpretation of heritability estimates from these few 
published studies. POAG phenotype components, such as IOP and vertical cup-to-disc 
ratio, may have more simple genetic architectures than an overall diagnosis of POAG, 
and may offer more insight into the genetic composition of the disease. The 
heritabilities of IOP and vertical cup-to-disc ratio have been estimated at 0.29-0.36 and 
0.48-0.56 respectively (Klein et al. 2004; Chang et al. 2005), both strongly consistent 
with a genetic component to these parameters. 
POAG is clearly genetically heterogeneous; three genes for adult onset POAG have 
been identified; MYOC (MIM: 601652) encoding myocilin (Stone etal. 1997), OPTN 
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(MIM: 602432) encoding optineurin (Rezaie et al. 2002), and WDR36 (MIM:609669) 
encoding WD40-repeat 36 (Monemi et al. 2005), however mutations in these genes 
account for only a fraction of familial POAG. In addition, five other loci for POAG 
have been mapped: GLC1B (Stoilova et al. 1996), GLC1C (Wirtz etal. 1997), GLC1D 
(Trifan etal. 1998), GLC1F (Wirtz etal. 1999) and GLC I I (Allingham et al. 2005), 
however the genes at these loci remain to be identified (Table 1.1). GLC1B was 
localised using six pedigrees with 3-7 affected individuals per family and GLC11 was 
localised in a subset of 15 out of 81 pedigrees with an average of 2-3 affected 
individuals per family, while the remaining POAG loci have been localised using single 
pedigrees containing 10-16 affected individuals. Although four of these loci were 
originally identified between 1996 and 1998, only two have been replicated in published 
studies; GLC1B (Raymond et al. 1999 [abstract], Charlesworth et al. 2006) and GLC IC 
(Kitsos etal. 2001); one of these as a result of this dissertation (Charlesworth etal. 
2006). The results of several additional studies using an affected sib pair strategy and 
genome-wide approach suggest several additional chromosomal regions may be 
involved in POAG susceptibility (Wiggs et al. 2000; Nemesure et al. 2003). 
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Locus Maximum Location Original Reference Region width Gene 
LOD (cM) 
GLC IA 6.5 1q21-31 Sheffield et al. 1993 20 MYOC (myocilin) 
GLC1B 6.48 2cen-q13 Stoilova et al. 1996 11.2 Not identified 
GLC IC 3.02 3q21-24 Wirtz etal. 1997 11.1 Not identified 
GLC1D 3.61 8q23 Trifan et al. 1998 6.3 Not identified 
GLC1E 10 10p15-14 Sarfarazi etal. 1998 21 OPTN (optineurin) 
GLC IF 4.06 7q35-36 Wirtz et al. 1999 5.3 Not identified 
GLC I G 5.41 5q22.1 Monemi et al. 2005 2 WDR36 (WD40 repeat 36) 
GLC1I 3.24 15q11-13 Allingham et al. 2005 11 Not identified 
Gene reference 
Stone et al. 1997 
nil 
nil 
nil 
Rezaie et al. 2002 
nil 
Monemi et al. 2005 
nil 
Table 1.1 - Summary of the known POAG loci and original references 
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The recent identification of GLC1G and the responsible gene WDR36 on chromosome 
5q22.1 (Monemi et al. 2005) and GLC1I on chromosome 5q11-13 (Allingham et al. 
2005) occurred after completion of the analysis phase of this investigation, hence these 
loci are not described in the remaining chapters of this dissertation. 
1.8.1 GLC1A and Myocilin 
Sheffield et al. (1993) identified the first genetic locus for juvenile onset open-angle 
glaucoma in a single North American family of 67 individuals, 37 of whom participated 
in the study, including 22 affected with JOAG. Affected individuals were characterised 
clinically by an early age of onset (often during the second decade of life), apparently 
normal trabecular meshwork, very high IOP (often greater than 50mmHg) and relatively 
pressure-resistant optic nerves. The locus was refined to a 20 cM region of 
chromosome 1q21-31, flanked by D15191 and D1S194 (Sheffield et al. 1993), and 
subsequently assigned the name GLC IA by the Human Genome Organisation (HUGO). 
Linkage of this locus to JOAG was confirmed and refined in several families (Richards 
etal. 1994; Wiggs etal. 1994; Graff 1995; Morissette etal. 1995; Wiggs et al. 1995; 
Lichter et al. 1996; Meyer et al. 1996). Most of the confirmation studies included 
families with similar characteristics to the JOAG family used in the initial localisation 
of GLC1A (Richards et al. 1994; Wiggs et al. 1994; Graff 1995; Lichter et al. 1996). 
Two of these confirmation studies identified linkage to GLC1A in pedigrees containing 
individuals with juvenile and adult-onset POAG (Morissette etal. 1995; Meyer etal. 
1996). These findings provided the first suggestion that the phenotype determined by 
the GLCIA locus may be more heterogeneous than originally thought; potentially 
influencing both JOAG and adult-onset POAG. 
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Stone et al. (1997) discovered that the causative gene at the GLC IA locus encoded the 
trabecular-meshwork induced glucocorticoid response (TIGR) protein (GenBan.k 
accession number NM 000261) (Stone et al. 1997). The TIGR protein was originally 
cloned as a steroid response protein from cultured trabecular meshwork cells (Polansky 
et al. 1997). Kubota et al. (1997) independently isolated a gene from retinal cDNA and 
showed it localised to cilium connecting the inner and outer segments of photoreceptor 
cells. They named the protein product myocilin due to its sequence homology to 
Dictyostelium discoideum myosin (Kubota et al. 1997). Myocilin and the TIGR protein 
were later determined to be the same protein, and the official HUGO nomenclature for 
the gene became MYOC (MIM: 601652) with protein product myocilin. 
MYOC is a three exon gene spanning approximately 17kb of genomic DNA on 
chromosome 1q24.3 (Figure 1.5). Myocilin is expressed as a 2.3kb transcript encoding 
a 504 amino acid (57kDa) protein (Fingert et al. 1999). The MYOC gene has two major 
domains: a 5' (proximal) myosin-like domain, encoded by exon 1, that shows 
similarities to Dictyostelium discoideum (slime mould) non-muscle myosin heavy chain 
and the 3' (distal) olfactomedin-like domain (Kubota etal. 1997), encoded by exon 3. 
Olfactomedins are olfactory epithelium-specific extracellular proteins found 
predominantly in nasal mucus. Upstream of the coding sequence, the promoter contains 
a TATA box, a Sac box, an AP-1 like sequence, an AP-2 site, an NF-KI3-related site and 
an E-box (Kirstein et al. 2000; Fingert et al. 2002) (Figure 1.5). The transcription factor 
USF binds to the myocilin promoter at the E-box site and is essential for myocilin 
transcription (Kirstein et al. 2000). 
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Figure 1.5 - Putative functional motifs of the MYOC gene and myocilin protein 
Proximal promoter elements are denoted by coloured diamonds. Exon 1 contains both the cleavage site of the putative signal 
peptide, predicted from analysis of the myocilin protein sequence, and the leucine zipper protein binding domain. Exon 3 
contains the region of homology with olfactomedin, including the hydrophobic domain. 
Adapted from Fingert JH, Stone EM, Sheffield VC and Alward WL (2002). Myocilin glaucoma. Surv Ophthalmol 47(6): 547- 
61. 
The myocilin protein contains a leucine zipper motif (eight leucine residues evenly 
spaced every seven residues between amino acids 117 and 166) that form a coiled-
coiled structure able to facilitate interactions between proteins (Nguyen et al. 1998). It 
remains unknown which proteins, if any, bind to the leucine zipper of myocilin, 
however there is evidence that myocilin is able to form homodimers via this domain 
(Fautsch and Johnson 2001). 
Myocilin is a glycoprotein, existing in both glycosylated and non-glycosylated forms, 
and has been detected in both intra- and extra-cellular locations (Polanslcy et al. 1997; 
Nguyen et al. 1998). Expression of myocilin has been demonstrated in most tissues, 
ranging from bone marrow to cardiac muscle (Fingert et al. 1998). In the eye, myocilin 
expression is high in the trabecular meshwork, sclera, ciliary body and iris and 
considerably lower in the optic nerve head and retina (Tamm 2002). Secreted myocilin 
is also present in the aqueous humor (Fautsch and Johnson 2001). 
In the original study by Stone etal. (1997), mutations in the MYOC gene were found to 
segregate in five out of eight JOAG families linked to GLC1A on chromosome 1 q 
(Stone etal. 1997). Although many MYOC mutations were subsequently identified in a 
range of JOAG pedigrees, disease causing variants of this gene are not the exclusive 
cause of JOAG. Wiggs etal. (1998) found identifiable MYOC mutations in only two of 
25 JOAG pedigrees (8%); while Alward et al. (2002) detected MYOC mutations in three 
of 47 (6.4%) unrelated JOAG patients. 
Although initially identified in JOAG pedigrees, mutations in the MYOC gene have now 
been shown to account for approximately 3% of adult-onset POAG (Pinged et al. 1999; 
Alward et al. 2002). Fingert et al. (1999) screened 1,703 POAG patients from five 
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populations representing three racial groups for mutations in MYOC. These populations 
included Caucasians from the United States, Australia, and Canada, African Americans 
from the United States and Asians from Japan. These diverse populations revealed 
similar frequencies of MYOC mutations in POAG patients, ranging from 2.6 to 4.3% 
(Fingert et al. 1999). The majority (90%) of mutations were located in exon 3, which 
contains the olfactomedin domain. Similar MYOC mutation prevalence rates in POAG 
patients were obtained by other investigators: 4.0% in a Japanese population (Suzuki et 
al. 1997), 4.6% in predominantly Caucasian populations from the United States and 
Australia (Alward et al. 1998) and 4% in a predominantly Caucasian population from 
the United States (Shimizu et al. 2000). More than 50 different myocilin mutations 
have been reported in POAG and, consistent with earlier findings, the majority of the 
disease causing MYOC variants for POAG occur in the third exon of the gene (Alward 
et al. 2002). 
The most common MYOC mutation is Q368X, which is associated with a late onset 
POAG phenotype (Alward et al. 1998). The Q368X MYOC mutation was identified in 
1.6% of 1,703 unrelated POAG patients from Australia, Canada, Japan and the United 
States; and found in all populations except the Japanese (Fingert et al. 1999). This 
mutation results in a truncated protein missing 135 amino acids from the C terminus of 
myocilin, which represents approximately half the olfactomedin domain. Fingert et al. 
(1999) detected Q368X in 27 POAG pedigrees, thought to be unrelated, from Australia, 
Canada and the United States, including both African American and Caucasian 
individuals. The authors typed microsatellite markers closely flanking MYOC in all 27 
pedigrees, and the amount of DNA sharing at these sites was found to be significantly 
higher than in normal controls (p<0.05), suggesting a common ancestor for the mutation 
- (Fingert et al. 1999). Evidence of a founder effect has since been identified in 15 
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Australian POAG pedigrees, with a common origin prior to European settlement (Baird 
et al. 2003). 
Patients with the Q368X mutation generally present with normal to elevated IOP 
(Allingham etal. 1998; Alward etal. 1998; Wiggs etal. 1998; Angius etal. 2000; 
Craig et al. 2001) that is often well controlled by medical therapy (Allingham et al. 
1998; Angius etal. 2000). Q368X carriers generally present with a late age of onset of 
between 50-60 years of age (Allingham etal. 1998; Alward etal. 1998; Wiggs et al. 
1998; Craig et al. 2001); later than most other, generally missense, MYOC mutations in 
the olfactomedin domain (Allingham et al. 1998). However, Shimizu et al. (2000) 
reported two mixed age of onset POAG families (including both JOAG and adult onset 
POAG) where carriers of the Q368X mutation were diagnosed by 40 years of age. The 
generally observed delayed age of onset may indicate rapid elimination of the obviously 
truncated protein by control mechanisms in the endoplasmic reticulum, while more 
subtly mutated forms might escape these processes. 
Although extensive analysis of the myocilin gene and protein sequences has been 
conducted, the normal physiological role of myocilin and the mechanisms by which 
mutations lead to glaucoma have yet to be fully elucidated. It is postulated that mutant 
myocilin accumulates in the secretory compartments of trabecular meshwork cells, 
thereby interfering with the normal functions of these cells such as scavenging the 
debris that may obstruct aqueous humor outflow (Fingert et al. 2002). It is less clear 
whether wild-type myocilin plays a role in aqueous humor outflow under normal 
conditions. 
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1.8.2 GLC1B 
The second POAG locus, designated GLC1B and located on chromosome 2cen-q13, 
was identified in 1996 (Stoilova et al. 1996). Seventeen Caucasian families, including 
203 subjects and 90 affected individuals, were genotyped with 215 microsatellite 
markers across the genome. Families consisted of at least two to three affected 
offspring and one available parent. Six families showed linkage to D2S436, while eight 
other families were not linked and three produced ambiguous results. Additional 
markers, genotyped only in the linked families, were used to localise GLC1B to an 11.2 
cM region flanked by D2S2161 and D2S176. This locus was replicated in an American 
Society of Human Genetics conference abstract (Raymond et al. 1999) and in studies 
undertaken as part of this Ph.D. research project (Charlesworth et al. 2006; see Chapter 
5). 
1.8.3 GI, C1C 
Wirtz et al. (1997) identified a third POAG locus using a single 76-member North 
American family including 9 POAG patients and seven glaucoma suspect individuals. 
A 15 cM genome-wide scan mapped the disease locus to an 11.1 cM region flanked by 
D3S3637 and D3S1744 on chromosome 3q21-24. This linkage was confirmed by 
Kitsos et al. (2001) in a Greek family of 34 individuals, including 10 affected with 
POAG, however the authors were unable to refine the region of interest. 
1.8.4 GLC1D 
Trifan et al. (1998) identified the fourth POAG locus using a single 23-member North 
American family spanning four generations, 20 of whom were available and eight 
affected with POAG. Haplotype reconstruction and recombination analysis placed the 
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new locus within a 6.3 cM region, flanked by D8S1830 and D8S592, on 8q23 (Trifan et 
al. 1998). 
1.8.5 GLC1E and Optineurin 
Sarfarazi et al. (1998) identified the fifth POAG locus using a single British family with 
the normal tension form of POAG. The family used in the study consisted of 60 
individuals over four generations, 46 of whom were available to participate in the study 
including 15 classified as affected. Random selections of microsatellite markers from 
across the genome were typed until suggestive evidence of linkage was identified at 
D 1 0S1172. An additional 23 markers localised GLC1E to a 21 cM region on 10p15-14 
flanked by D 1 OS 1729 and D10S1664 (Sarfarazi etal. 1998). 
The susceptibility gene at GLCIE on chromosome 10p14 was identified by Rezaie et al. 
(2002) in a study of 54 POAG families. The gene identified at this locus, designated 
OPTN (MIM: 602432) for its protein product optineurin Coptic neuropathy inducing' 
protein), was previously known as FIP-2 (Li et al. 1998) or NRP (Schwamborn et al. 
2000). OPTN spans approximately 37kb of genomic DNA, including three non-coding 
exons in the 5' untranslated region and 13 translated exons (Figure 1.6), producing a 577 
amino acid protein of unknown function. Alternative splicing in the 5'-UTR generates 
at least three different isoforms, all with the same reading frame (Genbank accession 
numbers AF420371 to AF420373) (Rezaie et al. 2002). 
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Putative functional motifs and regions interacting with known proteins are shown. The approximate locations of the mutations identified by 
Rezaie et al. (2002) are also displayed. Exons 1-3 are non-coding, with the ATG start site marked in exon 4. 
Adapted from Rezaie T, Child A, Hitchings R, et al. (2002). Adult-onset primary open-angle glaucoma caused by mutations in optineurin. 
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After originally mapping GLCIE to 10p14-p15 in a normal-tension glaucoma family, 
Sarfarazi et al. (1998) reduced the critical region to 5 cM and began screening candidate 
genes. Four genes were excluded before OPTN was sequenced and a segregating E5OK 
missense mutation identified in the original kindred (Rezaie et al. 2002). The authors 
then screened a set of 54 POAG families, each including at least one member with 
NTG, revealing four additional OPTN mutations. As a result of these findings the 
authors suggest mutations in OPTN may be responsible for 16.7% of hereditary normal-
tension glaucoma (Rezaie et al. 2002). 
Funayama et al. (2004) identified a possible disease causing mutation (H26D) in the 
Japanese population, although this change was found in only 1 of 411 (0.24%) POAG 
patients and 0 of 218 controls (Funayama et al. 2004). Several other sequence changes, 
predicted to be disease causing, have been described in Chinese open-angle glaucoma 
cases (Leung et al. 2003). However, recent studies involving Caucasian, African 
American and Japanese POAG patients and controls have shown little to no association 
between the four previously identified OPTN sequence variants and POAG or the 
normal to low tension subtypes (Alward et al. 2003; Wiggs et al. 2003). No mutations 
were detected in the 13 coding exons of OPTN in a study of 8 POAG families from 
Finland (Forsman et al. 2003). The majority of reports therefore conclude that, with the 
exception of E5OK which appears to cause severe autosomal dominant NTG, most 
OPTN sequence variants may be susceptibility alleles or risk factors for POAG, rather 
than disease causing variants, or at most rare causes of NTG (Alward et al. 2003; Leung 
et al. 2003; Wiggs et al. 2003; Baird et al. 2004; Toda et al. 2004; Jansson et al. 2005; 
Mukhopadhyay et al. 2005a; Weisschuh et al. 2005). The contribution of OPTN to 
NTG, and to POAG as a whole, remains to be fully elucidated. 
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Optineurin is expressed in the trabecular meshwork, non-pigmented ciliary epithelium, 
retina and brain (Rezaie et al. 2002), and interacts with many proteins including 
Huntingtin (Faber et al. 1998), Ras-associated protein RAB8 (Hattula and Peranen 
2000), adenovirus E3-14.7K (Li et al. 1998), transcription factor II1A (Moreland et al. 
2000) and two unknown kinases (Schwamborn et al. 2000) as shown in Figure 1.6. 
Optineurin has been suggested as a component of the tumour necrosis factor-alpha 
(TNF-a) signalling pathway; able to shift the equilibrium towards induction of apoptosis 
(Li etal. 1998). TNF-a may be able to induce retinal ganglion cell apoptosis in patients 
with POAG (Yan et al. 2000; Yuan and Neufeld 2000). Rezaie et al. (2002) speculated 
that wild-type optineurin plays a neuroprotective role in the eye and optic nerve through 
the TNF-a pathway, resulting in vision loss and optic neuropathy typical of glaucoma 
when defective (Rezaie et al. 2002). Sustained elevated IOP, TNF-a exposure, and 
prolonged dexamethasone treatment all significantly up-regulate OPTN expression, 
suggesting that OPTN is part of the transcriptome activated in response to glaucomatous 
insult, which also supports the protective role of optineurin in the trabecular meshwork 
(Vittitow and Borras 2002). 
1.8.6 GLC1F 
Wirtz etal. (1999) localised GLC1F using a 36 person family, including 25 individuals 
available to participate in the study, 10 of whom were affected with POAG. A 5-10 cM 
genome-wide scan detected linkage to D7S2439. Haplotype analysis refined GLC1F to 
a 5.3 cM region on chromosome 7q35-36, flanked by markers D752442 and D7S483 
(Wirtz etal. 1999). 
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1.8.7 GLC1G and WD4O-Repeat 36 
There were several initial indications of linkage to chromosome 5q reported between 
2003 and 2004 (Monemi et al. 2003; Kramer et al. 2004; Samples etal. 2004). Follow-
up saturation mapping in a total of seven POAG families allowed Monemi et al. (2005) 
to refine the GLC1G locus to a region of approximately 2 cM, flanked by markers 
D551466 and D5S2051 on chromosome 5q21.3-22.1. 
The GLC1G region of interest contained several predicted and seven known genes, 
including MAN2A1, TSLP, WDR36 and CAMK4. Monemi etal. (2005) directly 
sequenced the known genes and identified WDR36 (MIM:609669) as the gene of 
interest at GLC1G, after detecting a mutation in exon 17 of WDR36 (D658G) in all 
seven affected individuals. The change was also present in nine asymptomatic 'carriers' 
but was absent in another nine unaffected family members and the six married in 
unaffected spouses (Monemi et al. 2005). This mutation was absent in 476 normal 
control chromosomes. The authors sequenced a total of 130 unrelated POAG cases and 
identified 24 sequence alterations, four of which were predicted to be disease causing 
and 12 which were intronic alterations (Monemi etal. 2005). The most common 
disease causing mutation identified (D658G) was identified in 13 of 670 unrelated 
familial probands and sporadic cases of POAG (1.9%), six with high- and seven with 
low-tension glaucoma. The three other predicted disease causing mutations were 
identified in a combined total of four out of 130 (3%) unrelated POAG cases. None of 
these mutations were detected in (at least 200) control chromosomes. The authors 
concluded that WDR36 accounted for at least 5% of both familial and sporadic POAG in 
their study population (Monemi et al. 2005). The impact of this gene on the wider 
population of POAG patients has yet to be determined. 
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WDR36 is a 23 exon gene that encodes a 951 amino acid protein containing a G-protein 
beta WD-40 repeat, which consists of eight tandem repeats of approximately 40 
residues each containing a central Trp-Asp dipeptide. These repeat motifs are also 
present in a wide variety of other proteins of diverse functionality, and are involved in 
protein-protein interactions. WDR36 was also identified by Mao et al. (2004) as one of 
the genes uniquely involved in T cell activation and highly co-regulated with interleuldn 
2 (11,2). The gene is therefore also known as TA - WDRP after the T-cell activation WD 
repeat protein (Mao et al. 2004). 
Monemi et al. (2005) observed expression of two distinct mRNA transcripts in human 
heart, placenta, liver, skeletal muscle, kidney and pancreas. Expression was also 
observed in ocular tissues, including the lens, iris, ciliary body, trabecular meshwork, 
retina, and optic nerve (Monemi et al. 2005). The in vivo functions of WDR36 and its 
involvement in POAG pathogenesis are yet to be elucidated. 
1.8.8 GLC1I 
Allingham et al. (2005) used a stratification technique known as ordered subset analysis 
(Hauser etal. 2004) to identify linkage to an 11 cM region of chromosome 15q11-13, 
with a peak LOD of 3.24, in a subset of 15 early adult-onset POAG families. This 
region was originally identified as an area of interest in a genome-wide scan, although 
the original detection did not reach significance, with a LOD of 1.27 at D15S165 
(Wiggs et al. 2000). The collection of 81 multiplex POAG families (MYOC and OPTN 
mutation free), including an average of 2-3 affected individuals, was stratified based on 
mean age at diagnosis per family, as a surrogate for age of onset. Maximal evidence for 
linkage was found with a subset of 15 pedigrees with a mean family-specific age at 
diagnosis of 44.1 ± 9.1 years, much lower than the 61.3 ± 10.4 years in the 
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complimentary set of 70 families (Allingham et al. 2005). The 15 pedigree subset 
consisted of 10 Caucasian families including a total of 35 affected individuals and 4 
African American families including 12 affected individuals. The peak LOD of 3.24 
(without correction for multiple testing) was identified at the GABRB3 locus, with 
LOD-1 interval boundaries at the centromere and marker D 15S822 (Allingham et al. 
2005). 
1.8.9 Other POAG loci 
The results of Wiggs et al. (2000) using a 7 cM genome-wide scan of affected sib pairs 
(ASP) suggest several additional chromosomal regions may be involved in POAG 
susceptibility. The study initially used a set of 113 ASP from 41 multiplex families, 
including 126 affected individuals. Regions of interest (defined by a LOD score greater 
than 1) were followed up in a second set of 69 ASP from 33 multiplex families, 
including 81 affected individuals. The majority of pedigrees consisted of two to four 
affected siblings in a generation; however several larger families were included in the 
dataset, one of these with nine affected individuals. Five regions produced LOD scores 
greater than 2.0: chromosomes 2p14, 14q11, 17p13, 17q25 and 19q13 (Wiggs et al. 
2000). 
Nemesure et al. (2003) conducted a genome-wide scan for POAG loci on Afro-
Caribbean individuals from the Barbados Family Study of open-angle glaucoma. This 
study was designed to evaluate the genetic component of POAG in a population of 
African descent. A 10 cM genome-wide scan was conducted on 662 individuals, 256 of 
whom were classified as affected, from 146 families. Two-point LOD scores greater 
than one were identified on chromosomes 1q43, 2q3I-33, 9q34, 10q24-p12, 11q14 and 
14q11-21 (Nemesure et al. 2003). Multipoint analyses reduced the regions of interest, 
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with LOD scores greater than two obtained for chromosomes 2q, 10p and 14q. The 
region of interest on chromosome 14q11.2-21.2, spanning D14S283 and D14S288 
overlaps the region identified by Wiggs et al. (2000), however this peak did not reach 
significance (Lander and Kruglyak 1995) (maximum LOD=2.02), nor could it be 
excluded (Nemesure et al. 2003). The authors concluded this result may provide weak 
support for the suggestion of a glaucoma locus near D I4S283. The regions of interest 
on chromosomes 2q31.1-34 (spanning D2S2314 and D2S2178) and 10p13-12.1 
(spanning D 1 0S1477 and DIOS601 but not including OPTIV) produced multipoint LOD 
scores greater than 3 and empirical p-values <0.002 (Nemesure et al. 2003). 
A recent genome-wide scan revealed evidence for two novel loci at 9q22 and 20p12 
involved in JOAG (Wiggs et al. 2004), although the relevance of these loci to POAG as 
a whole remains to be seen. 
1.9 Complexity of POAG genetics 
There appears to be much complexity in the genetics of POAG; made apparent by the 
variable impact of the susceptibility genes MYOC and OPTN following their initial 
identification, and the existence of many additional susceptibility loci where the genes 
of interest remain to be discovered. Dissecting the genetics of POAG is further 
complicated by evidence of interaction and additional genes acting as phenotypic 
modifiers of the disease. 
1.9.1 CYP1B1 
One of the genes causing autosomal recessive primary congenital glaucoma is CYP1B1 
(MIM:601771), encoding a 543 amino acid member of the cytochrome p450 gene 
- superfamily, subfamily 1 (Stoilov et al. 1997). A mutation in the CYP1B1 gene was 
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shown by Vincent et al. (2002) to modify the phenotype of POAG when inherited 
together with a MYOC mutation, decreasing the age of onset from 51 years (range 48-64 
years; MYOC alone) to 27 years (range 23-38 years). The authors concluded that 
digenic inheritance with a CYPIBI mutation modifies the MYOC glaucoma phenotype 
(Vincent et al. 2002). 
1.9.2 APOE 
Apolipoprotein E is an essential protein in lipid transport and variants of the APOE gene 
(MIM:107741) have been associated with cholesterol related myocardial infarction 
(Mahley and Huang 1999; Lambert et al. 2000) and predisposition to Alzheimer's 
disease (Roses 1996; Bullido et al. 1998; Lambert et al. 1998). APOE is up-regulated 
in response to oxidative stress (Miyata and Smith 1996) and is involved in neuronal 
degeneration and stress-induced injury. Variants of APOE appear able to influence the 
phenotype components of POAG through several pathways, including interaction with 
MYOC. 
Copin et al. (2002) determined that the G allele of the APOE -219 SNP was associated 
with both visual field loss and increased cup-to-disc ratio (p=0.0012 and 0.015 
respectively) in a study of 191 unrelated Caucasian POAG patients and 102 control 
subjects. The authors suggest that optic nerve degeneration may be influenced by 
genetic factors, independent of TOP (Copin et al. 2002). A highly significant interaction 
between the APOE -491T allele and a MYOC promoter SNP -1000G, associated with 
increased IOP and limited effectiveness of LOP lowering treatment in POAG patients, 
was also identified. The involvement of APOE variants with POAG may account for 
the previously identified linkage to 19q (Wiggs et al. 2000), and for the reported 
increased frequency of Alzheimer's disease in glaucoma-patients (Bayer et al. 2002). 
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Vickers et al. (2002) examined the APOE s2, E3 and c4 alleles in a sample of 70 NTG 
patients, 72 POAG patients and 51 control subjects from the Tasmanian population. 
The study indicated that approximately twice as many NTG (38.0%) and POAG 
(34.2%) patients carried an c4 allele compared with control subjects (18.9%). The 
authors suggest inheritance of the c4 allele in this population is associated with elevated 
risk of glaucomatous changes that are not necessarily related to IOP (Vickers et al. 
2002). 
There is, however, still some debate as to the extent of the involvement between APOE 
and POAG. One study recently examined the frequency of APOE alleles c2, c3 and c4 
in 137 POAG patients (no NTG) and 75 controls and detected no association with 
POAG (Ressiniotis et al. 2004). The original investigation of Copin et al. (2002) has 
been criticised by suggestions that some of the results associating APOE with POAG 
may be invalid due to the methods used to analyse visual field loss and cup-to-disc ratio 
(Bunce et al. 2003), and case/control studies to date have been based on small sample 
sizes. 
1.9.3 Genetic contributions to 10P 
Duggal et al. (2005) recently conducted a segregation analysis on 2337 individuals from 
620 Beaver Dam Eye Study families to determine the genetic contribution to IOP as a 
component of the POAG phenotype. The segregation analysis determined the best 
model of IOP consisted of an unmeasured environmental effect in combination with a 
polygenic genetic component (Duggal et al. 2005). A genome-wide scan of 218 sib-
pairs confirmed the heterogeneity of 10P, identifying two novel loci for the trait. Peak 
evidence for linkage was obtained on chromosome 6 with marker D6S1027 (p=0.008) 
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and on chromosome 13 with marker D13S317 (p=0.00071). However, multipoint 
linkage analysis weakened any suggestion of linkage in both regions and neither 
reached genome-wide significance (Duggal et al. 2005). While this study lacked power 
and would benefit from the inclusion of additional pedigrees and/or fine mapping, it 
does suggest that investigating the genetic contributions to each of the phenotype 
components of POAG, such as IOP or cup-to-disc ratio, may be a valuable approach to 
investigating the genetics of this complex disease. 
1.10 Impact of gene identification 
POAG is clearly a complex disease with much overlap within the clinical phenotypes 
(such as POAG and JOAG) and the genetics of the disease. MYOC for example was 
identified as a causative gene for the rare disease JOAG, and now appears to also be 
responsible for 3% of adult onset POAG (Stone et al. 1997; Alward et al. 2002). 
Results obtained following the identification of OPTN, the second POAG susceptibility 
gene, have been variable across populations; for example the original study by Rezaie et 
al. (2002) suggested OPTN could be responsible for 16.7% of familial POAG and NTG, 
while Alward et al. (2003) identified a low prevalence of OPTN mutations (less than 
0.1%) in unselected cases of both POAG and NTG. Variants of other genes such as 
APOE and CYPIB1 further complicate genetic studies of glaucoma by apparently 
modifying the POAG phenotype (Copin et al. 2002; Vincent et al. 2002). The findings 
for MYOC suggest the identification of additional glaucoma genes may be relevant to a 
wider population of POAG patients than the rare pedigrees in which they were initially 
identified, although the studies of OPTN are less supportive of this claim. Identifying 
genes involved in the normal tension subtype of glaucoma may offer insights that are 
relevant to elucidating the pathogenesis of POAG as a whole, such as the genetic 
mechanisms of optic nerve susceptibility and damage in the absence of elevated 10P. 
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There is also considerable clinical overlap between the sub-classifications of the various 
forms of glaucoma. Arbitrary threshold values for age of onset and IOP are used to 
classify subtypes of POAG, whereas these different forms are likely to be part of a 
spectrum of disease. Determining the molecular pathogenesis and contributing risk 
factors of POAG may provide more accurate classification of the disease. 
The isolation and characterisation of glaucoma genes will allow a better understanding 
of the pathogenesis of the disease, and may lead to the development of more suitable 
treatment strategies. It is anticipated that the identification of novel POAG genes could 
be translated into direct health outcomes via predictive testing. Once a disease causing 
variant is identified, at-risk unaffected individuals can be screened for the mutation and 
counselled about the implications of results. Management strategies, including 
increased frequency of ophthalmic examination in those carrying a mutation, could then 
be implemented to provide the best possible chance of disease detection prior to 
permanent visual loss. These strategies have been implemented in some situations, such 
as determining an appropriate frequency of clinical screening for individuals within a 
pedigree segregating a disease causing MYOC mutation based on mutation status 
(Mackey and Craig 2003). 
1.11 Aims of the study 
Several genes for POAG have been identified (Fingert et al. 1999; Rezaie et al. 2002; 
Monemi et al. 2005), yet mutations in these genes appear to account for only a small 
portion of familial POAG. The disease is clearly genetically heterogeneous, and while 
five additional loci have been mapped (Stoilova etal. 1996; Wirtz etal. 1997; Trifan et 
al. 1998; Wirtz etal. 1999; Allingham etal. 2005), the genes within these regions 
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remain to be elucidated. Genome-wide scan data also suggest that several additional 
chromosomal regions may be involved in POAG susceptibility (Wiggs et al. 2000; 
Nemesure et al. 2003). Follow-up analyses of POAG susceptibility loci and subsequent 
gene identification has been hindered by the late age of onset (in most cases), unclear 
mode of inheritance and penetrance, the asymptomatic progression of the disease that 
results in approximately half of cases remaining undiagnosed, the phenotypic 
uncertainty and often poor disease classification and the potential for phenocopies. 
This dissertation explores different approaches to the genetic analysis of POAG, taking 
into consideration the complex nature of the disease and the size and structure of 
available pedigrees, to dissect the genetic aetiology of this phenotypically and 
genetically heterogeneous disease in extended pedigrees from the Tasmanian 
population. 
One of the principal objectives of this study was to investigate the primary open-angle 
glaucoma loci known at the time of inception (GLC1A, -B, -C,-D, -E and -F) in 10 
extended pedigrees from the Glaucoma Inheritance Study in Tasmania (GIST), a 
population-based study of glaucoma genetics in Tasmania representing almost complete 
population ascertainment. This dataset, including pedigree structure and clinical 
information, is described in Chapter 2, while the molecular methodology is described in 
Chapter 3. Initial and exploratory linkage analyses, including marker selection, 
simulations, Markov chain Monte Carlo based analyses and exact parametric and 
nonparametric analyses are described in Chapter 4. Follow-up analyses of suggestive 
results are described in Chapter 5. 
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Genome-wide scan data were also available for an additional extended POAG pedigree 
from Tasmania, previously investigated using nonparametric dichotomous trait analysis 
approaches. A second aim of this dissertation was to use variance components analyses 
(also nonparametric) on quantitative trait data, derived from phenotypic information 
collected as part of the routine clinical examination of POAG patients, to identify loci 
contributing to these traits. These analyses are described in Chapter 6. 
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Chapter 2 - Extended Pedigrees from the Glaucoma Inheritance Study 
in Tasmania 
2.1 Background 
2.1.1 Genetic studies in Tasmania 
Tasmania, the 'island state of Australia', is an island population which is not 
significantly inbred (Lafranchi et al. 1988), but displays many of the benefits for studies 
of the genetic aetiology of complex disease. Island populations with a high standard of 
health care, but a limited number of facilities and specialists, support the easy 
identification and follow-up of disease cases; while the preservation of comprehensive 
and accurate genealogical records facilitates the reconstruction of extended pedigrees 
and increases the likelihood of identifying and linking additional disease cases into pre-
identified pedigrees. 
Tasmania has a population of approximately 474,000 (Australian Bureau of Statistics 
2002), and was colonized as a penal settlement of the British empire in 1803. Free 
settlers were also encouraged to migrate to the colony through the early to mid 19 th 
Century. Convict transportation ceased in 1853, coinciding with reduced immigration 
of free settlers. 
Tasmania's early history and genealogy has been well documented, including extensive 
convict records of transportation, military records, records of free passage, and land 
grants provided for assisted immigrants. In 1838 Tasmania was the first Australian state 
to pass an Act requiring the civil registration of births, deaths and marriages, not long 
after England (July 1837). Previously, baptism, marriage and burial records were 
primarily recorded by the church and the actual number was understated. 
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Furthermore, this population is a relatively homogenous one whose ancestry is 
principally from the British Isles. Census data from 2001 indicates that 84.9% of 
Tasmania's current 472,000 residents were born in Australia (compared with 71.1% for 
Victoria, the nearest Australian state), while almost 90% of Tasmanians were born in 
Australia or the United Kingdom (compared with 75.6% for Victoria; Australian Bureau 
of Statistics 2001). A further indicator of relative population homogeneity is given by 
ancestry, where 88.7% of the Tasmanian population is of North-West European 
ancestry (based on parental origin), compared with 69.4% for Victoria (Australian 
Bureau of Statistics 2001). 
A founder effect has been observed for a small number of Mendelian diseases in 
Tasmania. For example, a large kindred segregating Huntington disease has been traced 
back nine generations to the father of a female migrant who came to Tasmania in 1842 
and gave rise to 765 living descendents (Pridmore 1990). Founder effects have been 
observed in Tasmanian families with multiple endocrine neoplasia type 1 (MEN 1) 
(Shepherd 1985; Teh et al. 1995), Leber hereditary optic neuropathy (LHON) (Mackey 
and Howell 1992), and also in 15 Australian (primarily Tasmanian) POAG families 
segregating a common haplotype around the MYOC Q368X mutation (Baird et al. 
2003). 
2.1.2 The Glaucoma Inheritance Study in Tasmania 
This study was conducted as a part of the Glaucoma Inheritance Study in Tasmania 
(GIST) (Mackey and Craig 2002), a large population study of glaucoma genetics based 
- in Tasmania, Australia. Through the collaborative involvement of Tasmanian 
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ophthalmologists, the aim of the GIST was to identify and involve all diagnosed 
glaucoma patients in Tasmania. The study represents almost complete population 
ascertainment based on population prevalence predictions derived from the Blue 
Mountains Eye Study (Mitchell et al. 1996). 
The study identified adult-onset POAG families by first attempting to recruit all 
diagnosed glaucoma patients and then using genealogical data provided by participants, 
combined with Tasmania's comprehensive genealogical records, to determine familial 
relationships between patients. Once initial pedigrees were identified and expanded, all 
available family members over 40 years of age were invited to participate in the study. 
To date, blood has been collected from over 1,353 individuals from 116 Tasmanian 
families containing at least two first-degree relatives, 435 (32%) of whom are affected. 
All were examined by specialised ophthalmologists and have had IOP measured, 
Humphrey visual fields and stereo disc photographs taken, and clinical history 
documented (methodology used by the examining clinicians is described in Appendix 
1). Many individuals have been examined sequentially since the inception of the study. 
The GIST dataset contains several large families with five or more affected individuals 
that compare favourably with pedigrees used to localise the known POAG loci in the 
published literature. 
For this dissertation 10 extended pedigrees, with a total of 457 individuals, were 
selected from the GIST dataset for linkage analysis with the known POAG loci. Blood 
or buccal mucosa swabs for DNA isolation were collected from 237 of these individuals 
as part of the GIST. 
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2.1.3 Definition of glaucoma affection status 
Clinical examination and diagnosis of patients involved in the GIST is well documented 
(Coote et al. 1996). In brief, POAG was defined as an optic neuropathy which has 
present at least two of the following features: (1) optic nerve head excavation with 
thinning of the neuroretinal rim (generally measured by an enlarged vertical cup-to-disc 
ratio>0.7), often but not necessarily including significant focal or generalised loss of 
retinal nerve fibre layer, notching, pitting, or `Drance' type nerve fibre layer 
haemorrhages; (2) elevation of the IOP over a population-based normal range, or over 
the average of the unaffected individuals within a pedigree (generally IOP>21mmHg or 
2 standard deviations from the population mean); and (3) reproducible visual field 
defects consistent with the disc changes and with common descriptions of glaucomatous 
field loss (Coote et al. 1996). An individual with only one of the previously mentioned 
clinical features was classified as being 'glaucoma suspect'. Glaucomatous changes 
secondary to rubeosis or trauma were excluded, as were cases of anterior segment 
dysgenesis. More detail on the clinical methodology of the GIST is provided in 
Appendix 1. 
2.2 Methods 
2.2.1 Ethics approval 
Ethics approval for this study was obtained from the Human Research Ethics 
Committees of the Royal Children's Hospital, Victoria, the Royal Victorian Eye and Ear 
Hospital, the Royal Hobart Hospital and the University of Tasmania. This study was 
conducted in accordance with the Declaration of Helsinki (revised in 1989) and the 
statement of the National Health and Medical Research Council of Australia on ethical 
conduct in research involving humans (NRIVIRC 1999). Written informed consent was 
obtained from all participants. 
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2.2.2 Extended pedigrees for linkage analysis (Chapters 4 and 5) 
POAG pedigrees for linkage analysis were selected from the GIST database on the basis 
of size, number of clinically diagnosed POAG cases, lack of spouses also diagnosed 
with POAG (to avoid, where possible, multiple sources of inheritance), and lack of any 
previously identified myocilin mutations in the pedigree. Several individuals from each 
POAG pedigree in the GIST had been previously screened for mutations in the MYOC 
gene in collaboration with Dr Edwin Stone in Iowa (see Fingert et al. 1999). At least 
five affected individuals from each pedigree selected for use in this study had been 
screened for mutations in all three exons of MYOC in Dr Stone's Laboratory. Although 
these individuals may not be indicative of the entire pedigree, they offered a guide to 
selecting pedigrees without known MYOC involvement, where possible. The aim, for 
this study, was to select large but compact pedigrees from the GIST, with five or more 
closely related POAG cases. The existence of loops, both marriage and 
consanguineous, within the pedigrees was not a consideration for exclusion. 
2.2.3 Family GTas02 for variance components linkage analysis (Chapter 6) 
GTas02, the largest of the GIST pedigrees, had been under investigation by Dr Paul 
Baird and collaborators at the Walter and Eliza Hall Institute (Victoria) for several years 
prior to the inception of this study. These investigations included single-stranded 
conformational polymorphism (SSCP) screening of MYOC mutations (Craig et al. 2001; 
Baird et al. 2003) and a 10 cM genome-wide scan (Baird et al. 2005). The resulting 
data provided an opportunity to apply the method of variance components linkage 
analysis to the problem of POAG genetics, and were made available to this investigation 
for that purpose. 
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The details of family GTas02 are provided in Chapter 6; hence the remainder of this 
chapter describes the extended pedigree dataset selected for the linkage analyses 
described in Chapters 4 and 5. 
2.2.4 Control individuals for population frequency information 
DNA was collected from 156 elderly Tasmanian nursing home residents who were 
ophthalmically examined. A subset of 72 of these individuals, entirely free of glaucoma 
or glaucoma suspect status, was used a control dataset for population-specific allele 
frequencies and mutation detection. 
These individuals were ascertained using a restricted sampling method, selected only 
from participating nursing homes, which could in theory lead to sample bias by 
selecting for individuals who have survived to old age. However, these individuals 
were recruited from Tasmania, the same source population as the POAG patients, and 
while not entirely representative of the population at large they provide more 
appropriate allele frequency data than most publicly available databases, such as the 
Centre d'Etude du Polymorphisme Humain (CEPH; http://www.cephb.fricephdb ). 
2.2.5 Genetic material extraction 
Blood samples, or in some cases buccal mucosal swabs, were collected as part of the 
GIST (Mackey and Craig 2002). Genetic material was extracted from these sources 
using a variety of methods, depending on the age, condition and type of sample 
available, as described in Chapter 3.1. 
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2.3 Description of the pedigrees 
2.3.1 Dataset overview 
The final dataset selected for power calculations and linkage analyses, contained 10 
large POAG pedigrees including a total of 457 people. Of these individuals there were 
237 with both DNA and clinical information available. This dataset included 87 
individuals diagnosed with POAG according to the criteria in Chapter 2.1.3. In order to 
be conservative, individuals classified as 'glaucoma suspects' (see Chapter 2.1.3) were 
classed as unknown, rather than unaffected, for the purposes of the linkage analyses. 
Table 2.1 describes these pedigrees, including the number of individuals with both 
clinical information and genetic material available for use in the investigation, and the 
number of individuals with clinically diagnosed POAG. 
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Family ID Total Available Affected 
GTas03 123 59 15 
GTas03a* 76 39 9 
GTas03b* 41 19 6 
GTas04 45 25 9 
GTas35 32 15 6 
GTas37a 51 29 8 
GTas37b 37 24 15 
GTas54 33 17 7 
GTas11 15 10 5 
Gtas15 31 14 6 
GTas17 45 26 9 
GTas121 45 18 7 
Totalf 457 237 87 
Table 2.1 - Size of the selected GIST pedigrees 
*GTas3a and GTas3b represent two branches of family GTas03. 
tThe 'Total' is derived from the 10 main pedigrees with GTas03 considered as one 
pedigree (not including GTas3a and GTas3b). 
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2.3.2 Description of selected GIST pedigrees 
A system of symbols is used throughout the pedigree diagrams to describe the clinical 
features of each individual. In this system the pedigree symbol is broken down into 
quadrants with each quadrant denoting a component of the clinical phenotype (Figure 
2.1). A brief description of the clinical thresholds used for each component is given in 
section 2.1.3, while more detail on the clinical methodology is provided in Appendix 1. 
Four unfilled quadrants denote unexamined family members with unknown POAG 
status, or ophthalmically examined participants that had no evidence of any of the 
clinical characteristics of POAG at the time of their most recent examination. The latter 
have hyphenated ID numbers below their pedigree symbol. 
The 10 extended pedigrees selected for linkage analysis are described below, including 
figures showing pedigree structure and clinical features of POAG (Figures 2.2 — 2.11). 
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Raised  r intra-ocular pressure 
Figure 2.1 - Pedigree symbol key 
A filled quadrant in the upper right indicates the individual has raised LOP; the lower 
right indicates characteristic visual field loss; the left top and bottom quadrants indicate 
optic disc abnormalities characteristic of POAG and are filled from bottom (mild) to 
bottom plus top (severe). 
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Figure 2.2 Family GTas03 
The original 123 member pedigree GTas03 is shown. Individuals are labelled with their ID number. Individuals with available clinical and genetic data have hyphenated ID numbers. 
Clinically diagnosed POAG cases are highlighted. The consanguineous marriage loops can be seen between individuals  1 and 2, and individuals 231 and 232. Dizygotic twins 3-7 and 
3-8 are also shown. 
Pedigree Symbol Key 
The pedigree symbol is broken down into quadrants with each quadrant denoting a component of the clinical phenotype. A filled quadrant in the upper right indicates the individual 
has raised 10P; the lower right indicates characteristic visual field loss; the left top and bottom quadrants indicate optic disc abnormalities characteristic of POAG and are filled 
from bottom (mild) to top (severe). 
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Figure 2.3 Family GTas03 subdivided into GTas03a and GTas03b 
The original 123 member pedigree GTas03 (shown in Figure 2.2) was divided into sub-pedigrees GIas3a and CiTas3b are shown in Panels A and II respectively. Individuals arc labelled 
with their ID number. Individuals with available clinical and genetic data have hyphenated ID numbers. Clinically diagnosed POAG cases are highlighted. The consanguineous marriage 
loop can be seen in GTas3b (Panel B), while the dizygotic twins can be seen in GTas3a (Panel A). 
Pedigree Symbol Key 
The pedigree symbol is broken down into quadrants with each quadrant denoting a component of the clinical phenotype. A filled quadrant in the upper right indicates the individual 
has raised IOP; the lower right indicates characteristic visual field loss; the left top and bottom quadrants indicate optic disc abnormalities characteristic of POAG and are tilled 
from bottom (mild) to top (severe). 
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Figure 2.4 Family GTas04 
Individuals are labelled with their ID number. Individuals with available clinical and genetic data have hyphenated ID numbers. Clinically diagnosed POAG cases are highlighted. 
The marriage loop can be seen between individual 5 and sisters 4 and 40. 
Pedigree Symbol Key 
The pedigree symbol is broken down into quadrants with each quadrant denoting a component of the clinical phenotype. A filled quadrant in the upper right indicates the individual 
has raised 10P; the lower right indicates characteristic visual field loss; the left top and bottom quadrants indicate optic disc abnormalities characteristic of POAG and are tilled 
from bottom (mild) to top (severe). 
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Figure 2.5 Family GTagl I 
Individuals are labelled with their ID number. Individuals with available clinical and genetic data have hyphenated ID numbers. Clinically diagnosed POAG cases are highlighted. 
Pedigree Symbol Key 
The pedigree symbol is broken down into quadrants with each quadrant denoting a component of the clinical phenotype. A filled quadrant in the upper right indicates the individual 
has raised lOP; the lower right indicates characteristic visual field loss; the left top and bottom quadrants indicate optic disc abnormalities characteristic of POAG and are tilled 
from bottom (mild) to top (severe). 
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Figure 2.6 Family GTas15 
Individuals are labelled with their ID number. Individuals with available clinical and genetic data have hyphenated ID numbers. Clinically diagnosed POAG cases are highlighted. 
Individual 15-02 was removed from all analyses since she was the monozygotic twin of 15-01. 
Pedigree Symbol Key 
The pedigree symbol is broken down into quadrants with each quadrant denoting a component  of the clinical phenotype. A filled quadrant in the upper right indicates the individual 
has raised IOP: the lower right indicates characteristic visual field loss: the left top and bottom quadrants indicate optic disc abnormalities characteristic of POAG and arc tilled 
from bottom (mild) to top (severe). 
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Figure 2.7 Family GTas17 
Individuals are labelled with their ID  number. Individuals with available clinical and genetic data have hyphenated ID numbers. Clinically  diagnosed POAG cases are highlighted. 
Pedigree Symbol Key 
The pedigree symbol is broken down into quadrants with  each quadrant denoting a component of the clinical phenotype. A filled quadrant in the upper right indicates the individual 
has raised 10P; the lower right indicates characteristic visual field loss; the left top and bottom quadrants indicate optic disc abnormalities characteristic of POAG and are filled 
from bottom (mild) to top (severe). 
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Figure 2.8 Family GTas35 
Individuals are labelled with their ID number. Individuals with available clinical and genetic data have hyphenated ID numbers. Clinically diagnosed POAG cases are highlighted. 
Pedigree Symbol Key 
The pedigree symbol is broken down into quadrants with each quadrant denoting a component of the clinical phenotype. A filled quadrant in the upper right indicates the individual 
has raised 10P; the lower right indicates characteristic visual field loss; the left top and bottom quadrants indicate optic disc abnormalities characteristic of POAG and are filled 
from bottom (mild) to top (severe). 
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Figure 2.9 Families GTas37a and GTas37b 
Individual 48 in family GTas37a (Panel A) is the daughter of individual LI (shown with asterisk next to pedigree symbol) from family GTas37b (Panel B). Individual LI was not included 
in the study. The marraige loop in family (iTas37b can be seen between brothers 16 and 26 and sisters 15 and 37-30 (Panel 13). 
Individuals are labelled with their ID number. Individuals with available clinical and genetic data have hyphenated If) numbers. Clinically diagnosed POAG cases are highlighted. 
Pedigree Symbol Key 
The pedigree symbol is broken down into quadrants with each quadrant denoting a component of the clinical phenotype. A filled quadrant in the upper right indicates the individual 
has raised 1013; the lower right indicates characteristic visual field loss; the left top and bottom quadrants indicate optic disc abnormalities characteristic of POAG and are tilled 
from bottom (mild) to top (severe). 
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Figure 2.10 Family GTas54 
Individuals arc labelled with their II) number. Individuals with available clinical and genetic data have hyphenated ID numbers. Clinically diagnosed POAG cases are highlighted. 
Pedigree Symbol Key 
The pedigree symbol is broken down into quadrants with each quadrant denoting a component of the clinical phenotype. A filled quadrant in the upper right indicates the individual 
has raised 10P; the lower right indicates characteristic visual field loss; the left top and bottom quadrants indicate optic disc abnormalities characteristic of POAG and are filled 
from bottom (mild) to top (severe). 
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Figure 2.11 Family GTas121 
Individuals are labelled with their ID number. Individuals with available clinical and genetic data have hyphenated ID numbers. Clinically diagnosed POACi cases are highlighted. 
Dizygotie twins 121-12 and 121-14 are shown. 
Pedigree Symbol Key 
The pedigree symbol is broken down into quadrants with each quadrant denoting a  component of the clinical phenotype. A filled quadrant in the upper right indicates the individual 
has raised 10P; the lower right indicates characteristic visual field loss; the left top and bottom quadrants indicate optic disc abnormalities characteristic of POAG and are filled 
from bottom (mild) to top (severe). 
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2.33 Multiple sources of inheritance and subdivided pedigrees 
Family GTas03, the largest of the selected GIST pedigrees, has two apparent branches 
(Figure 2.2); however the origin of POAG within each branch may either have come 
from a single source (individuals 150 to 155) or from two different founders (for 
example individual 149 or 153). As a result of both size and the possibility of digenic 
inheritance, GTas03 was split into two sub-pedigrees at individual 2 (as shown in 
Figure 2.3). One sub-pedigree, named GTas3a (Figure 2.3, Panel A), was founded by 
individuals I and 2 while the second, GTas3b (Figure 2.3, Panel B), was founded by 
individuals 154 and 155. This was not considered a permanent division of GTas03, but 
an option for analyses depending on the method used. 
Pedigrees GTas37a and GTas37b (Figure 2.9, Panel A and B respectively) are separate 
branches of an originally larger pedigree. The two branches of the pedigree were linked 
by marriage. Individual 48, the spouse of 37-06 in family GTas37a (Figure 2.9, Panel 
A) is the daughter of individual Li in family GTas37b (Figure 2.9, Panel B). Individual 
Li was not available for this study, but is another child of the founding couple of family 
GTas37b, individuals 3 and 4. The presence of POAG within each branch clearly 
originated from different sources, thus the larger pedigree was permanently divided, 
allowing the branches to be analysed separately. 
23.4 Consanguinity and marriage loops 
Several of the GIST pedigrees contained loops, both consanguineous and marriage 
loops. The existence of loops can result in computational problems with likelihood 
calculations, and analysis approaches based on the Elston-Stewart algorithm (Elston and 
Stewart 1971), such as LINKAGE, require these loops be broken prior to analysis. The 
MAKEPED component of the LINKAGE software package (Lathrop and Lalouel 1984; 
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Lathrop et al. 1984; Lathrop et al. 1986) was used to break each loop at a specified 
individual, and reconstruct the pedigrees prior to analysis, as described in Chapter 4.4.1. 
Family GTas03 contains two consanguineous loops (Figure 2.2); the first links the two 
branches of the pedigree with a marriage between individual 1 and his second-cousin 
once removed (individual 2); the second is a first cousin marriage (individuals 231 and 
232). This second loop is also present in GTas03b (Figure 2.3, Panel B). When 
required by the analysis approach, these loops were broken at individual 2 and 232 
respectively. 
Family GTas04 (Figure 2.4) contains a marriage loop at individuals 4, 5 and 40 (Figure 
2.4), with individual 5 marrying two sisters, individuals 4 and 40. For some analysis 
approaches this loop was broken at individual 4. 
Family GTas37b (Figure 2.9, Panel B) includes a marriage loop, with sisters 15 and 37- 
30 marrying brothers 16 and 26 respectively. For some analysis approaches this loop 
was broken at individual 16. 
2.3.5 Monozygotk and dizygotic twins 
Several of the GIST pedigrees included either monozygotic or dizygotic twins. The 
nature of the twin relationship was confirmed by comparing genotypes across the entire 
set of microsatellite markers used in this study (see Chapter 4.3.1 for marker 
information). 
Family GTas03 (or pedigree GTas3b when subdivided) includes a set of dizygotic twins 
(individuals 3-7 and 3-8; see Figure 2.2), of whom only individual 3-7 was clinically - 
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classified as affected (individual 3-8 is a glaucoma suspect, presenting with some 
characteristic loss of visual field which may indicate the presence of as yet 
unclassifiable optic disc damage). Both individuals were included in all analyses. 
Family GTas15 includes a set of monozygotic twins (individuals 15-01 and 15-02; see 
Figure 2.6). Both individuals have clinically diagnosed POAG, although at last 
examination individual 15-02 was less severely affected in terms of optic nerve 
degeneration compared with individual 15-01. While this phenotype difference would 
not have influenced the results, as analyses were based on 'affected' or 'unknown' 
glaucoma status, individual 15-02 was removed from all analyses to prevent error due to 
the apparent doubling of genetically identical individuals within the pedigree. 
Family GTas121 also includes a set of dizygotic twins (individuals 121-12 and 121-14; 
see Figure 2.11), both of whom have been diagnosed with severe POAG, including 
raised IOP, characteristic visual field loss and severe optic nerve degeneration as 
manifested by vertical cup-to-disc ratios of greater than 0.8. Both individuals were 
included in all analyses. 
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Chapter 3 - Molecular Methodology 
3.1 Genetic material 
Whole blood was collected in 10m1 EDTA tubes from consenting individuals during the 
initial stages of the GIST and at several follow-up stages, hence storage time for the 
blood samples varied from 6 months to more than 5 years old. The bulk of the DNA 
extraction was conducted as part of the GIST, however extraction of additional samples 
using the methods described below was required and conducted as part of this 
dissertation. 
3.1.1 DNA extraction from whole blood - resin method 
DNA was extracted using the Nucleon BACC3 kit (Amersham Pharmacia Biotech). 
Four times the volume of the sample of Reagent A was added and mixed for 4 minutes 
at room temperature. The samples were centrifuged at 1300g for 5 minutes and the 
supernatant discarded. The pellet was resuspended in 2m1 of Reagent B and transferred 
to a clean tube before adding 15111 of 50 gg/m1RNase and incubating at 37°C for 30 
minutes. Protein was precipitated by the addition of 500g1 of sodium perchlorate 
solution and the samples mixed by inversion. Two ml of chloroform was added and 
mixed by inversion before the addition of 300111 of Nucleon resin without remixing the 
phases. The samples were centrifuged at 1300g for 3 minutes. The upper phase was 
transferred to a clean tube and 2 volumes of cold absolute ethanol added. The sample 
was mixed by inversion until the precipitate appeared, followed by centrifuging at 
4000g for 5 minutes. The supernatant was discarded. The pellet was washed with cold 
70% ethanol and centrifuged again at 4000g for 5 minutes. The pellets were air dried 
and resuspended in 100g1 of TE buffer. DNA was stored in screw-capped tubes at 4°C. 
Typical yields were 180 to 350gg of DNA per 10m1 of blood. 
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3.1.2 DNA extraction from whole blood - salting out method 
This method was used for blood samples that has been stored for 5 years or more, or 
samples producing low yields with the resin method (3.1.1). Any frozen blood samples 
were thawed on ice. 10m1 of whole blood was transferred to a 50m1 tube and 35m1 lysis 
buffer [10mM Tris-HC1 (pH 7.5); 400mM NaCI; 2mM EDTA (pH 8.0)] added. The 
sample was inverted several times, cooled on ice for 15 minutes then centrifuged at 
1300g for 10 minutes. The supernatant was then discarded and another 30m1 of lysis 
buffer added. The red-white nuclei pellet was disrupted by inversion of the sample and 
kept on ice for 15 minutes. The sample was then centrifuged at 1300g for 10 minutes 
and the supernatant discarded. The nuclei pellet was placed on ice and 3m1 of lysis 
buffer added. The sample was shaken but not fully resuspended, removed from the ice 
and 400p.1 of 10% SDS and 65111 of 20mg/rnlproteinase K (Sigma-Aldrich) added. The 
pellet was digested at 50°C for a minimum 4 hours and 1.5m1 of saturated NaC1 [6M; 
Millipore filtered] added, followed by vigorous shaking for 15 seconds. The sample 
was then centrifuged at 1300g for 15 minutes. The supernatant was transferred to a 
fresh 50m1 tube avoiding transfer of any salt contamination and 10m1 of cold 100% 
ethanol added to the sample. The sample was swirled gently and precipitated DNA 
transferred by pipette to an Eppendorf tube containing lml of cold 70% ethanol. The 
sample was spun in a microcentrifuge at 15,000g for 5 minutes. The supernatant was 
gently discarded and lml of cold 70% ethanol added to the pellet. The sample was 
again centrifuged at 15,000g for 5 minutes, the ethanol removed and the pellet allowed 
to air dry. The DNA pellet was resuspended slowly overnight in 1251x1TE buffer 
[10mM Tris-HC1; 1mM Na2EDTA (pH 8.0)]. DNA was stored in screw-capped tubes 
at 4°C. Typical yields were 50 to 150gg of DNA per 10m1 of blood. 
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3.1.3 DNA extraction from buccal mucosa swabs 
DNA was extracted from the buccal mucosa swabs using the PureGene DNA isolation 
kit (Gentra Systems). All reagents were supplied in the kit unless otherwise indicated. 
The buccal mucosa of participants was scraped with a cytology brush, which was then 
immersed in 300g1 of cell lysis solution in a screw-cap tube. Brushes were transported 
in this state then stored at 4°C until required for extraction. Samples were incubated 
overnight at 55°C with 1.5d of 20 mg/ml Proteinase K (Sigma-Aldrich). After cooling 
to room temperature, 1.5111 of 5 mg/ml RNaseA was added, the tube inverted several 
times to mix, and the sample incubated at 37°C for 15 minutes. The sample was again 
allowed to cool to room temperature before the addition of 100111 of Protein 
Precipitation Solution (Gentra Systems), mixing by inversion and incubation on ice for 
5 minutes. The sample was centrifuged at 15,000g for 3 minutes and the supernatant 
added to a clean tube containing 200111 of isopropanol (Sigma-Aldrich) and 0.51.t1 of 
20mg/m1 glycogen (Sigma-Aldrich). The tube was again mixed by inversion and 
incubated at room temperature for 5 minutes before centrifuging at 15,000g for 5 
minutes. The supernatant layer was then discarded and 300g1 of 70% molecular grade 
ethanol (Sigma-Aldrich) added to the pellet. The sample was again centrifuged at 
15,000g for 1 minute, the supernatant discarded and the pellet allowed to air dry. Once 
completely dry, the pellets were resuspended in 20111 of TE buffer with heating to 65°C 
for 1 hour. All DNA samples were stored in screw-capped tubes at 4°C. Typical yields 
were 10 to 20j.tg of DNA per swab. Family GTas121 (Figure 2.11) was the only GIST 
pedigree included in this study containing individuals whose genetic material was only 
available from buccal mucosa swabs (individuals 121-18 and 121-19). Buccal samples 
were occasionally provided to augment diminished stocks of DNA for other individuals 
in the study, although these swabs were generally extracted and stored to protect against 
complete exhaustion of the samples. 
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3.1.4 DNA quantitation and quality control 
For all collections, we determined the total DNA yield by measuring the A260 
absorbance and diluted aliquots for use to approximately 50pg/ml. The quality of 
genomic DNA was also ascertained by electrophoresing 1111 of 501g/mlDNA on 0.8% 
(w/v) agarose (Gibco BRL) gels in 1xTBE buffer [0.5M Tris base, 0.5M Boric acid 
10mM EDTA (pH 8.0)] with 0.3ng/m1 ethidium bromide. Samples were 
electrophoresed at 80 volts for 45 minutes and photographed under 100% UV light 
(Figure 3.1). High molecular weight smears are visible in lanes 2 to 9 (containing lul of 
50p.g/m1 DNA), and the bulk of product is generally larger than 500bp (Figure 3.1). 
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Figure 3.1 - Visualisation of genomic DNA by agarose gel electrophoresis 
Electrophoresis of genomic DNA samples on a 0.8% agarose gel stained with ethidium 
bromide and photographed under 100% UV light. Lane 1 contains a 100bp ladder 
(Promega). Lanes 2-9 contain liAl of 5011g/m1 genomic DNA samples from individuals 
35-08 to 35-15. 
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3.2 General PCR conditions 
All PCR reactions were conducted using Corbett Research 960C cooled thermal cyclers, 
unless otherwise noted. 10x PCR buffer was prepared, containing 100mM Tris HC1, 
500mM KC1, and variable concentrations of MgC12 (see below). PCR reactions were 
carried out in a total volume of either 10 or 30111 and contained between 1.0 and 3.5mM 
final Mg2+ concentration, 0.2mM dNTP (Promega), 0.81.IM of each primer and 0.005 
U/1.11 Tag DNA polymerase (Qiagen). Reactions underwent 30 cycles of denaturing at 
94°C for 30 seconds, primer pair specific annealing temperature for 30 seconds and 
extension at 72°C for 30 seconds followed by a final extension at 72°C for 15 minutes. 
Annealing temperatures and optimal Mg2+ concentrations were deterrnined empirically 
for each primer pair by cycling over a range of temperatures and Mg 2+ concentrations in 
a PC-690G gradient thermal cycler (Corbett Research) and assessment of the optimal 
conditions made by visualisation on 1.5% agarose gels containing 0.3ng/m1 ethidium 
bromide. Actual primer conditions and temperatures are listed in Appendix 2. Results 
of a typical microsatellite optimisation experiment are shown in Figure 3.2; whereby 
optimum conditions for marker D 1 OS1713 were determined to be a magnesium 
concentration of 1.5mM with an annealing temperature between 53 and 58°C, with 
55°C used for amplification of DNA from study subjects for analyses in Chapter 4. 
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Figure 3.2 - Gradient Optimisation of the Primer Pair for marker D10S1713 
Electrophoresis of optimisation PCR samples for marker D I 0S1713 on a 1.5% agarose gel stained with 
ethidium bromide and photographed under 100% UV light. Lanes 1 to 8 contain optimisation samples with 
a magnesium concentration of 1.5mM and graduate in temperature from 53°C (lane 1) to 60°C (lane 8) in 1 
degree increments. Lanes 10 to 17 contain optimisation samples with a magnesium concentration of 2.0mM 
and graduate in temperature from 53°C (lane 10) to 60°C (lane 17) in 1 degree increments. Lanes 19 to 26 
contain optimisation samples with a magnesium concentration of 2.5mM and graduate in temperature from 
53°C (lane 19) to 60°C (lane 26) in 1 degree increments. Lanes 9 and 18 contain 100bp ladder (Promega) 
sizing reference. The sizes of the expected alleles for microsatellite repeat Dl OS 1713 are between 245 and 
255bp. 
3.3 Whole genome amplification by Primer Extension Preamplification 
Primer Extension Preamplification (PEP), a PCR-based technique of whole genome 
amplification originally developed by Zhang etal. (1992), was modified and used to 
provide sufficient DNA for multiple PCR-based analyses from buccal mucosa swabs or 
diminished blood samples. Each reaction contained 5Ong genomic DNA, 2.0mM 
Mg2+, 0.2mM dNTP (Promega), 20pmol/plpolyN 15mer primer (Operon technologies) 
and 5U Taq DNA polymerase (Qiagen). Reactions underwent 50 cycles of 94°C for 1 
minute, 37°C for 2 minutes and 55°C for 4 minutes followed by a final extension of 
72°C for 10 minutes. Products were electrophoresed on 1% agarose gels containing 
0.3ng/m1 ethidium bromide to confirm the presence of high molecular weight product 
(Figure 3.3). High molecular weight smears are visible in lanes 2 to 15 of Figure 3.3, 
showing that most of the PEP product is greater than 500bp, although a large proportion 
of the product is smaller that the genomic DNA samples shown in Figure 3.1. PEP 
DNA samples were diluted 1:8 with distilled water for use in PCR. 
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Figure 3.3 - Agarose gel electrophoresis visualisation of DNA amplified by Primer 
Extension Preamplification (PEP) 
Electrophoresis of PEP product on a 1% agarose gel stained with ethidium bromide and 
photographed under 100% UV light. Lane 1 contains the 100bp ladder (Promega) size 
reference. Lanes 2 to 15 contain 51.11 of LNH control samples amplified by the Primer 
Extension Preamplification protocol. 
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3.4 Fluorescent genotyping of microsatellites 
The forward PCR primer for each marker was labeled at the 5' end with either 6-FAM 
or HEX (Sigma-Aldrich). PCR reactions were carried out in 10t.il reaction volumes as 
described in 3.3, with the following exception. Fragments labeled with 6-FAM 
underwent 25 amplification cycles, while those with HEX underwent 35 cycles. The 
optimum primer annealing temperature and magnesium concentration for each marker 
was determined according to section 3.2. One microlitre of each PCR reaction was 
pooled into an 81.11 final volume, with between 5 and 8 markers per pool, with a 
minimum of 20bp between the maximum and minimum expected allele sizes of markers 
labeled with the same dye. Primer sequence, pool and fluorescent label information is 
provided in Appendix 2. Pooled samples were electrophoresed using an ABI PRISM 
310 Genetic Analyzer (Applied Biosystems) with POP4 polymer (Applied Biosystems). 
Data were analysed with Genescan® (version 3.7) and Genotyper®  (version 3.7) 
software (Applied Biosystems). Example electropherograms from pedigree GTas03 are 
shown in Figure 3.4. 
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03-14 
03-16 
03-10 
03-17 
Figure 3.4 - Genotyping Data for 6-FAM labeled marker D10S1713 
The four panels represent electropherograms generated by genotyping D1OS1713 and 
electrophoresed using an ABI PRISM 310 Genetic Analyzer (Applied Biosystems). 
Individual ID numbers are shown in the top right of each trace. The electropherogram 
peaks have been labeled with their representative size in base pairs. Individual 03-14 is 
homozygous for the 251bp allele. 
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3.5 DNA sequencing 
Amplified fragments for sequencing were PCR amplified in 30111 volumes, purified with 
Ultra Clean PCR clean up kit spin columns (MoBio) and cycle sequenced with Big Dye 
Terminator Ready Reaction Mix (Applied Biosystems) over 25 cycles. Products were 
precipitated with 2[1.1 of 3M sodium acetate (pH 4.2) and 50g1 of 100% molecular grade 
ethanol (Sigma-Aldrich). Following a 15 minute incubation at room temperature, 
samples were centrifuged at 13,000rpm for 20 minutes. The supernatant was discarded 
and the pellet washed with 200111 of 70% molecular grade ethanol. Samples were then 
centrifuged at 13,000rpm for 5 minutes and the supernatant discarded. The pellet was 
dried by a one minute incubation at 95°C with the lid open and was resuspended in 15g1 
of Template Suppression Reagent (Applied Biosystems). Samples were electrophoresed 
on an ABI PRISM 310 Genetic Analyzer (Applied Biosystems) with POP6 polymer 
(Applied Biosystems). Data were analysed using Sequence Analysis® (Applied 
Biosystems) and Sequencher0 (GeneCodes) software. 
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Chapter 4 — Investigating the Known POAG loci GLC1A-F in 10 
Extended Pedigrees from the Glaucoma Inheritance Study in Tasmania 
4.1 Background 
Only the first six named POAG loci (GLC 1A-F) and the studies involved in their 
detection and replication are considered in this dissertation. The loci GLC1G (Monemi 
et al. 2005) and GLCII (Allingham et al. 2005) as well as the genes OPTN (Rezaie et 
al. 2002) at GLCIE and WDR36 (Monetni et al. 2005) at GLC1G were identified after 
completion of the initial linkage analysis phase of this investigation. 
Since the analysis phase of this investigation was initiated prior to the identification of 
OPTN as the gene at GLC1E (Rezaie et al. 2002), markers were selected within the 
GLC1E locus for linkage analysis, rather than mutation screening of the OPTN gene. 
Following the identification of OPTN we decided to continue with the linkage analysis 
and consider mutation screening of the OPTN gene in pedigrees showing linkage to the 
GLC1E region on chromosome 10p15-p14. OPTN consists of three non-coding and 13 
translated exons, hence initial linkage analysis of the region may also be a more 
economic (although less powerful) screening method. 
As mentioned in Chapter 1.3.1, the lack of consistency in the clinical definition of 
POAG in published studies may have contributed to the lack of success in gene 
identification and replication studies. There is no universally accepted definition of this 
phenotypically complex and subtle disease (Kahn and Milton 1980; Wolfs et al. 2000; 
Kroese and Burton 2003), and there is still much debate as to an appropriate definition 
of POAG diagnosis to be used by published studies (Bathija etal. 1998; Foster etal. 
2002; Kroese and Burton 2003). 
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In the original identification of GLC1B (Stoilova et al. 1996), GLC1C (Wirtz et al. 
1997), and GLC1D (Trifan etal. 1998), POAG affection status was based on the 
presence of at least two of the triad of key clinical features: raised IOP, characteristic 
visual field loss and characteristic optic disc abnormalities. In the case of GLC1E 
(Sarfarazi etal. 1998), and GLC1F (Wirtz etal. 1999), IOP was not a major 
consideration in the classification of affection status, contributing only as an auxiliary 
measure to visual field defects and vertical cup-to-disc ratio. 
The 10 extended pedigrees selected from the GIST for use in this study compare 
favourably with pedigrees used in previous studies to localise the named POAG loci. 
Only the original GLC1B study (Stoilova et al. 1996) used a dataset containing multiple 
POAG pedigrees. The remaining studies were based on single, large POAG pedigrees. 
In the identification of GLC1C Wirtz et al. (1997) used a single 76 member pedigree 
from North America containing 44 available individuals, including nine affected 
individuals. This linkage was confirmed in a Greek family of 34 individuals, including 
10 affected individuals (Kitsos et al. 2001). Similarly, Trifan et al. (1998) used a single 
23 member North American family spanning four generations, 20 of whom were 
available and eight affected with POAG in the identification of GLC1D. The fifth 
POAG locus (GLC1E) was identified in a family of 60 individuals over four 
generations, 46 of whom were available to participate in the study including 15 
classified as affected (Sarfarazi et al. 1998). GLC1F was identified in a 36 person 
family including 25 individuals who were available to participate in the study, 10 of 
whom were affected with POAG (Wirtz et al. 1999). Stoilova et al. (1996) used 17 
Caucasian families, including 203 subjects and 90 affecteds, in their initial identification 
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of GLC1B. The pedigrees consisted of at least two to three affected offspring and one 
available parent. While several of the pedigrees in the current study (described in 
Chapter 2) are smaller than those in the aforementioned datasets, pedigrees such as 
GTas03 and GTas37b are equivalent in size to previous studies of POAG genetics, and 
the collection as a whole is more substantial. 
The POAG loci GLC I A-F were originally identified using two-point and/or multipoint 
parametric linkage analysis (Sheffield et al. 1993; Stoilova et al. 1996; Wirtz et al. 
1997; Sarfarazi etal. 1998; Trifan etal. 1998; Wirtz etal. 1999). While not all studies 
provided full details of the parametric model used (for example Stoilova etal. 1996), 
the majority of studies assumed autosomal dominant inheritance, with a disease gene 
frequency of 0.0001. In most cases complete penetrance was assumed, although Wirtz 
etal. (1997) used an age-dependent penetrance for GLC1C, and the same group used a 
fixed penetrance of 0.75 for the detection of GLC1F (Wirtz etal. 1999). The data 
available suggests most studies did not include phenocopies in the model, although a 
phenocopy rate of 2% was employed in the study where GLC IF was identified (Wirtz et 
al. 1999). The GLC1C replication study of Kitsos etal. (2001) used an initial 
penetrance of 0.75, and then examined the effect on the peak LOD of varying the 
penetrance between 0.6 and 0.8. Most of these studies appeared to use equal allele 
frequencies rather than population generated frequencies. The two-point parametric 
linkage results from the original identification of the known POAG loci are shown in 
Table 4.1. The decreased LOD scores obtained by affected only analysis are also 
shown. 
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Locus Maximum LOD Marker 
Max. LOD 
affected only Reference 
GLC1A 
GLCIB 
GLC1C 
GLCID 
GLCIE 
GLC1F 
6.50 
6.48 
3.02 
3.61 
10.0 
4.01 
D1S212 
D2S113 
D3S1535 
D8S1471 
D10S1216 
D7S2439 
Not assessed 
3.40* 
2.12 
Not shown 
3.43 
2.96 
Sheffield etal. 1993 
Stoilova et al. 1996 
Wirtz etal. 1997 
Sarfarazi et al. 1998 
Trifan et al. 1998 
Wirtz etal. 1999 
Table 4.1 - Two-point parametric linkage results from the original identification of 
the POAG loci GLC1A-F 
* Affected only peak LOD was distal to the original peak, at marker D2S373. 
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4.2 Aims 
The aims of this study were: to genotype the 10 extended POAG pedigrees from the 
GIST (described in Chapter 2) with microsatellite markers at the previously identified 
loci GLC1A-F, at an average marker spacing of 3 to 4 cM; extract comprehensive allele 
frequency information from a similar control population source; check the dataset for 
genotyping errors; and use Markov chain Monte Carlo (MCMC) estimation based 
parametric and nonparametric linkage analyses as a first pass approach to identify any 
pedigrees showing suggestive linkage to any of the known POAG loci. Families 
showing suggestive results in these initial analyses were to be retained for additional 
genotyping and follow-up analysis (described in Chapter 5). 
A secondary aim was to utilise exact parametric and nonparametric linkage analyses, 
based on previously published investigations into the genetic contribution to POAG, 
with the remaining dataset. The dataset for this secondary aim was to be derived from 
pedigrees exhibiting regions of interest from the initial MCMC based analyses, 
excluding those selected for the additional genotyping and follow-up analyses described 
in Chapter 5. 
4.3 General Methods 
4.3.1 Microsatellite marker selection 
Microsatellite markers were selected to cover the six known regions of linkage to 
POAG, GLC 1 A-F (Sheffield et al. 1993; Stoilova etal. 1996; Wirtz et al. 1997; 
Sarfarazi etal. 1998; Trifan etal. 1998; Wirtz et al. 1999). As this project was initiated 
prior to the online release of the Human Genome Project sequence maps (Lander et al. 
2001), gene and marker maps from the 1996 Genetic Location Database (Collins et al. 
-1996) were used for marker selection. Heterogeneity information from the Genome 
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Database (http://www.gdb.org/), availability of typed genotyping controls from the 
Centre d'Etude du Polymorphisme Humain (http://www.cephb.fr/cephdb),  marker 
location and spacing were used to weight marker choice. 
The final set of markers used to investigate linkage to the known POAG loci GLC1A-F 
are shown in Table 4.2. The table shows the POAG locus and chromosomal region, as 
well as marker location and heterozygosity. A total of 25 markers were selected, at an 
approximate density of one marker per 4 cM for each region. 
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Locus Region Marker Distance (cM)* Heterozygosityt 
GLC1A 1q21-q31 DI S2635 176.5 0.87 
D1S2707 181.3 0.82 
D1S2675 182.0 0.73 
GLC1B 2cen-q13 D2S2161 97.3 0.77 
D2S113 99.0 0.77 
D2S2264 102.6 0.77 
D2S1897 105.8 0.89 
D2S1892 107.8 0.80 
GLC1C 3q21-q24 D3S3637 146.4 0.90 
D3S1301 151.7 0.77 
D3S3694 153.5 0.84 
D3S1569 158.1 0.80 
D3S1608 160.3 0.61 
GLC1D 8q23 D8S1749 113.0 0.74 
D8S556 120.4 0.80 
D8S198 133.1 0.83 
GLC1E 10p15-p14 DI0S1729 3.6 0.72 
D10S1713 6.7 0.60 
D10S1691 9.3 0.67 
DI0S547 12.6 0.74 
DI0S1664 16.1 0.75 
GLC1F 7q35-q36 D7S2511 158.1 0.79 
D7S505 160.3 0.69 
D7S2439 163.0 0.80 
D7S2546 166.9 0.75 
Table 4.2 - The 25 microsatellite markers used to investigate linkage to the known 
POAG loci GLC1A-F 
*Marker location in centiMorgans, based on the 1996 Genetic Location Database 
(Collins et al. 1996). 
t Heterozygosity based on CEPH data (http://www.cephb.fr/cephdb).  
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43.2 Genotyping methods 
The PCR conditions for each of the microsatellite markers were optimised as described 
in Chapter 3.2. The final collection of 237 individuals from 10 extended pedigrees was 
genotyped with the 25 selected microsatellite markers, using the methods described in 
Chapter 3.4. Forward primers were labelled with fluorescent dyes and organised into 
four pools for optimum analysis on the ABI310 Genetic Analyzer (Applied 
Biosystems), as shown in Appendix 2. DNAs from CEPH families 884 and 1331 
(http://www.cephblecephdb ) were genotyped as allele sizing controls. 
4.33 Genotype error checking 
Mendelian inconsistent genotyping errors were detected using PedCheck version 1.1 
(O'Connell and Weeks 1998) at levels 1-4. Level 1 detects inconsistencies between 
parent child relationships, such as allele incompatibility or more than 4 alleles in a 
sibship. Level 2 uses genotype elimination to detect inconsistencies across wider 
pedigree relationships and multiple generations. Level 3 identifies critical erroneous 
genotypes by sequentially untyping individuals. Level 4 uses an odds-ratio algorithm to 
pinpoint the most likely source of error (O'Connell and Weeks 1998). In general, most 
errors were detected at level 1; and level 4 was rarely employed since level 3 checking 
often returned only one critical genotype. Genotypes flagged by these inheritance 
checks were double checked and rescored (blind) by a second individual. Any 
remaining discrepancies were flagged and the genotyping repeated. Any unresolved 
errors following repeat genotyping were removed from the dataset and the error 
checking program rerun with the updated data until no more errors were detected. 
The mistyping analysis component of SimWalla version 2.86 (Sobel and Lange 1996) 
was used to identify possible Mendelian consistent genotyping errors and unlikely 
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double-recombinants (Sobel et al. 2002). SimWalla determines the posterior mistyping 
probability for each allele based on the marker map and an a priori error model. In this 
study the empirical error model (Sobel et al. 2002) was used to flag possible problem 
genotypes. This model incorporates common errors such as false homozygosity and 
recognises that mistyping of one allele is more common than two. The empirical model 
is comprised of five default error rates: (c1) 0.0125 for false homozygosity; (c2) 0.0075 
for misreading one allele; (c3) 0.005 for misreading both alleles; (c4) 0.01 for 
misreading a homozygote as a heterozygote; and (c 5) 0.0025 for random mistyping; 
which translates to an overall error rate of 0.0175 (e3+ c4 + c5) for a true homozygous 
genotype and to 0.0275 (c1+ c2+ c3+ c 5) for a true heterozygous genotype (Sobel et al. 
2002). The program output consists of the sample identification number, marker name, 
and the genotype purported to be erroneous, along with the probability of mistyping for 
the first, second, both, and either allele(s) when any probability is greater than a chosen 
significance threshold. In this study a stringent significance threshold of 0.25 for the 
probability of mistyping was used to flag potentially erroneous data. 
As with Mendelian inconsistent errors, genotypes were double checked and rescored 
blind by a second individual, and only altered where errors were obvious on reanalysis 
of the data. For example, where repeat genotyping revealed a case of false 
homozygosity due to allele dropout in the initial sample, data was updated to include 
both alleles. Any remaining errors, discrepancies or areas of uncertainty were removed 
from the dataset. 
In the case of all genotypes flagged as potentially erroneous, the data were never 
changed based only on statistical inference, but always on regenotyping. 
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4.3.4 Allele frequency generation 
Marker allele frequencies for linkage analysis were derived from a set of 72 elderly 
glaucoma-free individuals (described in Chapter 2.2.4) genotyped with each of the 25 
selected microsatellite markers. 
4.3.5 Data storage and file generation 
All individual, family, genotype, phenotype and genetic map data were stored in a 
dedicated database program developed by Tim Albion (Menzies Research Institute, 
unpublished). This program not only provided data storage and an interface for data 
manipulation, but also could be interrogated to produce input files for various software 
packages. The linkage utility program MEGA2 (Mulchopadhyay et al. 2005b) was also 
used to generate program specific input files for the majority of the analysis programs 
used in this dissertation. 
4.4 Statistical methods 
4.4.1 Maximum LOD simulation analyses 
Linkage simulations were conducted using FASTSLINK (Ott 1989; Weeks etal. 1990), 
to provide a sense of the power of each pedigree to produce a significant or suggestive 
LOD score. Simulations were conducted using a marker with 6 alleles: one common 
(frequency=0.299), four less common (frequency=0.175) and one rare allele 
(frequency =0.001). For each pedigree, 1000 simulations were conducted assuming 90% 
penetrance, a 2% phenocopy rate and a disease allele frequency of 0.0001. Simulated 
genotypic data was analysed using the MSIM component of FAST SLINK to 
approximate the expected maximum LOD score. 
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Several of the pedigrees contained both marriage and inbreeding loops (described in 
Chapter 2.3.4), all of which were broken using the LINKAGE utility program 
MAKEPED (Lathrop and Lalouel 1984; Lathrop etal. 1984; Lathrop etal. 1986) by 
duplicating a selected individual with both parents and children in the pedigree. 
4.4.2 Markov chain Monte Carlo algorithm for inheritance information extraction 
A Markov chain Monte Carlo (MCMC) algorithm based approach was employed to 
obtain multipoint inheritance information from the entire dataset, using SimWalla 
version 2.86-2.91 (Sobel and Lange 1996). Starting with an estimate of the most likely 
genetic descent graph (the path of gene flow within a pedigree) as the initial position, 
SimWalla uses the MCMC algorithm to traverse the space of genetic descent graphs 
consistent with the available data for each pedigree, using the Metropolis acceptance 
criterion (Metropolis etal. 1953) to move to the next configuration (Sobel and Lange 
1996). During this process, the MCMC 'random walk' samples the configurations in 
proportion to their likelihood, given the available genotype data. A sample average is 
then used to provide estimated results for the original pedigree (Sobel and Lange 1996). 
It is important to note that this is an estimation based method, as configurations that are 
possible, but highly unlikely, will not be sampled. It is also important to note that this 
method is able to extract multipoint inheritance information from the entire pedigree, 
including even the largest of the GIST pedigrees, without trimming the pedigree or 
analysing markers individually. This inheritance information can be used for a range of 
analysis purposes, including parametric linkage analysis (determining if the inheritance 
pattern fits a specific model for a trait causing gene) or nonparametric linkage analyses 
(determining whether the inheritance information deviates from the expectation under 
independent assortment). These two analysis approaches were applied, as described 
below. 
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4.4.3 MCMC based nonparametrie linkage analysis 
Nonparametric linkage analysis was conducted using the MCMC based estimation 
method employed in SimWalk2 version 2.86-2.91 (Sobel and Lange 1996). While 
intrinsically estimation based, this method increases the power of the clustering 
statistics by using information from all genotyped individuals, unaffected as well as 
affected, to sample the identity by descent (IBD) configurations proportional to their 
likelihood. Alleles are identical by descent if they are copies of the same ancestral 
allele, thus IBD configurations are a measure of the sharing of genetic material. The 
nonparametric statistics D and E were evaluated for all pedigrees and for the combined 
dataset. Statistic D calculates the extent of allele sharing among affected relative pairs 
(Sobel and Lange 1996) and is similar to the NPLpairs statistic used in GeneHunter and 
Merlin (Whittemore and Halpern 1994; Kruglyak et al. 1996), while statistic E, 
equivalent to NPLan , measures the degree of allele sharing in all subsets of affected 
individuals at once (Whittemore and Halpern 1994; Kruglyak et al. 1996). SimWalk2 
uses gene-dropping to calculate empirical p-values for each statistic by comparing the 
observed value of the statistic to that found under the null hypothesis, which is 
generated by repeated sampling of fully informative marker data simulated with a gene-
dropping algorithm, without linkage to the phenotype. In the absence of complete IBD-
inheritance information, for example when individuals in the pedigree are unavailable 
for genotyping, the p-values from this procedure are potentially conservative (Sobel and 
Lange 1996), possibly understating the statistical significance. Approximate MCMC 
inference of IBD probabilities may also be more conservative than exact Lander-Green 
inference, further understating the significance. 
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4.4.4 MCMC based parametric linkage analysis 
Multipoint parametric linkage analysis was conducted using the MCMC estimation 
based approach employed in SimWalk2 version 2.86-2.91 (Sobel and Lange 1996). 
SimWallc2 utilises the method of location scores to indicate the likelihood of the trait 
loci at various locations within the marker map. Location scores indicate the relative 
likelihood of several positions among the marker loci for the trait locus, given the 
pedigree data and the marker map. These pedigrees are then used to estimate the 
location score curve for the original pedigree. The location scores are directly 
comparable to multipoint LOD scores and are presented in logo units. 
The initial model used was based on previous studies of POAG genetics (Sheffield et al. 
1993; Stoilova etal. 1996; Sarfarazi etal. 1998; Trifan etal. 1998), including an 
assumption of autosomal dominant inheritance, a disease gene frequency of 0.0001, 
penetrance of 0.9 and a 2% phenocopy rate. An alternative low penetrance model 
(0.75) was also included, based on the studies of Wirtz et al. (1999) and Kitsos etal. 
(2001). 
Given the variable late age of onset, combined with the complexities of defining 
affection status for POAG, all parametric analyses were affected only, where all 
individuals were scored as either affected or unIcnown for the purposes of the analysis. 
This approach is far more conservative than including trait information from unaffected 
individuals, but prevents errors due to misclassification of affection status. 
4.4.5 Haplatype analysis 
The most likely haplotypes for regions of interest within the GIST pedigree dataset, 
including information from individuals classed as POAG status unknown, were 
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estimated using the haplotyping component of SimWallc2 version 2.86-2.91 (Sobel and 
Lange 1996). SimWalk2 employs the MCMC algorithm combined with simulated 
annealing to determine the most likely haplotype configuration for each pedigree. A 
slight modification to the criteria for moving between configurations during the MCMC 
random walk produces the simulated annealing procedure, which samples from the 
configuration space in search of the single most likely configuration (Sobel and Lange 
1996). The process was repeated (up to eight times) with different random seeds until a 
stable configuration was obtained. 
Haplotypes were displayed using Pedigree/Draw 5.1 (SFBR; 
http://wwvv.sfbr.org/sfbr/public/software/pedraw/peddrw.html  now available from 
http://www.pedigree-draw.com). The size and complexity of the GIST pedigrees, 
combined with a lack of complete information (due to deceased linking individuals and 
unascertained spouses) complicated the haplotype reconstruction process by reducing 
the phase information. As a result, the final haplotype output must be considered the 
most likely configuration, but not necessarily an exact result. 
4.4.6 Sekction of pedigrees for follow-up analysis 
Pedigrees displaying 'interesting' results in the SimWalla nonparametric and 
parametric analyses were considered for follow-up analysis including additional 
genotyping within the region of interest. The criteria for consideration was a p-value 
for a nonparametric statistic of less than 0.1 combined with a location score of at least 
1.0 within the same pedigree and region of interest. Depending on the number of results 
flagged as interesting, not all pedigrees fulfilling the criteria for consideration would 
necessarily be accepted for follow-up analysis. 
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4.4.7 Exact nonparametric linkage analysis of selected pedigrees 
Exact nonparametric linkage analyses were conducted on select pedigrees and regions 
of interest using GeneHunter-Plus version 1.2 (Kruglyak et al. 1996; Kong and Cox 
1997). This analysis is an affecteds-only approach based on the Lander-Green 
algorithm (Lander and Green 1987), which is restricted by pedigree size. GeneHunter 
can analyse a maximum pedigree size of 20 bits (2n-f 5_ 20; where n=number of 
founders, f=number of non-founders); hence pedigrees were manually trimmed to 20 
bits prior to analysis. Pedigrees were analysed individually, due to the expectation of 
high genetic heterogeneity across the dataset, using the NPLan statistic (Whittemore and 
Halpern 1994). 
4.4.8 Exact two-point parametric linkage analysis of selected pedigrees 
Exact two-point parametric analyses were conducted only on regions of interest in select 
pedigrees using FASTLINK (Cottingham etal. 1993; Schaffer et al. 1994), a modified 
version of LINKAGE (Lathrop and Lalouel 1984; Lathrop etal. 1984; Lathrop etal. 
1986). As in section 4.4.4, the initial model including an assumption of autosomal 
dominant inheritance, a disease gene frequency of 0.0001, penetrance of 0.9 and a 2% 
phenocopy rate, with an alternative 0.75 penetrance model included also. All 
FASTLINK parametric analyses were also affected only, where all individuals were 
scored as either affected or unknown for the purposes of the analysis. This analysis 
method is the most similar to the methodology used in previous studies of POAG loci 
(Sheffield etal. 1993; Stoilova etal. 1996; Wirtz etal. 1997; Sarfarazi etal. 1998; 
Trifan et al. 1998; Wirtz etal. 1999). 
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4.5 Results 
4.5.1 Maximum LOD simulation 
The linkage simulation results are shown in Table 4.3. The maximum and average LOD 
scores simulated under the model of one marker with six alleles, including one common 
and one rare allele, are shown along with the percentage of the total simulated LOD 
scores greater than 1, 2 and 3. Seven of the families produced maximum simulated 
LOD scores greater than 3, with the largest at 4.17 for family GTas37b. The smallest 
family (GTas11) produced a simulated maximum LOD of 1.19, and while not large 
enough to enable the identification of significant linkage alone, this family was retained 
as a valuable component of the overall dataset. The subdivided pedigrees GTas3a and 
GTas3b are included in Table 4.3 and shown in italics. These pedigrees were analysed 
in place of GTas03 when required. 
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Family ID 
Total 
individuals 
Available 
individuals 
Affected 
individuals 
Max 
LOD 
Average 
LOD % > 1 % >2 % >3 
GTas03# 123 59 15 5.88 2.38 86.5 62.5 30.0 
Gras03a 76 39 9 3.73 1.42 61.0 27.5 5.5 
GTas03b# 41 19 6 1.86 0.66 26.5 0.0 0.0 
GTas04# 45 25 9 2.59 0.99 49.0 8.5 0.0 
GTas35 32 15 6 1.71 0.73 40.0 0.0 0.0 
GTas37a 51 29 8 3.29 1.22 56.0 20.0 1.5 
GTas37b# 37 24 15 4.17 1.73 71.5 38.5 10.5 
GTas54 33 17 7 3.75 1.13 53.5 16.5 1.0 
GTas11 15 10 5 1.19 0.59 29.0 0.0 0.0 
GTas15 31 14 6 3.14 1.12 50.0 16.0 0.5 
GTas17 45 26 9 3.34 1.26 57.0 17.0 1.0 
GTas121 45 18 7 2.57 0.98 47.0 6.0 0.0 
Table 4.3 - Maximum LOD simulations for the GIST pedigrees 
# indicates the pedigree has had at least one loop broken prior to simulation analyses. 
Italics: subdivided pedigrees GTas03a and GTas03b, branches of family GTas03 
Bold: LOD>3 
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4.5.2 Genotype error checking 
Mendelian inconsistent genotyping errors were detected at a frequency of 2.6% in the 
first pass of genotyping (157 genotypes), and at approximately 0.8% during the repeat 
genotyping process (seven genotypes). 
Possible Mendelian consistent errors were flagged by SimWallc2 in approximately 3% 
of genotypes (181 samples), and approximately a third of these (63) were considered 
true errors following repeat genotyping and scoring (overall Mendelian consistent error 
rate of 1.1%). The high level of flagged errors was due to the stringent significance 
threshold used (0.25) which required more genotypes be checked than the default 
threshold of 0.5. 
4.5.3 MCMC based nonparametric linkage analysis 
The SimWalla nonparametric linkage analysis results for each of the investigated 
POAG loci GLC1A-F, including the value for the statistics D and E and corresponding 
empirical p-values, are shown in Tables 4.4 to 4.9. Nonparametric linkage statistics and 
p-values are also given for the combined dataset. Empirical p-values less than or equal 
to 0.1 were highlighted for follow-up consideration. 
There were 5 pedigrees/regions highlighted for potential follow-up in the initial 
nonparametric linkage analysis. Family GTas15 produced p-values between 0.05 and 
0.07 for the last three markers on chromosome 2 (D2S2264 to D2S1892) with a peak 
value of 1.13 (p=0.05) for Statistic E at marker D2S1897 (Table 4.5). Families GTas03 
and GTas11 both produced interesting results for markers D3S3694 to D3S1608 on 
chromosome 3, with peak scores of 1.54 (p=0.03) for Statistic E at marker D3S3694 for 
family GTas03 and 1.35 (p=0.04) for Statistic E also at marker D3S3694 for family 
GTas11 (Table 4.6). GTas121 also showed some interesting signs of linkage to 
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chromosome 3, at the two most distal markers D3S 1569 and D3S 1608 with a peak score 
of 1.39 (p=0.04) with Statistic E at marker D3S1569 (Table 4.6). Family GTas35 
showed signs of interesting results with both statistics on chromosome 10 at markers 
D1OS1691 to DI0S1664, with peak scores of 1.30 (p=0.05) for the distal markers 
D 10S547 and DIOS1664 with Statistic D (Table 4.8). There were no highlighted 
nonparametric linkage results for the investigated regions of interest on chromosomes 1 
(GLC1A; Table 4.4), chromosome 8 (GLC1D; Table 4.7) and chromosome 7 (GLC1F; 
Table 4.9) with this set of 10 pedigrees from the GIST. 
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Family ID Marker Haldane cM Statistic D p-value Statistic E p-value 
All D1S2635 0.00 0.08 0.84 0.21 0.62 
D 1 S2707 4.95 0.02 0.95 0.08 0.83 
D1S2675 5.70 0.03 0.92 0.09 0.81 
GTas03 D1S2635 0.00 0.09 0.81 0.07 0.85 
D 1 S2707 4.95 0.07 0.86 0.05 0.90 
D1S2675 5.70 0.08 0.84 0.06 0.88 
GTas04 D1S2635 0.00 0.17 0.67 0.19 0.64 
D 1 S2707 4.95 0.17 0.68 0.19 0.65 
D1S2675 5.70 0.17 0.68 0.19 0.65 
GTas1 I D I S2635 0.00 0.64 0.23 0.71 0.20 
D1S2707 4.95 0.60 0.25 0.67 0.22 
D 1 S2675 5.70 0.59 0.26 0.65 0.23 
GTas15 D1S2635 0.00 0.20 0.63 0.26 0.54 
D 1 S2707 4.95 0.12 0.77 0.17 0.68 
D1S2675 5.70 0.13 0.75 0.17 0.67 
GTas17 D1S2635 0.00 0.26 0.55 0.27 0.53 
D 1 S2707 4.95 0.23 0.59 0.25 0.56 
D 1 S2675 5.70 0.32 0.48 0.30 0.50 
GTas35 D I S2635 0.00 0.09 0.81 0.07 0.85 
D1S2707 4.95 0.05 0.90 0.03 0.94 
D1S2675 5.70 0.07 0.85 0.05 0.89 
GTas37a D 1 S2635 0.00 0.39 0.40 0.35 0.45 
D1S2707 4.95 0.38 0.41 0.34 0.46 
D1S2675 5.70 0.39 0.41 0.34 0.45 
GTas37b D I S2635 0.00 0.25 0.56 0.26 0.56 
D 1 S2707 4.95 0.39 0.40 0.34 0.46 
D1S2675 5.70 0.31 0.49 0.26 0.55 
GTas54 D I S2635 0.00 0.20 0.64 0.22 0.61 
D1S2707 4.95 0.08 0.83 0.11 0.78 
D I S2675 5.70 0.15 0.72 0.17 0.68 
GTas121 D1S2635 0.00 0.12 0.76 0.12 0.76 
D I S2707 4.95 0.03 0.93 0.03 0.94 
D I S2675 5.70 0.04 0.91 0.04 0.92 
Table 4.4 - Simwalk2 MCMC based nonparametric linkage results for 
chromosome 1 (GLC1A) 
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Family ID Marker Haldane cM Statistic D p-value Statistic E p-value 
All D2S2161 0.00 0.29 0.52 0.31 0.50 
D2S113 1.77 0.36 0.43 0.39 0.41 
D2S2264 5.45 0.19 0.65 0.21 0.62 
D2S1897 8.76 0.24 0.58 0.32 0.48 
D2S1892 10.76 0.18 0.66 0.22 0.60 
GTas03 D2S2161 0.00 0.57 0.27 0.52 0.30 
D2S113 1.77 0.58 0.26 0.54 0.29 
D2S2264 5.45 0.50 0.32 0.49 0.32 
D2S1897 8.76 0.28 0.53 0.27 0.54 
D2S1892 10.76 0.16 0.70 0.17 0.67 
GTas04 D2S2161 0.00 0.77 0.17 0.77 0.17 
D2S113 1.77 0.80 0.16 0.80 0.16 
D2S2264 5.45 0.15 0.71 0.17 0.67 
D2S1897 8.76 0.30 0.50 0.29 0.51 
D2S1892 10.76 0.30 0.50 0.29 0.51 
GTas11 D2S2161 0.00 0.25 0.56 0.22 0.60 
D2S113 1.77 0.38 0.41 0.39 0.41 
D2S2264 5.45 0.11 0.77 0.13 0.74 
D2S1897 8.76 0.11 0.77 0.13 0.74 
D2S1892 10.76 0.04 0.91 0.04 0.91 
GTasI5 D2S2161 0.00 0.42 0.38 0.47 0.34 
D2S113 1.77 1.11 0.08 1.27 0.05 
D2S2264 5.45 1.27 0.05 1.44 0.04 
D2S1897 8.76 1.47 0.03 1.68 0.02 
D2S1892 10.76 1.26 0.06 1.40 0.04 
GTasI7 D2S2161 0.00 0.35 0.44 0.39 0.41 
D2S113 1.77 0.35 0.44 0.39 0.41 
D2S2264 5.45 0.36 0.44 0.39 0.40 
D2S1897 8.76 0.36 0.44 0.40 0.40 
D2S1892 10.76 0.36 0.44 0.39 0.41 
GTas35 D2S2161 0.00 0.06 0.86 0.04 0.91 
D2S113 1.77 0.07 0.86 0.04 0.91 
D2S2264 5.45 0.06 0.88 0.03 0.93 
D2S1897 8.76 0.06 0.87 0.03 0.94 
D2S1892 10.76 0.17 0.67 0.16 0.69 
GTas37a D2S2161 0.00 0.06 0.88 0.04 0.90 
D2S113 1.77 0.08 0.83 0.07 0.85 
D2S2264 5.45 0.50 0.31 0.47 0.34 
D2S1897 8.76 0.39 0.41 0.36 0.44 
D2S1892 10.76 0.38 0.41 0.35 0.45 
GTas37b D2S2161 0.00 0.22 0.60 0.16 0.70 
D2S113 1.77 0.21 0.62 0.14 0.72 
D2S2264 5.45 0.15 0.71 0.08 0.83 
D2S1897 8.76 0.22 0.61 0.15 0.70 
D2S1892 10.76 0.22 0.61 0.16 0.69 
GTas54 D2S2161 0.00 0.24 0.58 0.27 0.54 
D2S113 1.77 0.23 0.59 0.26 0.55 
D2S2264 5.45 0.23 0.59 0.26 0.55 
D2S1897 8.76 0.27 0.54 0.30 0.50 
D2S1892 10.76 0.27 0.53 0.30 0.51 
GTas121 D2S2161 0.00 0.18 0.66 0.19 0.65 
D2S113 1.77 0.19 0.65 0.19 0.64 
D2S2264 5.45 0.20 0.63 0.21 0.62 
D2S1897 8.76 0.35 0.44 0.35 0.44 
D2S1892 10.76 0.39 0.41 0.38 0.42 
Table 4.5 - Simwalk2 MCMC based nonparametric linkage results for 
chromosome 2 (GLC1B) 
Bold: Statistics D or E p-value5_0.1. 
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Family ID Marker Haldane cM Statistic D p-value Statistic E p-value 
All D3S3637 0.00 0.76 0.17 1.04 0.09 
D3S1301 5.54 0.48 0.33 0.92 0.12 
D3S3694 7.38 0.58 0.27 0.95 0.11 
D3S1569 12.19 0.61 0.25 0.62 0.24 
D3S1608 14.52 0.59 0.26 0.60 0.25 
GTas03 D3S3637 0.00 1.43 0.04 1.54 0.03 
D3S1301 5.54 1.07 0.09 1.10 0.08 
D3S3694 7.38 1.02 0.10 1.04 0.09 
D3S1569 12.19 0.43 0.37 0.44 0.36 
D3S1608 14.52 0.42 0.38 0.43 0.38 
GTas04 D3S3637 0.00 0.17 0.68 0.15 0.71 
D3S1301 5.54 0.23 0.59 0.19 0.64 
D3S3694 7.38 0.27 0.53 0.23 0.60 
D3S1569 12.19 0.30 0.50 0.24 0.57 
D3S1608 14.52 0.29 0.52 0.23 0.59 
GTas11 D3S3637 0.00 1.21 0.06 1.35 0.04 
D3S1301 5.54 1.09 0.08 1.24 0.06 
D3S3694 7.38 1.11 0.08 1.27 0.05 
D3S1569 12.19 0.55 0.28 0.56 0.27 
D3S1608 14.52 0.55 0.28 0.56 0.28 
GTas15 D3S3637 0.00 0.43 0.37 0.38 0.42 
D3S1301 5.54 0.24 0.58 0.21 0.62 
D3S3694 7.38 0.26 0.55 0.25 0.56 
D3S1569 12.19 0.26 0.55 0.25 0.56 
D3S1608 14.52 0.26 0.55 0.26 0.56 
GTas17 D3S3637 0.00 0.31 0.49 0.31 0.50 
D3S1301 5.54 0.35 0.44 0.34 0.46 
D3S3694 7.38 0.34 0.46 0.33 0.47 
D3S1569 12.19 0.23 0.59 0.24 0.58 
D3S1608 14.52 0.21 0.62 0.22 0.60 
GTas35 D3S3637 0.00 0.29 0.51 0.31 0.49 
D3S1301 5.54 0.12 0.76 0.13 0.75 
D3S3694 7.38 0.10 0.79 0.11 0.78 
D3S1569 12.19 0.20 0.63 0.21 0.62 
D3S1608 14.52 0.19 0.65 0.20 0.64 
GTas37a D3S3637 0.00 0.09 0.81 0.14 0.73 
D3S1301 5.54 0.07 0.86 0.08 0.84 
D3S3694 7.38 0.28 0.52 0.30 0.50 
D3S1569 12.19 0.34 0.46 0.34 0.46 
D3S1608 14.52 0.33 0.47 0.32 0.47 
GTas37b D3S3637 0.00 0.18 0.66 0.19 0.64 
D3S1301 5.54 0.06 0.87 0.12 0.77 
D3S3694 7.38 0.11 0.78 0.15 0.71 
D3S1569 12.19 0.20 0.63 0.23 0.59 
D3S1608 14.52 0.21 0.61 0.24 0.58 
GTas54 D3S3637 0.00 0.26 0.55 0.31 0.49 
D3S1301 5.54 0.55 0.28 0.63 0.23 
D3S3694 7.38 0.52 0.30 0.62 0.24 
D3S1569 12.19 0.70 0.20 0.70 0.20 
D3S1608 14.52 0.78 0.17 0.72 0.19 
GTas121 D3S3637 0.00 0.64 0.23 0.68 0.21 
D3S1301 5.54 0.65 0.22 0.70 0.20 
D3S3694 7.38 0.55 0.28 0.57 0.27 
D3S1569 12.19 1.32 0.05 1.39 0.04 
D3S1608 14.52 1.23 0.06 1.31 0.05 
Table 4.6 - SimWalk2 MCMC based nonparametric linkage results for 
chromosome 3 (GLC1C) 
Bold: Statistics D or E p-value0.1. 
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Family ID Marker Haldane cM Statistic D p-value Statistic E p-value 
All peds D8S1749 0.00 0.135 0.73 0.225 0.60 
D8S556 7.95 0.071 0.85 0.106 0.78 
D8S198 22.24 0.330 0.47 0.463 0.34 
GTas03 D8S1749 0.00 0.14 0.73 0.14 0.72 
D8S556 7.95 0.12 0.76 0.14 0.73 
D8S198 22.24 0.08 0.83 0.09 0.82 
GTas04 D8S1749 0.00 0.28 0.53 0.32 0.48 
D8S556 7.95 0.32 0.48 0.39 0.41 
D8S198 22.24 0.47 0.34 0.51 0.31 
GTas11 D8S1749 0.00 0.25 0.57 0.30 0.50 
D8S556 7.95 0.13 0.74 0.19 0.65 
D8S198 22.24 0.43 0.37 0.46 0.35 
GTas15 D8S1749 0.00 0.29 0.51 0.26 0.56 
D8S556 7.95 0.29 0.51 0.25 0.56 
D8S198 22.24 0.34 0.45 0.29 0.51 
GTas17 D8S1749 0.00 0.30 0.51 0.30 0.50 
D8S556 7.95 0.22 0.60 0.22 0.60 
D8S198 22.24 0.26 0.55 0.26 0.55 
GTas35 D8S1749 0.00 0.49 0.33 0.46 0.35 
D8S556 7.95 0.37 0.42 0.36 0.44 
D8S198 22.24 0.33 0.47 0.32 0.48 
GTas37a D8S1749 0.00 0.12 0.76 0.11 0.77 
D8S556 7.95 0.05 0.89 0.05 0.90 
D8S198 22.24 0.25 0.56 0.27 0.54 
GTas37b D8S1749 0.00 0.37 0.43 0.42 0.38 
D8S556 7.95 0.39 0.41 0.45 0.35 
D8S198 22.24 0.43 0.37 0.49 0.32 
GTas54 D8S1749 0.00 0.37 0.42 0.43 0.37 
D8S556 7.95 0.39 0.41 0.43 0.37 
D8S198 22.24 0.51 0.31 0.59 0.26 
GTas121 D8S1749 0.00 0.15 0.71 0.16 0.70 
D8S556 7.95 0.15 0.71 0.16 0.69 
D8S198 22.24 0.23 0.59 0.23 0.59 
Table 4.7 - SimWalk2 MCMC based nonparametric linkage results for 
chromosome 8 (GLC1D) 
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Family ID Marker Haldane cM Statistic D p-value Statistic E p-value 
All DIOSI 729 0.00 0.22 0.61 0.25 0.56 
D10S1713 3.24 0.20 0.64 0.23 0.59 
D10S1691 5.88 0.35 0.45 0.34 0.45 
D10S547 9.37 0.39 0.41 0.33 0.47 
D10S1664 12.94 0.33 0.47 0.30 0.51 
GTas03 D10S1729 0.00 0.08 0.84 0.12 0.76 
D10S1713 3.24 0.04 0.91 0.07 0.86 
D10S1691 5.88 0.22 0.60 0.28 0.53 
DI 0S547 9.37 0.36 0.44 0.40 0.40 
D10S1664 12.94 0.62 0.24 0.65 0.23 
GTas04 D10S1729 0.00 0.30 0.50 0.30 0.50 
D10S1713 3.24 0.30 0.50 0.29 0.51 
D10S1691 5.88 0.30 0.51 0.29 0.51 
D 1 0S547 9.37 0.30 0.50 0.30 0.51 
D10S1664 12.94 0.18 0.66 0.16 0.69 
GTas11 D10S1729 0.00 0.30 0.50 0.23 0.59 
D10S1713 3.24 0.27 0.53 0.21 0.62 
D10S1691 5.88 0.26 0.55 0.19 0.64 
D10S547 9.37 0.21 0.62 0.15 0.70 
D10S1664 12.94 0.12 0.76 0.08 0.83 
GTas15 D10S1729 0.00 0.62 0.24 0.65 0.22 
D10S1713 3.24 0.63 0.24 0.66 0.22 
D10S1691 5.88 0.62 0.24 0.65 0.22 
DI 0S547 9.37 0.52 0.30 0.53 0.30 
D10S1664 12.94 0.47 0.34 0.48 0.33 
GTasI7 D10S1729 0.00 0.36 0.43 0.39 0.41 
D10S1713 3.24 0.35 0.44 0.38 0.42 
D10S1691 5.88 0.21 0.62 0.23 0.59 
D10S547 9.37 0.27 0.54 0.27 0.53 
D10S1664 12.94 0.11 0.77 0.13 0.74 
GTas35 D10S1729 0.00 0.64 0.23 0.66 0.22 
D10S1713 3.24 0.70 0.20 0.74 0.18 
D10S1691 5.88 1.18 0.07 1.19 0.06 
D10S547 9.37 1.30 0.05 1.31 0.05 
D10S1664 12.94 1.30 0.05 1.31 0.05 
GTas37a DI0SI729 0.00 0.24 0.58 0.20 0.63 
D10S1713 3.24 0.32 0.48 0.27 0.54 
D10S1691 5.88 0.40 0.39 0.33 0.46 
D I 0S547 9.37 0.49 0.33 0.39 0.41 
D10S1664 12.94 0.59 0.26 0.49 0.32 
GTas37b D10S1729 0.00 0.36 0.43 0.54 0.29 
D10S1713 3.24 0.33 0.47 0.42 0.38 
D10S1691 5.88 0.31 0.49 0.35 0.45 
D I 0S547 9.37 0.22 0.61 0.28 0.53 
D10S1664 12.94 0.10 0.79 0.21 0.62 
GTas54 D10S1729 0.00 0.37 0.42 0.36 0.44 
D10S1713 3.24 0.38 0.42 0.35 0.45 
D10S1691 5.88 0.40 0.40 0.34 0.46 
DI 0S547 9.37 0.26 0.55 0.21 0.62 
D10S1664 12.94 0.27 0.54 0.22 0.60 
GTasI21 DI0SI729 0.00 0.07 0.85 0.07 0.85 
D10S1713 3.24 0.05 0.89 0.05 0.89 
D10S1691 5.88 0.05 0.90 0.04 0.91 
DI 0S547 9.37 0.06 0.86 0.06 0.87 
D10S1664 12.94 0.09 0.82 0.08 0.83 
Table 4.8 - SimWalk2 MCMC based nonparametric linkage results for 
chromosome 10 (GLC1E) 
Bold: Statistics D or E p-value0.1. 
102 
Family ID Marker Haldane cM Statistic D p-value Statistic E p-value 
All D7S2511 0.00 0.15 0.70 0.14 0.73 
D7S505 2.29 0.20 0.63 0.10 0.80 
D7S2439 5.01 0.22 0.60 0.12 0.77 
D7S2546 9.12 0.15 0.71 0.09 0.81 
GTas03 D7S2511 0.00 0.29 0.52 0.27 0.54 
D7S505 2.29 0.34 0.46 0.31 0.49 
D7S2439 5.01 0.25 0.56 0.22 0.61 
D7S2546 9.12 0.26 0.54 0.24 0.58 
GTas04 D7S2511 0.00 0.51 0.31 0.45 0.35 
D7S505 2.29 0.54 0.29 0.49 0.32 
D7S2439 5.01 0.59 0.26 0.55 0.28 
D7S2546 9.12 0.23 0.59 0.20 0.63 
GTas11 D7S2511 0.00 0.04 0.90 0.04 0.91 
D7S505 2.29 0.03 0.93 0.03 0.93 
D7S2439 5.01 0.03 0.93 0.03 0.93 
D7S2546 9.12 0.03 0.93 0.03 0.93 
GTas15 D7S2511 0.00 0.45 0.36 0.38 0.42 
D7S505 2.29 0.44 0.37 0.36 0.44 
D7S2439 5.01 0.37 0.42 0.30 0.50 
D7S2546 9.12 0.52 0.31 0.46 0.35 
GTas17 D7S2511 0.00 0.14 0.73 0.13 0.74 
D7S505 2.29 0.20 0.63 0.19 0.64 
D7S2439 5.01 0.25 0.56 0.24 0.58 
D7S2546 9.12 0.30 0.51 0.28 0.52 
GTas35 D7S2511 0.00 0.23 0.58 0.26 0.55 
D7S505 2.29 0.33 0.47 0.36 0.44 
D7S2439 5.01 0.37 0.43 0.39 0.41 
D7S2546 9.12 0.38 0.42 0.41 0.39 
GTas37a D7S2511 0.00 0.53 0.30 0.63 0.24 
D7S505 2.29 0.29 0.51 0.39 0.41 
D7S2439 5.01 0.31 0.50 0.41 0.39 
D7S2546 9.12 0.09 0.82 0.09 0.81 
GTas37b D7S2511 0.00 0.13 0.73 0.22 0.60 
D7S505 2.29 0.35 0.45 0.42 0.38 
D7S2439 5.01 0.35 0.44 0.43 0.37 
D7S2546 9.12 0.37 0.43 0.44 0.36 
GTas54 D7S2511 0.00 0.36 0.44 0.37 0.43 
D7S505 2.29 0.41 0.39 0.42 0.38 
D7S2439 5.01 0.45 0.36 0.47 0.34 
D7S2546 9.12 0.57 0.27 0.62 0.24 
GTas121 D7S2511 0.00 0.25 0.56 0.28 0.53 
D7S505 2.29 0.25 0.57 0.28 0.53 
D7S2439 5.01 0.25 0.57 0.27 0.53 
D7S2546 9.12 0.21 0.62 0.23 0.59 
Table 4.9 - SimWalk2 MCMC based nonparametric linkage results for 
chromosome 7 (GLC1F) 
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4.5.4 MCMC based parametric linkage analysis 
The SimWalk2 parametric linkage analysis results for each of the investigated POAG 
loci GLCIA-F, including both the high penetrance (0.90) and the alternative lower 
penetrance (0.75) model are shown in Tables 4.10 to 4.15. The maximum location 
score for each pedigree within each region is reported, along with the corresponding 
map position in Haldane centiMorgans. Location scores greater than or equal I are 
highlighted for follow-up consideration while negative location scores are shown in red. 
The SimWalk2 parametric analyses revealed three results of interest corresponding to 
regions identified in the SimWalk2 nonparametric analysis. Family GTas15 produced a 
maximum location score of 1.12 on chromosome 2 (GLC1B) at 10.8 cM (at marker 
D2S1892) with the high penetrance model (with similar results for the low penetrance 
model; Table 4.11). The location score dropped to 0.86 at the previous marker, 
D2S1897 (data not shown). GTas121 produced a maximum location score of 1.08 at 
12.19 cM (at marker D3S1569) with the high penetrance model, which dropped to 1.03 
with the alternative model (Table 4.12). The final flagged result from the SimWalla 
location score analysis was for family GTas35 on chromosome 10 (GLC1E), with a 
peak location score of 1.43 for both models at 12.94 cM (at marker DI0S1664; Table 
4.14). Neither GTas03 nor GTas11 showed any interesting results in the parametric 
analyses of chromosome 3 (Table 4.12). GTas37a generated a peak location score of 
1.10 on chromosome 7, however the location for this was off the end of the map at -5.0 
cM (Table 4.15), hence this result was not highlighted for potential follow-up. 
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Family ID 
Location Score 
(Penetrance 0.9) 
Position 
(Haldane cM) 
Location Score 
(Penetrance 0.75) 
Position 
(Haldane cM) 
GTas03 -0.24 55.7 -0.24 55.7 
GTas04 -0.12 55.7 -0.12 55.7 
GTas11 0.23 -10.0 0.22 -10.0 
GTas15 -0.01 45.7 -0.00 40.7 
GTas17 0.07 55.7 0.08 50.7 
GTas35 -0.16 -50.0 -0.16 -50.0 
GTas37a -0.02 -50.0 -0.02 -50.0 
GTas37b -0.03 55.7 -0.03 55.7 
GTas54 0.08 -30.0 0.09 -30.0 
GTas121 -0.17 -50.0 -0.17 -50.0 
Table 4.10 - SimWalk2 maximum MCMC based parametric location score results 
for chromosome 1 (GLC1A) 
Red: Negative location scores. 
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Family ID 
Location Score 
(Penetrance 0.9) 
Position 
(Haldane cM) 
Location Score 
(Penetrance 0.75) 
Position 
(Haldane cM) 
GTas03 0.15 -50.0 0.15 -50.0 
GTas04 0.78 -10.0 0.77 -10.0 
GTas11 -0.04 -50.0 -0.04 -50.0 
GTas15 1.12 15.8 1.11 10.8 
GTas17 0.14 -50.0 0.13 -50.0 
GTas35 -0.17 -50.0 -0.17 -50.0 
GTas37a -0.06 60.8 -0.05 60.8 
GTas37b -0.03 60.8 -0.03 60.8 
GTas54 -0.12 60.8 -0.12 60.8 
GTas121 0.04 -50.0 0.03 -50.0 
Table 4.11 - SimWalk2 Maximum MCMC based parametric location score results 
for chromosome 2 (GLC1B) 
Bold: Location scores greater than or equal 1. 
Red: Negative location scores. 
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Family ID 
Location Score 
(Penetrance 0.9) 
Position 
(Haldane cM) 
Location Score 
(Penetrance 0.75) 
Position 
(Haldane cM) 
GTas03 0.72 -20.0 0.73 -20.0 
GTas04 -0.18 -50.0 -0.18 -50.0 
GTas11 0.84 7.4 0.83 7.0 
GTas15 -0.12 64.5 -0.11 64.5 
GTas17 0.14 -50.0 0.14 -50.0 
GTas35 0.48 -10.0 0.47 -10.0 
GTas37a -0.33 64.5 -0.31 64.5 
GTas37b 0.01 -50.0 0.01 -50.0 
GTas54 0.23 44.5 0.24 39.5 
GTas121 1.03 12.4 1.08 12.2 
Table 4.12 - SimWalk2 maximum MCMC based parametric location score results 
for chromosome 3 (GLC1C) 
Bold: Location scores greater than or equal 1. 
Red: Negative location scores. 
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Family ID 
Location Score 
(Penetrance 0.9) 
Position 
(Haldane cM) 
Location Score 
(Penetrance 0.75) 
Position 
(Haldane cM) 
GTas03 0.00 -50.0 0.00 -50.0 
GTas04 0.40 22.2 0.39 22.2 
GTas11 0.45 22.2 0.44 22.2 
GTas15 -0.04 72.2 -0.03 72.2 
GTas17 0.16 -50.0 0.16 -50.0 
GTas35 -0.00 -50.0 -0.00 -50.0 
GTas37a -0.02 72.2 -0.01 72.2 
GTas37b 0.13 42.2 0.13 42.2 
GTas54 0.16 37.2 0.15 37.2 
GTas121 -0.06 72.2 -0.05 72.2 
Table 4.13 - SimWalk2 maximum MCMC based parametric location score results 
for chromosome 8 (GLC1D) 
Red: Negative location scores. 
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Family ID 
Location Score 
(Penetrance 0.9) 
Position 
(Haldane cM) 
Location Score 
(Penetrance 0.75) 
Position 
(Haldane cM) 
GTas03 0.91 22.9 0.93 22.9 
GTas04 -0.14 -50.0 -0.13 -50.0 
GTas11 -0.07 -50.0 -0.07 -50.0 
GTas15 0.01 -50.0 0.01 -50.0 
GTas17 0.27 -25.0 0.27 -25.0 
GTas35 1.43 12.9 1.44 12.9 
GTas37a 0.02 57.9 0.02 52.9 
GTas37b 0.76 0.0 0.73 0.0 
GTas54 -0.09 -50.0 -0.08 -50.0 
GTas121 -0.26 -50.0 -0.25 -50.0 
Table 4.14 - SimWalk2 maximum MCMC based parametric location score results 
for chromosome 10 (GLC1E) 
Bold: Location scores greater than or equal 1. 
Red: Negative location scores. 
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Family ID 
Location Score 
(Penetrance 0.9) 
Position 
(Haldane cM) 
Location Score 
(Penetrance 0.75) 
Position 
(Haldane cM) 
GTas03 -0.08 59.1 -0.08 59.1 
GTas04 0.15 -30.0 0.15 -30.0 
GTas11 -0.11 -50.0 -0.10 -50.0 
GTas15 0.03 -50.0 0.02 -50.0 
GTas17 -0.10 -50.0 -0.10 -50.0 
GTas35 0.53 8.3 0.56 8.3 
GTas37a 1.10 -5.0 1.08 -5.0 
GTas37b -0.10 59.1 -0.10 59.1 
GTas54 0.50 19.1 0.52 19.1 
GTas121 0.09 -50.0 0.09 -45.0 
Table 4.15 - SimWalk2 maximum MCMC based parametric location score results 
for chromosome 7 (GLC1F) 
Bold: Location scores greater than or equal 1. 
Red: Negative location scores. 
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4.5.5 Haplotype analysis 
Aside from family GTas15 at GLC1B on chromosome 2 and family GTas35 at GLC1E 
on chromosome 10 (described in Chapter 5), there was little evidence of a shared 
haplotype across each remaining region of interest. There was also no apparent 
evidence of common alleles shared across multiple pedigrees that could indicate the 
presence of a founder effect or common ancestry. 
flaplotype analysis revealed that the smallest pedigree, GTas11, shared a 3 marker 
haplotype across all 5 affected individuals for the first three markers of chromosome 3 
(D3S3637 to D3S3694), accounting for the low p-values obtained at these markers in 
the nonparametric analysis (section 4.5.3). Three unaffected individuals (11-07, 11-09 
and 11-10) also shared this haplotype; however, all three of these individuals were 
under the average age of diagnosis for the pedigree (62 years) and may yet manifest the 
disease. 
Family GTas03 showed evidence of a shared haplotype at the same three markers on 
chromosome 3 in eight of the 15 affected individuals, however the haplotype did not 
contain any of the alleles found in the haplotype in family GTas11. The GTas03 
chromosome 3 haplotype was also detected in four individuals showing no evidence of 
POAG (3-01, 3-17, 3-24 and 3-39) and, while one individual (3-17) was 66 at the time 
of examination and a potential example of non-penetrance, the remaining individuals 
were less than 50 years old when examined. 
In family GTas121, there appeared to be a shared two marker haplotype with the two 
most distal chromosome 3 markers, D3S1569 and D3S1608, in five of the seven 
affected individuals. This haplotype was also detected in three unaffected individuals 
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(121-08, 121-11 and 121-15), all less than 55 years old at the time of examination and 
well below the average age of onset for this family. 
In family GTas11 four of the five affected individuals share a haplotype for all three 
markers on chromosome 8. This haplotype was not detected in any of the unaffected 
individuals. However, while the haplotype spans approximately 20 cM, there are so few 
markers and so few typed individuals in the pedigree that even tentative conclusions 
could not be drawn without further evidence. 
Haplotype generation was routinely repeated three to four times with different random 
seeds and the results were highly consistent across all pedigrees except family GTas04 
on chromosome 2 which did not reach a stable configuration after eight iterations. 
4.5.6 Pedigrees selected for follow-up analysis 
Three pedigrees satisfied the criteria for further consideration described in 4.3.6: 
GTas15 on chromosome 2 (GLC1B), GTas121 on chromosome 3 (GLC IC) and 
GTas35 on chromosome 10 (GLC1E). Families GTas15 and GTas35 were selected for 
follow up analysis including additional genotyping within the regions of interest 
(reported in Chapter 5). This selection was eventually based on two factors: firstly that 
the interesting results generated by the nonparametric analyses of GTas15 and GTas35 
extended across three or more markers (Tables 4.5 and 4.8 respectively), whereas the 
region of interest on chromosome 3 for family GTas121 extended across only 2 markers 
(Table 4.6); and secondly that, at the point of this decision making process, the GLC1C 
locus on chromosome 3 had recently been replicated in a published study (Kitsos et al. 
2001), whereas the OPTN gene at GLC1E on chromosome 10 (Rezaie et al. 2002) had 
-not yet been identified. Additional genotyping and follow-up analysis of GTas15 at the 
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GLC I B locus on chromosome 2 and GTas35 at the GLC1E locus on chromosome 10 
are therefore described in Chapter 5, and these pedigrees are not included in subsequent 
analyses described in the remainder of this chapter. 
4.5.7 Exact nonparametric linkage analyses of selected pedigrees 
Exact nonparametric linkage analyses using GeneHunter-Plus version 1.2 were 
conducted on a selection of pedigrees that generated 'interesting' results with the 
estimation based SimWalk2 parametric and nonparametric linkage analyses. A 
summary of these results is given in Table 4.16. Families GTas03, GTas11 and 
GTas121 showed some evidence of linkage on chromosome 3 at the GLC1C locus 
(Table 4.6) and were selected for additional analyses at this locus. Since there was a 
paucity of other interesting results, several other pedigrees were also selected for 
additional analyses based on less interesting initial data: the GLC ID region on 
chromosome 8 in families GTas04 and GTas11 due to weakly positive SimWalk2 
parametric results at the last marker, D85 198 (Table 4.13); the GLC lE region on 
chromosome 10 in family GTas03, due to weakly positive SimWalk2 parametric results 
10 cM distal to the last marker, D 10S1664 (Table 4.14), and fmally the GLC1F region 
on chromosome 7 in family GTas37a due to a peak in the SimWallc2 parametric results 
5 cM proximal to the first marker, D7S2511 (Table 4.15). The final dataset contained 7 
regions of interest for additional analyses using exact methods, including 2 pedigrees 
(GTas03 and GTas11) under investigation at two separate regions. 
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Maximum nonparametric result Maximum parametric result 
Family ID Locus Marker p-value (statistic E) 
Location 
(Haldane cM) 
Location score 
(penetrance 0.9) 
Location 
(Haldane cM) 
GTas03 GLC1C D3S3637 0.03 0.0 0.73 -20.0 
GTas11 GLC1C D3S3637 0.04 0.0 0.83 7.0 
GTas121 GLC1C D3S1569 0.04 12.2 1.08 12.2 
GTas04 GLC1D D8S198 0.31 22.2 0.39 22.2 
GTas11 GLC1D D8S198 0.35 22.2 0.44 22.2 
GTas03 GLC1E D10S1664 0.23 12.9 0.93 22.9 
GTas37a GLC1F D7S2511 0.24 0.0 1.08 -5.0 
Table 4.16 - A summary of results from the preliminary MCMC based nonparametric and parametric analyses in the pedigrees selected for 
exact nonparametric analyses 
Bold: p-value<0.05 or LOD>1 
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For the exact nonparametric linkage analyses, pedigrees were manually trimmed to 20 
bits to include the maximum number of affected individuals without compromising the 
integrity of the pedigree structure, which in some cases resulted in splitting the original 
into several smaller pedigrees. The subdivided pedigrees GTas03a and GTas03b were 
used as the core pedigrees in place of GTas03 since the original pedigree consists of 132 
bits. Each of the trimmed pedigrees is described in Table 4.17, including the original 
and trimmed number of bits, the number of individuals removed and the genotyped 
individuals retained in the trimmed pedigree. 
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Family ID Total Available Affected Original bits Final bits Removed* Genotyped Individuals Remaining 
GTas03a 76 39 9 80 (24F 52N) 17 58 3-03, 3-05, 3-07, 3-10, 3-12, 3-18, 3-27, 
3-34 
GTas03b 41 19 6 42 (13F 28N) 19 22 3-11, 3-13, 3-14, 3-15, 3-55, 3-57, 3-58 
GTas04 45 25 9 48 (14F 31N) 20 24 4-04, 4-09, 4-10, 4-14, 4-16, 4-19, 4-24, 
4-30, 4-31, 4-32, 4-35 
GTas37a 51 29 8 57 (15F 36N) 19 28 37-01, 37-03, 37-05, 37-06, 37-10, 37-17, 
37-20, 37-40, 37-41, 37-50 
GTas11 15 10 5 15 (5F ION) 15 nil 11-01, 11-02, 11-03, 11-04, 11-05, 11-06, 
11-07, 11-08, 11-09, 11-10 
GTas121 45 18 7 42 (16F 29N) 19 22 121-01, 121-03, 121-07, 121-09, 121-11, 
121-12, 121-14, 121-19, 121-20 
Table 4.17 - Details of the trimming of GIST pedigrees used for analysis with GeneHunter-Plus 
*Number of individuals removed from the trimmed pedigree. 
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The GeneHunter-Plus nonparametric linkage analysis results for each of the selected 
pedigrees and regions are shown in Table 4.18. 
Table 4.18 reveals that only GTas11 and GTas121 produced a result of interest in the 
nonparametric follow-up analysis. GTas11 generated a nonparametric p-value of 0.031 
for the NPLali statistic at the first marker within the GLC1C region on chromosome 3 
(D3S3637). This result is similar to the result obtained using the equivalent statistic in 
SimWalk2 (Statistic E; Sobel and Lange 1996) with a p-value of 0.045 at D3S3637 
(Section 4.4.3). GTas121 also generated a p-value of 0.033 on chromosome 3 for the 
NPLaii statistic at the last marker within the GLC1C region (D3S1608). Again, this 
result is similar to the SimWalk2 Statistic E results (p=0.049 at D3S1608; Section 
4.4.3). 
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Locus Chromosome Family ID p-value Nearest marker 
GLC1C 3 GTas03a 0.316 D3S3637 
GLC1C 3 GTas03b 0.073 D3S3637 
GLC1C 3 GTas11 0.031 D3S3637 
GLC1C 3 GTas121 0.033 D3S1608 
GLC1D 8 GTas04 0.112 D8S198 
GLC1D 8 GTas11 0.172 D8S198 
GLC1E 10 GTas03a 0.227 D10S1664 
GLC1E 10 GTas03b 0.188 D10S1664 
GLC1F 7 GTas37a 0.468 D7S2511 
Table 4.18 - GeneHunter-Plus exact nonparametric p-values for selected GIST 
pedigrees and regions 
Bold: p-value<0.05 
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4.5.8 Exact two-point parametric linkage analyses of selected pedigrees 
Memory constraints and the presence of loops in some pedigrees prevented multipoint 
MUNK analyses, even with 3 markers, so two-point analyses were conducted on 
regions/pedigrees of interest. The dataset described in 4.5.6 was also used for the exact 
two-point parametric analyses. 
The results of the two-point parametric follow-up analyses on selected GIST pedigrees 
and regions are shown in Table 4.19, including the maximum LOD score for each 
marker and the value of theta at which is was obtained. 
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Locus Family ID Marker Max. LOD Location Max. LOD Location Pen. 0.9 (0) Pen. 0.75 (0) 
GLCIC GTas03 D3S3637 1.080 0.10 1.080 0.10 
GLC1C D3S1301 0.102 0.25 0.100 0.25 
GLC1C D3S3694 0.143 0.20 0.144 0.20 
GLCIC D3S1569 0.081 0.30 0.080 0.30 
GLC1C D3S1608 0.072 0.20 0.068 0.20 
GLCIC GTas03a D3S3637 neg neg - 
GLC1C D3S130I neg neg 
GLC1C D3S3694 neg neg - 
GLC1C D3S1569 0.235 0.10 0.242 0.01 
GLCIC D3SI608 neg neg - 
GLC1C Gras03b D3S3637 1.130 0.10 1.119 0.10 
GLC1C D3S1301 0.166 0.15 0.167 0.15 
GLC1C D3S3694 0.445 0.10 0.442 0.10 
GLC1C D3SI569 0.001 0.40 neg - 
GLC1C D3S1608 0.209 0.10 0.210 0.10 
GLC1C GTas11 D3S3637 0.643 0.10 0.642 0.10 
GLC1C D3S1301 0.244 0.10 0.245 0.10 
GLCIC D3S3694 0.680 0.10 0.627 0.10 
GLC1C D3S1569 neg neg - 
GLC1C D3S1608 0.100 0.10 0.100 0.10 
GLC1C GTas121 D3S3637 0.034 0.40 0.034 0.40 
GLC1C D3S1301 0.287 0.10 0.290 0.10 
GLCIC D3S3694 neg neg 
GLCIC D3S1569 0.369 0.10 0.381 0.10 
GLCIC D3S1608 0.323 0.10 0.322 0.10 
GLCID GTas04 D8S1749 0.053 0.30 0.051 0.30 
GLC1D D8S556 0.210 0.10 0.204 0.10 
GLCID D8S198 0.415 0.10 0.412 0.10 
GLCID GTas11 D8SI749 0.340 0.10 0.339 0.10 
GLC1D D8S556 0.050 0.20 0.053 0.20 
GLC1D D8S198 0.580 0.10 0.575 0.10 
GLCIE GTas03 DI0S1729 0.031 0.40 0.034 0.40 
GLCIE DI0SI713 0.082 0.40 0.081 0.40 
GLC1E D10S1691 0.218 0.10 0.218 0.10 
GLC1E D10S547 0.128 0.10 0.128 0.10 
GLCIE DI0SI664 1.340 0.10 1.336 0.10 
GLCIE GTas03a DI0SI729 0.029 0.40 0.025 0.40 
GLC1E D10S1713 0.043 0.40 0.042 0.40 
GLC1E D10S1691 0.751 0.10 0.747 0.10 
GLCIE D10S547 0.030 0.10 0.033 0.01 
GLCIE D10S1664 0.401 0.10 0.397 0.10 
GLC1E GTas03b DI0S1729 neg neg - 
GLCIE DI0SI713 neg neg 
GLC1E D10S1691 neg neg 
GLC1E DI0S547 neg neg 
GLC1E D10S1664 0.711 0.40 0.706 0.10 
GLCIF GTas37a D7S2511 0.806 0.10 0.803 0.10 
GLCIF D7S505 neg - neg - 
GLCIF D7S2439 0.298 0.20 0.296 0.20 
GLCIF D7S2546 0.026 0.40 0.025 0.40 
Table 4.19 - FASTLINK exact two-point parametric linkage results for select 
GIST pedigrees and regions 
Bold: Maximum LOD scores greater than 1. 
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There was very little difference between the results obtained using the two different 
penetrance models, 0.90 and 0.75. The only exact two-point parametric results with 
LODs>1 were generated by family GTas03 and its sub-pedigree GTas03b. Family 
GTas03 produced a maximum LOD of 1.08 at the most proximal marker within the 
GLC1C region on chromosome 3 (D3S3637). When subdivided into two smaller 
pedigrees, the GTas03b branch produced an even larger LOD (1.34) at this marker, 
while the other branch (GTas03a) showed no evidence of linkage to this region (Table 
4.19). Family GTas03 also produced a LOD of 1.34 at the most distal marker within the 
GLC1E region on chromosome 10 (Dl 0S1664), but this score was greatly reduced in 
both sub pedigrees (Table 4.19). Neither of these results extended across more that one 
marker. There were no other results with LOD> I identified using this exact two-point 
parametric approach. 
4.6 Discussion 
The first stage of the linkage analysis in this dataset was conducted using estimation 
based parametric and nonparametric analyses using the MCMC algorithm due to the 
complexity of the disease, the size of the available pedigrees, the number of markers 
under investigation and the desire for multipoint analyses. These analyses were used to 
provide first-pass linkage results for follow-up analysis, and since this approach can 
result in more conservative results than exact methods (Sobel and Lange 1996), low 
thresholds for follow-up analyses were set. Based on the first pass MCMC based 
analyses, two pedigrees were selected for additional genotyping and follow-up analyses. 
Family GTas15 produced p-values of 0.05-0.07 for three markers within the GLC1B 
region on chromosome 2 (D2S2264 to D2S1892) in the nonparametric analysis 
described in section 4.5.3. In the parametric analysis, this pedigree produced a 
maximum location score of 1.12 on chromosome 2 corresponding to marker D2S1892, 
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as described in section 4.5.4. Family GTas35 produced p-values of 0.05-0.06 for three 
markers within the GLC1E region on chromosome 10 (DI0S1691 to D 10S1664) in the 
nonparametric analysis described in section 4.5.3. The parametric analysis generated a 
peak location score of 1.43, also on chromosome 10, at marker D10S1664 (section 
4.5.4). These two pedigrees were selected for additional genotyping and follow-up 
analyses, described in Chapter 5. 
There were several other moderately suggestive results generated by the first pass 
analyses. Families GTas03 and GTas11 produced p-values less than 0.05 at the 
proximal end of the GLC1C locus on chromosome 3 while family GTas121 produced a 
p-value of 0.04 for marker D3S1569 at the distal end of the GLC1C locus in the initial 
nonparametric analysis (section 4.5.3). Family GTas121 also generated a location score 
of 1.08 at marker D3S1569 in the first pass parametric analysis, however neither 
GTas03 of GTas11 showed any evidence for linkage in the first pass parametric 
analyses for chromosome 3. Several other pedigrees also showed weakly positive 
results in the initial SimWalla analyses. Since none of these remaining pedigrees were 
to be followed-up in this investigation, they were used as a basis for an exploration of 
additional statistical analyses. The rationale behind this approach was partially to 
extract any additional linkage information, but also to compare the results of some exact 
statistical methodologies with the performance of the MCMC based analyses. In 
general, the SimWalk2 and exact GeneHunter nonparametric analyses compared 
favourably, for example GTas11 produced an exact p-value of 0.031 in GeneHunter 
compared with 0.04 in SimWalla, and GTas121 produced a p-value of 0.033 in 
GeneHunter compared with 0.05 in SimWalk2. Family GTas03, however, was more 
difficult to compare since GeneHunter was only able to process trimmed versions of 
each branch of the original pedigree, GTas03a and GTas03b, hence the GeneHunter p- 
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values did not approach the SimWalla result of p=0.03. The exact parametric analyses 
conducted using FASTLINK did not compare as favourably with the SimWalk2 
estimation based results, however it is important to note that due to the capacity of 
FASTLINK and server memory constraints, the exact parametric analyses were two-
point analyses whereas the SimWalla analyses were multipoint. The location score of 
1.03 obtained in the SimWalla analysis for family GTas121 at marker D3S1608 
dropped to a LOD of 0.32 in the exact two-point FASTLINK analysis. Similarly, the 
SimWallc2 location score of 1.10 for family GTas37a at marker D7S2511 dropped to a 
LOD of 0.81 in the two-point FASTLINK analysis. Conversely, GTas03 and its sub-
pedigree GTas03b produced LODs greater than 1 at marker D3S3637 in the two-point 
FASTLINK analysis compared with a location score of only 0.78 in the SimWallc2 
analysis. GTas03 also generated a LOD of 1.34 at marker Dl 0S1664 in the two-point 
FASTLINK analysis compared with a multipoint location score of 0.91. The 
differences in these results may be indicative of type 1 error. Of course, taking into 
account multiple testing would also eradicate the significance of any of the remaining 
results. However, these findings are useful in the selection of families and methods for 
further study in future explorations of the GIST. 
All statistical calculations in this dissertation were performed using a Sun Microsystems 
Enterprise 450 server with 4 Ultrasparc-II 480MHz central processing units, 4GB of 
RAM and 144GB of disk space, running Solaris 8. Server speed and memory 
constraints were a consideration in the selection of the most appropriate statistical 
analysis methodology. The simulation analyses were power restricted, due in part to 
pedigree size, but most significantly to the presence of loops in the pedigree. The 
smallest of the pedigrees (GTas11) took less that three minutes to complete 1000 
replicates, while the largest (GTas03), containing multiple loops, took 1625 hours (68 
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days) to complete only 500 replicates. While FASTLINK can theoretically analyse 
several markers in a multipoint parametric analysis, in practice our analyses were 
restricted to two-point only. Two-point analysis of the largest of the pedigrees analysed 
in this chapter, GTas03 (including several loops), took an average of 16 minutes to 
complete. The same analysis model with an additional marker included (two-marker 
multipoint) showed no signs of nearing completion after 60 days. In comparison, all of 
the MCMC based SimWalk2 analyses were completed within an acceptable timeframe 
using this server. For example, multipoint nonparametric analysis of the entire pedigree 
dataset (all pedigrees including all individuals), with all five markers on chromosome 2, 
took a total of six hours to complete. This made it possible to easily rerun analyses with 
different random seeds to reduce the chances of spurious results due to poor mixing 
(although we found no evidence of poor mixing or spurious results in the SimWalk2 
parametric and nonparametric analyses in this study; data not shown). However, 
analysis processing time is often trivial when compared with the time required for study 
design and initiation, sample collection, processing and genetic data extraction. 
Extended pedigrees may be powerful assets in the detection of disease loci (Wijsman 
and Amos 1997), however such datasets are also notoriously difficult to analyse, due to 
the number of possible configurations consistent with the available data, each of which 
has to be considered for an exact result. The Elston-Stewart algorithm (Elston and 
Stewart 1971) employed in the analysis programs LINKAGE and FASTLINK is an 
exact approach that is not affected by pedigree size, but is restricted by the number of 
markers and the presence of loops and missing data. In this study, a maximum of three 
markers could be analysed due to server memory restrictions, and less in the presence of 
loops. The Lander-Green algorithm (Lander and Green 1987), used in the analysis 
program GeneHunter, is also an exact approach but is restricted by the size of the 
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pedigree. GeneHunter-Plus can analyse a maximum of 20 bits. In this study, all but 
family GTas11 had to be manually trimmed prior to exact nonparametric linkage 
analysis. The analysis program Merlin (Abecasis et al. 2002) can analyse larger 
pedigrees than GeneHunter, using a Lander-Green algorithm with sparse binary trees, 
however memory constraint on our server restricted Merlin to approximately 23 bits, 
which was not enough of an improvement to replace GeneHunter for routine analyses. 
The Markov chain Monte Carlo based analyses employed by SimWalla (Sobel and 
Lange 1996) appear to be the most appropriate solution to the analysis of the selected 
GIST pedigrees based on pedigree size and complexity, the availability of genetic data, 
and the increased power of multipoimt analyses. SimWalk2 is practically unrestricted 
by pedigree size or the number of markers. The MCMC algorithm employed by 
SimWallc2 is able to analyse extended pedigrees because it considers the underlying 
configurations consistent with the available data in proportion to their likelihood, hence 
configurations that are theoretically possible but highly unlikely may not be considered. 
SimWallc2 includes a second speed up by using the MCMC algorithm on the set of 
genetic descent graphs (inheritance vectors), the paths of gene flow rather than the 
complete data arrangements, reducing the space of the underlying configurations (Sobel 
and Lange 1996). 
Compared with a collection of independent nuclear families, a single extended pedigree 
may contain more linkage information, less etiologic heterogeneity, and provide a 
greater possibility of identifying genotyping errors. While the genotyping error rates in 
this dataset were low, even small error rates have been shown to have a large impact on 
linkage results (Douglas et al. 2000; Abecasis et a/. 2001) and can affect trait 
localisation (Terwilliger et a/. 1990) if not removed prior to analysis. These effects 
might be even greater in large pedigrees, particularly with missing inheritance 
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information such as unrecruited spouses. There appeared to be no fundamental errors in 
the pedigree structures of the families included in this study since the Mendelian 
genotyping errors did not cluster in any particular pedigree or individual. Due to the 
limited availability of genotypic data in this study we were unable to use statistical 
approaches such as PREST (McPeek and Sun 2000) to check likely pedigree 
relationships. Genome-wide scan data is required for such approaches to be reliable. 
The first round of genotyping revealed that some of the selected microsatellite markers 
were more prone to error due to poor, non-specific or differential allelic amplification. 
Markers D252264, D3S1569, D7S2439 and DI0S1713 were subsequently re-optimised 
and re-genotyped due to the high locus-specific error rates for these markers. Removal 
of these markers from the initial genotyping dataset reduced the overall Mendelian error 
rate to approximately 1.4% (an average of three to four errors per marker). Other 
possible causes of Mendelian error include: interference from dye peaks within the 
allele size range of interest or interference from a broad peak at approximately 200bp in 
the blue channel caused by the use of old formarnide; interference from stutter peaks 
caused by polymerase slippage during elongation (especially in the case of adjacent 
allele heterozygotes) and incorrect peak height (too small or too large) due to variations 
in sample concentration. 
It has been estimated that approximately 40% of genotyping errors are Mendelian 
consistent (Douglas et al. 2002), and that Mendelian consistent error checking is an 
important part of data cleaning prior to analysis (Sobel et al. 2002). In this study the 
Mendelian consistent error rate was approximately one third of the overall error rate. 
The majority of Mendelian consistent errors detected by SimWalk2 were the result of 
false homozygosity due to differential allelic amplification. Proposed causes of this 
artefact include differences in allele length or GC richness, low template concentration 
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producing stochastic fluctuations in copy number for each allele, and the existence of 
polymorphisms interfering with primer binding (Walsh et al. 1992). Figure 4.1 displays 
Genotyper® data that are an example of mistyping due to differential allelic 
amplification. In these cases, reanalysis of apparently homozygous genotypes revealed 
the presence of a second, much smaller allele that was missed during the initial typing. 
In Panel A of Figure 4.1, Individual 1 was initially scored as homozygous for the 275bp 
allele; there is a small second peak at the 287bp which has not been labelled due to its 
size (peak height) relative to the 275bp peak. In Panel B of Figure 4.1, re-genotyping of 
Individual 1 clearly reveals the presence of a second allele at 287bp. During the typing 
process, recognition of the fact that marker alleles consisting of a large number of 
repeats are know to amplify less efficiently than alleles of few repeats may have helped 
to eliminate some of these errors in the initial stages of genotyping. On average, false 
homozygosity was detected at a rate of 2 occurrences per marker, although due to the 
unique peak pattern of each marker some were much more likely than others to present 
with allele dropout. 
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Figure 4.1 - Genotyping error due to false homozygosity (differential allelic 
amplification) 
Genotyper 0 data from the HEX-labelled marker D3S1569. 
Panel A shows the initial genotyping data for two individuals; Individual 1 (3-60) has 
been scored as homozygous for the 275bp allele and Individual 2 (3-61) as 
heterozygous for the 275 and 277bp alleles. 
Panel B shows the repeat genotyping data for these individuals, with individual 1 
scored as heterozygous for the 275 and 287bp alleles. 
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POAG is an insidious disease with a late age of onset which often makes ascertaining 
large, multigenerational families difficult, especially when it comes to collecting 
relevant clinical data across generations. The GIST pedigrees contained much 'missing' 
information in the form of individuals in the pedigrees with no clinical or genetic 
information. A more complex parametric model may have helped to compensate for 
this lack of information, by utilising liability classes and age dependent penetrances in 
place of the simplistic model derived from previous studies of POAG. The most critical 
type of missing data in this study appeared to be due to lack of genetic information from 
individuals married in to the pedigrees (unaffected spouses), who had neither blood nor 
clinical data collected during the GIST. The collection of information from married in 
individuals was not included in the GIST protocols. This missing information increases 
the number of possible descent state configurations, decreases the power of estimated 
results and complicates phase determination. A repeat of the simulation process 
described in 4.4.1, but with spouses of available individuals included (for example 
individual 18, husband of 3-7 in GTas03; Figure 2.2) was run in order to gain some 
understanding of the effect the addition of these individuals may create. Only spouses 
of individuals classed as 'available' were included, as it is more likely that these 
spouses are also alive and available. An average of four to five individuals were 
changed from 'unavailable' to 'available' in each pedigree. GTas03 was not included in 
this simulation due to its size and analysis time, however the subdivided pedigrees 
GTas03a and GTas03b were included. The simulation results are shown in Table 4.20, 
including an updated count of the number of 'available' individuals (with the number of 
spouses added shown in brackets). Across the entire dataset, the maximum simulated 
LOD score increased by an average of 0.24 (p=0.28; not significant) and the average 
LOD score was unchanged. While this result is not significant, it is nonetheless an 
increase. What may not have been improved in terms of LOD increases by the addition 
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of this information might still be gamed in terms of more accurate results and phase 
determination. A more effective way to compensate for missing pedigree information 
may be to use a denser marker map such as a SNP array (Evans and Cardon 2004; 
Evans et al. 2004). However, it is most important to note that these simulations have 
limited value in terms of the information they provide to this investigation. The 
simulation methodology used is intrinsically parametric and only provides two-point 
information with a theoretical marker, which does not emulate the dominant analysis 
methodology used in the study; hence these simulations were only used to provide an 
overall indication of the likely utility of these pedigrees for linkage analysis. 
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Family ID Total Available Affected 
Original 
Maximum LOD 
New 
Maximum LOD 
Average 
LOD 
New Average 
LOD 
GTas03a 76 48 (9) 9 3.73 4.45 1.42 1.44 
GTas03b# 41 23 (4) 6 1.86 2.14 0.66 0.71 
GTas04# 45 32 (7) 9 2.59 2.70 0.99 0.95 
GTas35 32 18 (3) 6 1.71 2.92 0.73 0.70 
GTas37a 51 35 (6) 8 3.29 3.65 1.22 1.20 
GTas37b# 37 26 (2) 15 4.17 4.29 1.73 1.68 
GTas54 35 19 (2) 7 3.75 2.90 1.13 1.08 
GTas11 15 13 (3) 5 1.19 1.18 0.59 0.58 
GTas15 31 17 (3) 6 3.14 3.04 1.12 1.12 
GTas17 45 29 (3) 9 3.34 3.99 1.26 1.21 
GTas121 45 23 (5) 7 2.57 2.71 0.98 0.99 
Table 4.20 - Maximum LOD simulations for the GIST pedigrees including married-in individuals 
# indicates the pedigree has had at least one loop broken prior to simulation. 
Bold: LOD>3. 
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Chapter 5— Follow-up Analysis and Fine-Mapping of the GLC1B 
Locus in Family GTas15 and the GLC1E Locus in Family GTas35 
5.1 Preface 
Sections of this chapter were published in Ophthalmologica (Karger) in 2006. The 
article, entitled 'Confirmation of the adult-onset primary open-angle glaucoma locus 
GLC1B at 2cen-q13 in an Australian family' (Charlesworth et al. 2006), is included in 
this dissertation as Appendix 3. This chapter also expands on work published in Human 
Mutation (Sale et al. 2002). 
5.2 Aims 
The aims of the work described in this chapter were: to undertake follow-up analysis, 
including additional genotyping, on the pedigrees and regions of interest identified in 
Chapter 4.5.6, namely family GTas15 at the GLC1B locus on chromosome 2 and 
GTas35 at the GLC1E locus on chromosome 10. In particular, the objectives were: to 
select additional microsatellite markers within the GLC1B region on chromosome 2 and 
the GLC1E region on chromosome 10 with a final average marker spacing of 1-2 cM 
within each region; to perform nonparametric multipoint linkage analyses on the new 
marker datasets, and to generate the most likely haplotypes and search for refined 
regions of interest. 
5.3 Methods 
5.3.1 Microsatellite marker selection 
Microsatellite markers were selected to fine-map the distal ends of the GLC1B locus on 
chromosome 2cen-q13 and the GLC1E locus on chromosome 10p15-p14, at a final 
average marker spacing of 1-2 cM. The primary map source used for marker selection 
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was the deCODE genetic map (Kong et al. 2002), with missing marker locations and 
distances inferred from the Marshfield genetic map (Broman etal. 1998), the Location 
DataBase integrated maps (Collins et al. 1996; Ke et al. 2001) and the human genome 
sequence (Build 34). Heterogeneity information from the Genome Database 
(http://www.gdb.org/), availability of typed genotyping controls from the Centre 
d'Etude du Polymorphisme Humain (CEPH; http://www.cephb.fr/cephdb),  and marker 
location and spacing, were used to weight marker choice. 
The final set of markers used to fine-map the GLC1B and GLC1E regions are shown in 
Tables 5.1 and 5.2 respectively. The tables show the POAG loci and chromosomal 
regions, as well as marker locations and heterozygosities. The addition of 6 markers 
within the GLC1B region resulted in a final set of 11 microsatellite markers at an 
average density of 1.6 cM across this 18 cM region (Table 5.1). An additional 7 
markers were selected within the GLCIE region, resulting in a total of 12 microsatellite 
markers at an average density of 1.9 cM across this 22 cM region (Table 5.2). 
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Marker 	Distance from first marker Heterozygosityt 
(cM)*  
D2S2161 	 0 	 0.77 
D2S113 	 3.00 	 0.77 
D2S2187 	 4.68 	 0.63 
D2S2264 	 7.32 	 0.77 
D2S373 	 7.82 	 0.74 
D2S2364 	 9.97 	 0.66 
D2S1897 	 10.97 	 0.89 
D2S1890 	 13.68 	 0.74 
D2S1893 	 14.68 	 0.75 
D2S1892 	 16.57 	 0.80 
D2S2269 	 17.63 	 0.88 
Table 5.1 - The final set of 11 microsatellite markers used to fine-map the GLC1B 
locus on chromosome 2cen-q13 in family GTas15 
Bold: The original markers selected in Chapter 4. 
*Location in centiMorgans relative to the first marker, primarily based on the deCODE 
genetic map (Kong et al. 2002). 
t Heterozygosity based on CEPH data (http://www.cephb.fr/cephdb).  
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Marker 	Distance from first marker Heterozygosityt 
(cM)*  
D10S1729 	 0 	 0.72 
D10S1713 	 0.59 	 0.60 
DI0S189 	 4.52 	 0.73 
D1OS1619 	 5.75 	 0.67 
DI0S1779 	 7.63 	 0.82 
D10S1649 	 10.54 	 0.84 
D10S547 	 12.70 	 0.74 
DI0S585 	 13.58 	 0.69 
D10S5704 	 16.69 	 0.81 
DI0S223 	 19.07 	 0.66 
D10S1664 	 20.78 	 0.75 
DI0S1653 	 22.88 	 0.78 
Table 5.2 - The final set of!! microsatellite markers used to fine-map the GLC1B 
locus on chromosome 10p15-p14 in family GTas35 
Bold: The original markers selected in Chapter 4. 
*Location in centimorgans relative to the first marker, primarily based on the deCODE 
genetic map (Kong et al. 2002). 
t Heterozygosity based on CEPH data (http://www.cephb.fr/cephdb).  
lOPTN is located on this map between markers D10S570 and D10S223, at 
approximately 17.1 cM. 
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5.3.2 Genotyping methods and error checking 
The genotyping methodology used is described in Chapter 4.3.2. Genotype error 
checking was conducted as described in Chapter 4.3.3. 
5.3.3 Allele frequency generation 
Marker allele frequencies for linkage analysis were derived from a set of 72 elderly 
glaucoma-free individuals (described in Chapter 2.2.3) genotyped with each of the 13 
additional microsatellite markers selected for fine-mapping of GLC1B and GLC1E. 
5.3.4 Data storage and file generation 
As described in Chapter 4.3.5, all individual, family, genotype, phenotype and genetic 
map data were stored in a dedicated database program developed by Tim Albion 
(Menzies Research Institute, unpublished). The linkage utility program MEGA2 
(Mukhopadhyay et al. 2005b) was used to generate program specific input files for the 
analysis programs described in this chapter. 
53.5 IL1B mutation screening in family GTas15 
We screened a synonymous interleulcin 1 beta (IL1B) exon 5 polymorphism in all 
available members of GTas15 using the method described by Lin et al. (2003). The 
ILIB polymorphism is a T to C transition at base 3953 that disrupts a Taql restriction 
site. The region of exon 5 containing the polymorphism was PCR amplified according 
to the methods described in Chapter 3.2, with the primers described by Lin etal. (2003), 
and digested with the Taql enzyme (New England Biolabs). Digest products were 
electrophoresed on a 1.5% agarose gel containing 0.3ng/inl ethidium bromide and 
viewed under 100% UV light. The El allele consisted of the digested product, visible 
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as two bands corresponding to 114 and 135bp fragments while the E2 allele was visible 
as a 249bp undigested fragment. 
5.3.6 1410delC PAX6 mutation screening in family GTas35 
A novel mutation in exon 12 of the PAX6 gene (1410delC) was identified by Sale etal. 
in 2002. This mutation was investigated in all available members of GTas35 by direct 
automated sequencing using ABI PRISM BigDye Terminator Cycle Sequencing Kits 
(Applied Biosystems) and a set of previously published exon 12 primers (Love et al. 
1998), according to the sequencing methodology described in Chapter 3.5. 
5.3.7 MYOC Phe4Ser polymorphism screening in family GTas35 
The Phe4Ser MYOC polymorphism was originally detected by Fingert etal. (1999). 
This change was investigated in all available members of GTas35 by direct automated 
sequencing using ABI PRISM BigDye Terminator Cycle Sequencing Kits (Applied 
Biosystems) and a set of previously published MYOC exon 1 primers (Alward etal. 
1998) according to the sequencing methodology described in Chapter 3.5. Was also 
investigated this polymorphism in 23 available individuals from a Tasmanian family 
segregating aniridia (MIM#106200) described by Sale et al. (2002). 
5.4 Statistical methods 
5.4.1 Nonparametric linkage analyses 
Multipoint MCMC estimation based nonparametric linkage analyses were conducted 
using SimWallc2 version 2.91 (Sobel and Lange 1996), as described in Chapter 4.4.2 - 
4.4.3. Multipoint analyses, utilising information from the entire set of genotyped 
individuals within the pedigree, were conducted using the set of 11 markers within the 
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GLC1B region in family GTas15 and the 12 markers within the GLC1E region in 
family GTas35. 
Exact nonparametric linkage analyses were conducted using GeneHunter-Plus version 
1.2 (Kruglyak et al. 1996; Kong and Cox 1997), as described in Chapter 4.4.7. Family 
GTas15 was trimmed from its original 29 bits (11 founders and 20 non-founders) to a 
16 bit version by removing eight non-founders (18, 19, 15-08, 15-09, 15-10, 15-13, 15- 
14 and 15-15) and three founders (36, 37 and 44). Family GTas35 was trimmed from 
31 bits in its original form to 20 bits for analyses with GeneHunter, by removing seven 
non-founders (35-01, 35-09, 35-10, 35-12, 35-13, 35-14 and 35-15), and three founders 
(17, 252 and 452). No affected individuals were removed from either pedigree. 
5.4.2 Haplotype generation and analysis 
The most likely haplotypes for the GLC1B region in family GTas15 and the GLC1E 
region in family GTas35, taking account of information from all genotyped individuals, 
were estimated using the haplotyping component of SimWalk2 version 2.86-2.91 (Sobel 
and Lange 1996) as described in Chapter 4.4.5. 
Haplotypes were displayed using Pedigree/Draw 5.1 (SFBR; 
http://www.stbr.org/sfbr/public/software/pedraw/peddrw.html now available from 
http://www.pedigree-draw.com). 
5.5 Results 
5.5.1 GTas15 pedigree and clinical data 
Family GTas15 contained seven individuals with clinically diagnosed POAG; 
_individuals 15-01, 15-02, 15-03, 15-07, 15-11, 15-12 and 15-16. The clinical features 
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of family GTas15 are represented in Figure 2.6. One individual (15-04) presented with 
characteristic visual field loss and could have been considered a glaucoma suspect. 
However, for our model free, affecteds-only approach it was not necessary to determine 
whether the remaining family members were glaucoma suspects or truly unaffected; this 
can be difficult given the late onset and subtleties of POAG. All other individuals were 
therefore classed as glaucoma status "unknown" for the purposes of the linkage 
analyses. 
The POAG within family GTas15 appears to be transmitted in an autosomal dominant 
fashion. All affected members of GTas15 and one glaucoma suspect (15-04) presented 
with characteristic visual field loss. Raised LOP was not present in three of the seven 
affected individuals, and two of the affected individuals (15-01 and 15-16) had 
equivocal optic disc appearances in the presence of visual field loss. The monozygotic 
twins 15-01 and 15-02 differed clinically in the appearance of their optic discs, however 
as they were genetically identical and both classified as "affected", 15-02 was not 
included in the genetic analyses. The mean age of diagnosis within the family was 55 
years, ranging from 47 to 60 years. Several individuals had their POAG diagnosed as a 
direct result of the family study. 
5.5.2 GTas35 pedigree and clinical data 
Family GTas35 contained six individuals with clinically diagnosed POAG; individuals 
35-03, 35-04, 35-05, 35-07, 35-08 and 35-11. The clinical features of family GTas35 
are represented in Figure 2.8. Two individuals presented with ocular hypertension 
(raised LOP; 35-06 and 35-10), and two with optic disc abnormalities characteristic of 
POAG but without other indicators of the disease (35-12 and 35-13). All four of these 
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individuals could have been considered glaucoma suspects, but were classed as 
glaucoma status "unknown" for the purposes of the linkage analyses. 
All affected members of GTas35 presented with raised IOP. Of the individuals with 
clinically diagnosed POAG, 35-08 and 35-11 presented with optic disc abnormalities 
without apparent visual field loss at the time of the investigation. Similarly, clinically 
diagnosed cases 35-03 and 35-04 had equivocal optic disc appearances in the presence 
of visual field loss (Figure 2.8). The mean age of diagnosis within the family was 59 
years, ranging from 46 to 74 years, with several individuals diagnosed as a direct result 
of the family study. 
During the course of this investigation we determined that family GTas35 is connected 
to another Tasmanian pedigree with aniridia. Aniridia (MIM#106200) is a rare 
panocular developmental disorder typically diagnosed postnatally by bilateral absence 
of the iris, although iris remnants may be observed. About two thirds of cases are 
familial, with autosomal dominant inheritance, high penetrance and variable 
expressivity (Hanson and Van Heyningen 1995). Aniridia is caused by mutations of the 
PAX6 gene (MIM#607108) (Ton et al. 1991; Jordan et al. 1992) located on 
chromosome 1 1p13. We detected a novel 1410deIC PAX6 mutation in an extended 
Tasmanian pedigree, as described in Sale et al. (2002). The deletion was identified in 
all 9 aniridia cased in family AN!, and in one individual unavailable for 
ophthalmological examination (AN 1-15), and not detected in seven unaffected 
individuals (Sale et al. 2002). Using genealogical records from the GIST database we 
determined that family AN1 was connected to family GTas35, as shown in Figure 5.1. 
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Figure 5.1 - Family GTas35 linked to the aniridia pedigree AN1 
The aniridia pedigree AN! is located to the left of the figure, with affected individuals fully shaded. Available individuals have ID numbers beginning 
in AN I-. Family GTas35 is located to the right of the image. More information on this family is given in the original Figure 2.8. Individuals 98 and 
99 are the common founders linking the two pedigrees. 
+ denotes the presence of the 1410decC PAX6 mutation. 
- denotes the absence of the 1410decC PAX6 mutation. 
M denotes the presence of the Phe4Ser MYOC polymorphism 
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5.5.3 Nonparametric linkage analyses of GTas15 at GLC1B 
SimWalla MCMC based multipoint nonparametric analysis of the 11 markers within 
the GLCIB region on chromosome 2cen-q13 produced empirical p-values of 0.01 or 
less at five markers, flanked by D2S1897 and D2S2269, as shown in Table 5.3. The 
lowest empirical p-value produced by SimWalla was 0.009 at marker D2S1897 (Table 
5.3). 
GeneHunter produced p-values of 0.01 or less at four markers, flanked by D2S1897 and 
D2SI892 (shown in Table 5.4), with an exact p-value of 0.005 at marker D2S1897, the 
same marker that generated the lowest p-value in SimWalk2. 
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Marker 	Distance from first marker 	Empirical p-value for 
(cM) 	 Statistic E  
D2S2161 	 0.00 0.34 
D2S113 	 3.00 	 0.06 
D2S2187 	 4.68 	 0.06 
D2S2264 	 7.32 	 0.04 
D2S373 	 7.82 	 0.03 
D2S2364 	 9.97 	 0.02 
D2S1897 	 10.97 	 0.009 
D2S1890 	 13.68 	 0.01 
D2S1893 	 14.68 	 0.01 
D2S1892 	 16.57 	 0.01 
D2S2269 	 17.63 	 0.01 
Table 5.3 - SimWalk2 empirical p-values for statistic E at the GLC1B locus (2cen-
q13) in family GTas15 
Bold: The original markers selected in Chapter 4 and p-va1ues<0.01. 
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Marker 	Distance from first marker 	Exact p-value for the 
(cM) 	 NPLa statistic  
D2S2161 	 0.00 0.35 
D2S113 	 3.00 	 0.06 
D2S2187 	 4.68 	 0.06 
D2S2264 	 7.32 	 0.05 
D2S373 	 7.82 	 0.05 
D2S2364 	 9.97 	 0.03 
D2S1897 	 10.97 	 0.005 
D2S1890 	 13.68 	 0.01 
D2S1893 	 14.68 	 0.01 
D2S1892 	 16.57 	 0.01 
D2S2269 	 17.63 	 . 	0.03 
Table 5.4 - GeneHunter-Plus exact p-values for the NPLail statistic at the GLC1B 
locus (2cen-q13) in family GTas15 
Bold: The original markers selected in Chapter 4 and p-values <0.01. 
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5.5.4 Nonparametrie linkage analyses of GTas35 at GLC1E 
SimWalk2 MCMC based multipoint nonparametric analysis of the 12 markers within 
the GLC1E region on chromosome 10p15-p14 produced non-significant empirical p-
values for all markers, as shown in Table 5.5. The smallest empirical p-value produced 
by SimWalla was 0.23 at marker DI0S1649 (Table 5.5). 
GeneHunter also produced non-significant p-values at all markers on chromosome 
10p15-p14 (shown in Table 5.6). 
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Marker 	Distance from first marker 	Empirical p-value for 
(cM) 	 Statistic E  
D10S1729 	 0 0.48 
D10S1713 	 0.59 	 0.48 
DI0SI89 	 4.52 	 0.46 
D10S1691 	 5.75 	 0.52 
DI0S1779 	 7.63 	 0.30 
DI0S1649 	 10.54 	 0.23 
D10S547 	 12.70 	 0.36 
DI0S585 	 13.58 	 0.40 
DI0S570 	 16.69 	 0.40 
D10S223 	 19.07 	 0.45 
D10S1664 	 20.78 	 0.50 
DI0S1653 	 22.88 	 0.48 
Table 5.5 - SimWalk2 empirical p-values for statistic E at the GLC1E locus 
(10p15-p14) in family GTas35 
Bold: The original markers selected in Chapter 4. 
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Marker 	Distance from first marker 	Exact p-value for the 
(cM) 	 NPLa statistic  
D10S1729 	 0 0.40 
D10S1713 	 0.59 	 0.40 
D10S189 	 4.52 	 0.40 
D10S1691 	 5.75 	 0.32 
DI0S1779 	 7.63 	 0.55 
D10S1649 	 10.54 	 0.55 
D10S547 	 12.70 	 0.40 
D10S585 	 13.58 	 0.40 
D I 0S570 	 16.69 	 0.40 
D 1 0S223 	 19.07 	 0.40 
D10S1664 	 20.78 	 0.32 
D10S1653 	 22.88 	 0.32 
Table 5.6 - GeneHunter-Plus exact p-values for the NPL all statistic at the GLC1E 
locus (10p15-p14) in family GTas35 
Bold: The original markers selected in Chapter 4. 
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5.5.5 Haplotype analysis of GTas15 at GLC1B 
Haplotype reconstruction using SimWallc2, shown in Figure 5.2, revealed a shared 
haplotype of eight markers (flanked by D2S2264 and D2S2269) in six of the seven 
affected individuals (including the monozygotic twins), present in both arms of the 
pedigree. Two of the currently unaffected individuals carry the entire haplotype (15-10 
and 15-14) while recombination events in another (15-08) have removed several alleles 
in the middle of the shared haplotype. Of these currently unaffected individuals, 15-08 
and 15-10 were 43 and 45 years of age respectively at examination, below the mean age 
of diagnosis within the family (55 years; range 47-60 years), however 15-14 was aged 
69, carries the full haplotype and showed no sign of glaucoma at the time of 
examination, indicating likely non-penetrance. Individual 15-04 also carries the full 
haplotype and although this individual's optic disc ratios were within normal limits, 
their clinical classification at age 79 years was as a glaucoma suspect based on visual 
field changes. 
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Figure 5.2- GTas15 pedigree structure, clinical features and haplotype at the GLC1B locus 
ID numbers commencing with "15-" indicate individuals who participated in the study. Filled quadrants indicate the clinical characteristics of POAG (Coote et al. 1996). A filled 
upper right quadrant indicates the presence of raised intra-ocular pressure; the bottom right quadrant indicates characteristic visual field loss. The left quadrants indicate optic disc 
abnormalities characteristic of POAG and are filled from bottom (mild) to top (severe). Individuals with two or more filled quadrants have been classified as affected for the linkage 
analysis while individuals with only one filled quadrant are glaucoma suspects and classified as unknown for linkage analyses. The haplotype of interest is marked by a vertical 
black bar. An unknown haplotype is denoted by an 'x'. Forward and backslashes between the haplotypes denote the direction of recombination events. Although confirmed 
monozygotic twins 15-01 and 15-02 are shown in the figure, individual 15-02 was removed from all linkage analyses. 
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5.5.6 Haplotype analysis of GTas35 at GLC1E 
Haplotype reconstruction of the GLC lE locus in family GTas35 revealed no evidence 
of a shared haplotype across any of the branches of the family. 
5.5.7 IL1B mutation screening in family GTas15 
Two individuals from family GTas15 were found to carry the synonymous ILI B exon 5 
polymorphism, determined by the presence of undigested product following the Taql 
digest. The polymorphism was present in individual 15-07, the affected child of 15-04 
(who does not carry the polymorphism) and individual 15-13 who is not affected and 
does not carry the haplotype of interest. Both individuals were heterozygous for the 
polymorphism. Figure 5.3 shows the digest results for family GTas15, with individual 
15-07 in lane 07 and individual 15-13 in lane 13. 
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Figure 5.3 — Results of the IL1B exon 5 digested with TaqI in family GTas15 
101.11 of the Tagl digest products were electrophoresed on 1.5% agarose gel stained with 
ethidium bromide and photographed under 100% UV light. Lanes A and B contain a 
100bp ladder size reference (Promega). All other lanes are labelled  with the last two 
digits of their family ID number; for example, lane 01 denotes individual 15-01. The 
digested fragments at 114bp and 135bp are inseparable on this gel, and appear as a wide 
band between 100bp and 200bp. The undigested 249bp fragment is clearly visible in 
lanes 07 (individual 15-07) and 13 (individual 15-13). 
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5.5.8 1410deIC PAX6 mutation screening in family GTas35 
The PAX6 1410deIC mutation was not detected in any of the 15 available individuals 
from family GTas35. 
5.5.9 MYOC Phe4Ser polymorphism screening in family GTas35 
The MYOC Phe4Ser polymorphism was originally detected in individual 35-08 by 
Fingert etal. (1998) when a subset of individual from the GIST were included as part of 
this multinational search for disease causing variants of the myocilin gene. Individual 
35-08 was the only member of family GTas35 included in the original screen, hence in 
this study we screened all 15 available individuals (including 35-08). 
The Phe4Ser MYOC polymorphism, was found in three individuals from family 
GTas35: 35-08 who had mild glaucoma at age 71 years, 35-09, who had no sign of 
ocular hypertension or glaucoma when last examined at age 45 years, and 35-10 who 
had ocular hypertension (peak KW 23minHg) at age 42 years (clinical features shown in 
Figure 2.8). The polymorphism was not detected in the remaining individuals from 
family GTas35 or in any of the 23 individuals from family AN1. An example of the 
sequence data is shown in Figure 5.4, including the wildtype sequence of individual 35- 
03 and the heterozygous sequence change from A to G in individual 35-08. 
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GCACAG 	AAGAACCT 
GC 	AC 	AG 	IIA6AAC 	CT 
AtoG 
A. 
B. 
Figure 5.4 —MYOC Phe4Ser sequence data from family GTas35 
Samples were electrophoresed on an ABI PRISM 310 Genetic Analyzer (Applied 
Biosystems). 
Panel A shows wildtype sequence from individual 35-03. 
Panel B shows the A to G change of the Phe4Ser polymorphism from individual 35-08. 
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5.6 Discussion 
5.6.1 Linkage of GTas15 to GLC1B on chromosome 2 
In Chapter 4 we found initial evidence for linkage to the GLC1B locus in family 
GTas15. Fine-mapping of this locus and follow-up analyses strengthened the evidence 
for linkage. The empirical p-values calculated using SimWalk2 (p=0.01 or less) and 
exact GeneHunter p-value (p=0.005) at the distal end of the region of interest provide 
supportive evidence for the existence of a POAG susceptibility locus at 2cen-q13. 
The POAG locus GLC1B was originally identified by Stoilova et al. (1996) using six 
Caucasian families, predominantly from the United Kingdom, with three to seven 
affected individuals per family. Utilizing a penetrance model based approach, the 
maximum two-point LOD score was 6.48 at marker D2S113 (0=0). The LOD score 
calculations were repeated for the affected meioses only to eliminate the effect of 
potential incomplete penetrance, which shifted the peak LOD distally to marker D2S373 
(LOD of 3.40 at 0=0). Both these markers were used in our study, however the region 
of linkage in family GTas15 is located 2.8 cM distally, with the most significant 
evidence for linkage at marker D2S1897 (p = 0.005). An American Society of Human 
Genetics conference abstract of Raymond et al. (1999) using a large French-Canadian 
family identified a peak LOD of 2.97 at marker D2S388 (located between D2S2161 and 
D2S113), within the proximal portion of the GLC1B region, however no other 
information relating to the location of their haplotype of interest was provided 
(Raymond etal. 1999). 
Fine-mapping and haplotype analysis by Stoilova et al. (1996) refined their smallest 
region of cosegregation to 11.2 cM flanked by D2S2161 and D2S176, however more 
recent genetic maps suggest a smaller distance of approximately 9.5 cM. A comparison 
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of the maps and critical regions from Stoilova et al. (1996) and our study are shown in 
Figure 5.5. The 8-marker shared haplotype from our study (flanked by D2S2264 and 
D2S2269) overlaps the lower portion of the original GLC1B region of interest and is of 
similar size (9.0 cM). The 8-marker haplotype commences within the critical region of 
Stoilova et al. (1996) at marker D2S2264; however the marker with the lowest p-values 
in our study (D2S1897) lies outside the overlapping region (Figure 5.5). 
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Figure 5.5 - A comparison of the marker map and critical region of the original 
and current investigations of the GLC1B locus 
The ideogram shows the approximate cytogenetic location of the GLC1B locus. The 
marker map to the left of the expanded region indicates the marker location and 
haplotype of interest from the original study by Stoilova et al. in 1996. The marker map 
and region of interest from the current study is shown to the right. Numbers in italics 
indicate centiMorgan distances between adjacent markers. 
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Key clinical features of the six families originally linked to GLC1B by Stoilova et al. 
were mean age of diagnosis of 47 years and slightly elevated 10P, although half of the 
affected individuals had lop within the normal range (<22mmHg) (Stoilova et al. 
1996). Family GTas15, used in the current study, had similar clinical features, with a 
slightly higher average age of diagnosis (55 years) and similar IOP distribution. Four of 
the seven affected individuals had IOP measures over 22mmHg, however only one of 
these had peak 10P over 28mmHg. The remaining three affected individuals could be 
considered to have normal-tension glaucoma. These results suggest the susceptibility 
locus at GLC1B may be involved in POAG pathogenesis through pathways that do not 
involve IOP in all cases. 
The analyses of the unaffected meioses in the six families originally linked to GLC1B 
revealed an example of incomplete penetrance; a healthy 86-year-old with no evidence 
of glaucoma who had inherited the entire affected haplotype (Stoilova et al. 1996). We 
similarly saw evidence for non-penetrance in at least one unaffected individual (15-14) 
aged 69 and carrying the entire haplotype of interest with no clinical sign of glaucoma. 
We also found evidence of a putative phenocopy, with one affected individual (15-12) 
who did not share the haplotype of interest. 
A candidate gene of interest located within the haplotype overlap is four-and-a-half lim 
domains 2 (FHL2: M1M# 602633), expressed in a wide range of tissues including optic 
nerve and eye anterior segment. The six member interleulcin-1 receptor cluster (Dale 
and Niciclin 1999) is also located within the haplotype overlap and includes the 
interleukin-1 receptors type land 11 (ILI RI: M1M# 147810 and ILI R2: MIM# 147811) 
and also interleukin-1 receptor like 1 (ILIRLI: M1M# 601203) expressed in the eye 
anterior segment. It has been suggested that the immune system, and in particular 
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interleukin-1, is involved in POAG pathogenesis (Franks et al. 1992; Wang et al. 2001). 
In addition, the interleukin-1 gene cluster (Nicklin et al. 2002) is located on 
chromosome 2q13, approximately 0.5 cM beyond the distal end of the GLC1B 
hap lotype identified in this study. The interleukin-1 gene cluster includes interleulcin-
la (IL1A; 147760) and interleukin-1 f3 (IL1B; 147720) as well as the interleulcin-1 
receptor antagonist (IL1RN: 147679) and several other interleukin-1 family members. 
ILIB is expressed in many tissues, including the trabecular meshwork, and a 
polymorphism within the gene has been associated with sporadic POAG in the Chinese 
population (Lin et al. 2003). The study found significant differences in the distribution 
of a synonymous ILI B exon 5 Taql digest E2 allele between 58 POAG patients and 105 
healthy volunteers (p=0.035) from the Chinese population (Lin et al. 2003). However, 
we screened this polymorphism in all available members of GTas15, as described in 
section 5.5.7, and found no evidence of segregation with the POAG phenotype or 
haplotype of interest in the pedigree. It is also interesting to note that mer tyrosine 
kinase protooncogene (MERTK: MIM# 604705), a gene associated with retinitis 
pigmentosa (Gal et al. 2000) (a disease that also results in visual field loss) is located 
near marker D2S2269 at the distal end of the haplotype of interest. 
The six smaller pedigrees originally linked to GLCIB (Stoilova et al. 1996) when 
combined with our replication study in an extended POAG pedigree provide support 
that the 2cen-q13 region contains a POAG susceptibility gene, and increase the 
likelihood of gene identification. Previous experience with positionally cloned POAG 
genes MYOC and OPTN suggests that once identified, the POAG susceptibility gene at 
GLC1B may also contribute to a significant proportion of sporadic POAG cases. 
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5.6.2 Lack of evidence for linkage to GLC1E in family GTas35 
Suggestive evidence of linkage to the GLC1E region on chromosome 10 in family 
GTas35 was identified in Chapter 4. Fine-mapping and follow-up analysis of this 
region, however, revealed the initial linkage signal to be a false positive result, as the 
final results clearly suggested no evidence for linkage, with p-values greater than 0.2 
across all 12 markers in the region. 
The initial linkage signal in GTas35, described in Chapter 4, may have been caused by 
incorrect inference of missing genotypes in SimWalk2, resulting in incorrect 
reconstruction of shared haplotypes. Several genotypes failed in the original round of 
typing described in Chapter 4, due to poor DNA sample quality. Isolation of 
replacement DNA samples from stored blood as described in Chapter 3.1.1, and repeat 
genotyping of all chromosome 10 markers described in Chapter 4.3.2, were conducted 
during the follow-up analysis described in this chapter. The resulting complete dataset 
did not support linkage to the GLC1E region in family GTas35. This is one of the 
potential limitations of using estimation based analyses; however a false positive result 
may not be unexpected given the low threshold used to select loci for follow-up 
analyses (defined in Chapter 4.4.6). Combined with the number of loci investigated and 
the number of pedigrees analysed independently, the expected rate of false positive 
results is 60% (higher if the markers at each locus are considered independently). 
During the course of this investigation we determined that family GTas35 was 
connected to family AN! (figure), a Tasmanian family in which we had previously 
identified a novel 1410deIC PAX6 mutation (Sale et al. 2002). We subsequently 
screened all of the available members of family GTas35 for the PAX6 1410delC 
mutation according to Sale et al. (2002), since glaucoma is part of the phenotype 
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spectrum of aniridia. However, the PAX6 mutation was not detected in any of the 15 
available individuals in family GTas35. 
In addition, the MYOC mutation screen conducted by Fingert et al. (1999) identified a 
Phe4Ser polymorphism in individual 35-08 from family GTas35. This polymorphism 
was also detected in several controls and did not appear to be involved in POAG 
pathogenesis. We speculated that, if also present in some individuals from family AN 1, 
this polymorphism may have phenotypic modifier effects on the presentation of aniridia 
in the family, and that this polymorphism may yet have some phenotypic modification 
effects on the POAG in family GTas35. However, while the polymorphism was 
detected in three individuals from family GTas35 (shown in Figure 5.1), including 
individual 35-08, it did not appear to have any obvious influence on POAG in this 
family (although it is impossible to draw firm conclusions from such a small dataset), 
nor was it detected in any of the 23 individuals from the aniridia branch. 
The effect of an as-yet unidentified `130AG gene' on the aniridia phenotype could not 
be evaluated in this dataset, but could, in theory, contribute to the phenotypic spectrum 
of the disease observed in individuals carrying the PAX6 mutation. While glaucoma 
was uncommon in affected individuals from the aniridia branch of this pedigree, optic 
nerve anomalies were particularly common. The presence of anomalous optic nerves 
and poor visual acuity in aniridia patients may lead to difficulties in the diagnosis and 
monitoring of progression of glaucoma. 
160 
Chapter 6 - Variance Components Analysis of POAG Phenotype 
Components Using Genome-Wide Scan Data from an 
Extended Pedigree 
6.1 Preface 
Sections of this chapter have been published as the first linkage study to investigate cup-
to-disc ratio and second linkage study to investigate IOP and as quantitative traits, using 
variance components analysis. The article, entitled 'Linkage to 10q22 for maximum 
intraocular pressure and 1p32 for maximum cup-to-disc ratio in an extended primary 
open-angle glaucoma pedigree' was published in /OVS (Charlesworth et al. 2005) and is 
included in this dissertation as Appendix 4. 
6.2 Background 
6.2.1 Quantitative traits for POAG 
For genetic analyses, the presence of an underlying quantitative trait or traits that may 
be consistent with the continuous nature of gene action must be considered in the 
definition of the disease phenotype. For example, type 2 diabetes is defined by 
exceeding a threshold level of a continuous physiological trait (fasting blood glucose 
level). POAG is similarly defined by exceeding a threshold level of several continuous 
or somewhat continuous traits. Intraocular pressure and cup-to-disc ratio are both prime 
examples of continuous traits underlying a threshold affection status. Visual field loss 
is likely to be continuous; however its usefulness as a trait is dependent on the method 
of clinical ascertainment. Visual field loss is generally ascertained as categorical data 
which are not useful for quantitative trait analysis. Studies of POAG genetics 
consistently use a combination of these three traits, with a threshold level for each, to 
generate a dichotomous affection status for the purposes of linkage analysis (Sheffield 
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et al. 1993; Stoilova etal. 1996; Wirtz etal. 1997; Sarfarazi etal. 1998; Trifan et al. 
1998; Wirtz etal. 1999; Wiggs etal. 2000; Nemesure etal. 2003). 
Given the limited success in identifying glaucoma susceptibility genes so far, one 
approach that may have greater success is quantitative trait linkage analysis using 
precursors or phenotype components of glaucoma, such as raised TOP and increased 
cupping of the optic nerve. Such traits may be more aetiologically homogeneous than 
an overall diagnosis of glaucoma, with more simple genetic architectures, making it 
easier to map causative loci (Almasy and Blangero 1998; Amos and de Andrade 2001; 
Freimer and Sabatti 2004). Furthermore, quantitative trait linkage analysis is inherently 
more powerful than dichotomous-trait linkage analysis (Duggirala et al. 1997; Williams 
and Blangero 1999a), and is particularly powerful with large families (Wijsman and 
Amos 1997; Williams and Blangero 1999b). 
The heritabilities of IOP and vertical cup-to-disc ratio have been estimated as 0.29-0.36 
and 0.48-0.56 respectively (Klein et al. 2004; Chang et al. 2005), providing evidence 
for genetic determinants for these components. A recent commingling analysis of lOP 
and glaucoma suggested the existence of a major gene accounting for 18% of the 
variance of IOP in the Blue Mountains Eye Study population (Viswanathan etal. 2004). 
Commingling analysis is a form of maximum likelihood model fitting that uses the 
distribution of quantitative trait values in a population to assesses the likelihood of the 
trait being influenced by a single biallelic locus of major effect, compared to the null 
hypothesis of no major trait locus (Maclean etal. 1976). A complex segregation and 
linkage analysis of IOP recently identified two potential regions of linkage, on 
chromosome 6 and chromosome 13 (Duggal etal. 2005). Prior to the study described in 
this chapter there had been no reported linkage analyses of cup-to-disc ratio. 
162 
The inclusion of quantitative phenotype components in the genetic analysis of POAG 
may offer significant power to identify the genetic basis of glaucoma in the face of 
limited family and population datasets. The discovery of genes contributing to the 
variation of maximum IOP and maximum cup-to-disc ratio, components of POAG 
phenotype, may provide significant insights into glaucoma pathophysiology as a whole. 
6.2.2 Variance components analysis for localising quantitative trait loci 
Variance component linkage analysis is an approach that enables penetrance model-free 
multipoint linkage analysis of complex quantitative (or qualitative) traits in extended 
pedigrees (Blangero and Almasy 1997; Duggirala et al. 1997; Almasy and Blangero 
1998; Williams et al. 1999b; Williams et al. 1999a). The superior information content 
of quantitative traits allows the analysis of quantitative risk factors to serve as a 
powerful tool for evaluating the genetic mechanisms influencing common disease 
(Almasy and Blangero 1998). Variance component analysis has been used successfully 
to localise quantitative trait loci (QTLs) influencing many important disease-related 
traits, including risk of alcoholism (Williams et al. 1999b), serum leptin levels 
(Comuzzie et al. 1997; Martin et al. 2002) and resting heart rate (Comuzzie et al. 1997). 
The variance component linkage method is based on the classical quantitative genetic 
decomposition of a phenotype, which assumes the phenotype is jointly influenced by 
genetic and environmental factors. These genetic factors can include specific loci at 
defmed chromosomal locations. Evidence for a locus is obtained by observing trait 
covariances among different classes of relatives. The linkage analysis utilises both the 
average IBD probability (the coefficient of relationship) across the genome and the 
location-specific IBD probabilities estimated from the genetic marker data. Evidence 
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for a QTL requires that the statistical 'fit' of the observed phenotypic covariances with 
the expected covariances (given the linkage model under consideration) be significantly 
better when the locus-specific component is considered than when only the average 
genomic component is allowed. In practice, this involves testing for the existence of a 
locus influencing the phenotype at each location in the genome (usually by performing a 
linkage test at every cM). If the variance component for a specific chromosomal 
location is significantly greater than zero, there is evidence for a locus influencing the 
phenotype at that location. 
As mentioned above, the variance component method is based on specifying the 
expected genetic covariances between arbitrary relatives as a function of IBD 
relationships at a given marker locus (Almasy and Blangero 1998). The total trait 
phenotypic variance (cep) is partitioned into components attributable to the effects of a 
specific QTL WO, residual additive genetic effects (0' 2 , and individual-specific 
random environmental effects (02e). The covariance matrix for the pedigree (St) is then 
given by: 
= Ha2q + 2002g + lecr2e , 
where H is a matrix with elements OW providing the estimated proportion of genes 
individuals i and j share IBD at a specific chromosomal location (q); q is the variance 
component corresponding to the additive genetic effects from the major locus; (1) is the 
matrix of average coefficients of relationship (kinship); 0 2g is the variance component 
corresponding to the residual polygenic effects; I is the identity matrix; and 0 2, is the 
variance component corresponding to the random environmental effects. The test for 
linkage compares the likelihood of this model, in which the variance due to the nth QTL 
is estimated, with the likelihood of a null model (no linkage), where the QTL effect size 
2 • T is fixed to be zero. The difference between the two log io likelihoods produces a 
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LOD score that can be interpreted in a similar fashion to the classical LOD scores of 
parametric linkage analysis (Blangero et al. 2001). 
6.2.3 GTas02 - the family of interest 
The family of interest in this investigation is a large, late-onset POAG pedigree 
identified as part of the GIST. The family originated from British settlers who arrived 
in Tasmania in the mid 1800s. The pedigree includes more that 1350 individuals, 
making it one of the largest families identified as part of the GIST. 
Segregation of POAG is evident in a core portion of the pedigree, referred to from this 
point as GTas02, which consists of 246 individuals (including deceased linking 
members), 139 of whom consented to clinical examination and blood collection for 
genotyping and mutation analysis. The pedigree extends over six generations and 
includes 24 available, clinically affected individuals who have elevated IOP and late 
onset POAG (Figure 6.1). The average age of POAG diagnosis within the pedigree is 
69 years. 
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GTas02 had been under investigation by Dr Paul Baird and collaborators at the Walter 
and Eliza Hall Institute (Victoria) and Royal Victorian Eye and Ear Hospital prior to the 
inception of this study. These investigations included SSCP screening and sequence 
analysis of MYOC mutations (Craig et al. 2001; Baird et al. 2003) and a 10 cM genome-
wide scan (Baird et al. 2005). The resulting genotype data provided an opportunity to 
apply the method of variance components linkage analysis to the problem of POAG 
genetics, and were made available to this investigation for that purpose. 
MYOC, encoding myocilin, is the glaucoma susceptibility gene at the GLC1A locus on 
chromosome 1q24.3, described in Chapter 1.8.1. Of the 139 individuals screened for 
mutations in the MYOC gene, 19 were found to carry the glutamine368STOP (Q368X) 
mutation (Figure 6.1). Q368X is the most common mutation identified in POAG 
patients, estimated to account for approximately 1.6% of POAG (Fingert et al. 1999). 
The Q368X mutation generally gives rise to a mild phenotype (in contrast to MYOC 
mutations associated with JOAG), with late age of onset and raised IOP (Allingham et 
al. 1998). Allele sharing of Q368X mutation carriers across multiple populations 
suggests a common origin for this mutation (Fingert et al. 1999). Haplotype analysis of 
Q368X has revealed a founder effect in 15 Tasmanian POAG families, including family 
GTas02, with a shared four marker haplotype surrounding the Q368X mutation 
suggesting a common origin prior to European settlement in the early 1800s (Baird et 
al. 2003). 
6.3 Aims 
The intention of this investigation was to explore the use of quantitative data, collected 
as a component of routine clinical examination for POAG, as the basis for the genetic 
linkage analysis. This investigation aimed to identify regions of linkage contributing to 
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maximum recorded IOP and maximum cup-to-disc ratio, key components of the POAG 
phenotype; to evaluate the possibility of interaction between these traits and investigate 
the effect of the myocilin Q368X mutation as a covariate in the analyses of these traits. 
Analysis of a dichotomous trait based on clinical diagnosis of POAG was also included 
in the analysis, to provide some comparison between the analysis of discrete and 
quantitative traits. 
6.4 Methods 
6.4.1 Clinical examination 
Of the 139 available individuals in the pedigree, 24 were diagnosed with POAG. The 
details of the clinical assessment of this family has been extensively reported (Craig et 
al. 2001) and clinical examination procedures are detailed in Appendix 1. Quantitative 
measures collected as part of the clinical examination of POAG patients and their 
relatives included maximum recorded IOP without medication and maximum cup-to-
disc ratio from the highest scoring eye (Coote et al. 1996; Craig et al. 2001) and these 
were used as quantitative traits in this study. Multiple IOP measures were available for 
each individual, hence maximum IOP was selected as the trait measure to reduce any 
bias introduced by using post-medication pressure values. The larger vertical cup-to-
disc ratio from either eye was used as the measure for this trait. 
6.4.2 Genotyping 
A 10 cM genome-wide scan was conducted by the Walter and Eliza Hall Institute 
(Victoria), using 401 microsatellite markers from the ABI version 2.0 and 2.1 
fluorescent marker sets, run on ABI377 Sequenators (Applied Biosystems) and 
analyzed using the Genescan® and Genotyper® software (Applied Biosystems), as 
_ described in Baird et al. (2005). The resulting raw genotype, pedigree and phenotype 
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data were provided by Dr Paul Baird from the Centre for Eye Research Australia 
(CERA). Inconsistencies in Mendelian inheritance of genotypes were detected using 
Pedcheck (O'Connell and Weeks 1998). Marker allele frequencies were estimated from 
72 elderly glaucoma-free control individuals drawn from the same population (Chapter 
2.2.4). 
Multipoint identity by descent (IBD) files were created using the Markov chain Monte 
Carlo (MCMC) based program Loki, version 2.4.7 (Heath 1997; Heath et al. 1997) from 
within SOLAR, version 2.1.1 (Almasy and Blangero 1998). Loki performs similar IBD 
calculations to SimWalla, described in chapter 4.4.2. The IBD matrices contain the 
probability of each pair of individuals sharing 0, 1, or 2 alleles IBD at specified 
intervals along each chromosome. The IBD matrices were calculated once and stored 
for all future analyses. 
All calculations were performed using a Sun Microsystems Enterprise 450 server with 
four Ultrasparc-II 480MHz central processing units, 4GB of RAM and 60GB of disk 
space. All computations were achievable in an acceptable timeframe using this system. 
6.4.3 Discrete and quantitative traits 
The covariates used for all analyses were age and sex. Age-sex interaction was initially 
included, but removed after it was found to be not significant in any dataset. POAG 
affection status (clinical diagnosis of POAG) was analysed as a discrete trait. The 
quantitative traits analysed were maximum recorded IOP and maximum cup-to-disc 
ratio. Visual field loss was not used as a trait due to its categorical nature and the 
incompatibility between the clinical assessment methods of the GIST and the 
assessment methods used to generate the general population data used in this study. 
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6.4.4 Population ascertainment correction 
Two datasets were created to provide the population ascertainment correction; one for 
the discrete trait and one for the quantitative traits. The first was an age based 
distribution of POAG (dichotomous affection based on clinical diagnosis) in 5332 
individuals, estimated from Australian population prevalence data provided by the Blue 
Mountains Eye Study (BMES) (Mitchell et al. 1996) and Melbourne Visual Impairment 
Project (MVIP) (Wensor etal. 1998). 
The second ascertainment correction data set was taken directly from the MVIP and 
included 3,905 individuals from the general population with data on age, sex, maximum 
recorded LOP and maximum cup-to-disc ratio (Wensor et al. 1998). This dataset 
provided a population ascertainment correction for the quantitative traits. The MVIP 
clinical data used in this study was collected using the same methods as the GIST. 
Mean values of age and trait variables in the GTas02 sample and the ascertainment 
correction sample were compared using 2-sided t-tests (or multivariate linear regression 
when it was necessary to adjust for other variables) to determine the necessity of the 
ascertainment correction. For example, if the distribution of the trait values between the 
general population and GTas02 are highly similar, a population based ascertainment 
correction may not necessarily have been required. 
The ascertainment corrections were conducted using SOLAR version 2.1.1 (Almasy and 
Blangero 1998) and the relevant population based ascertainment correction dataset, by 
maximising the sporadic model for the population correction dataset alone, including 
the trait of interest and covariates age and sex. In the sporadic model the variance is not 
decomposed into genetic and non-genetic components. The mean effects for each trait 
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were thereby estimated from the population dataset, including the regression 
coefficients 13A ge and Psex which were used to adjust the trait mean for the effect of the 
covariates age and sex. The resulting values for mean, standard deviation, 13A ge and Osex, 
obtained from the population based dataset, were then employed in the model used to 
analyse the pedigree data. By constraining these mean effects and the total variance to 
that of the general population, trait values for individuals in family GTas02 were given 
the appropriate weight. The standard deviation was not fixed for the dichotomous trait. 
6.4.5 Variance components analysis 
The heritability of each trait was estimated using genetic variance component modelling 
as implemented in SOLAR version 2.1.1 (Almasy and Blangero 1998). Variance 
component linkage analysis was performed to detect and localise quantitative trait loci 
influencing variation in the traits. 
An initial analysis was performed using the discrete trait based on POAG affection 
status. Of the 139 available individuals in the pedigree, 24 were classified as clinically 
affected. The continuous traits based on maximum recorded IOP and maximum cup-to-
disc ratio were then analysed as individual traits, with age and sex as covariates. A 
bivariate analysis of these continuous traits was performed to test for potential genetic 
and/or environmental correlations between the traits (Williams et al. 1999b). In this 
case the original ascertainment correction values for mean, standard deviation, 13Age and 
Psex for each trait were fixed in the bivariate analysis model. 
To test the impact of the MYOC Q368X mutation on the linkage results, Q368X status 
was included as a covariate in a second round of analyses for each quantitative trait, but 
not in the analysis of the discrete trait. The regression coefficient for Q368X mutation 
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status (13my0c), used in the analysis of each trait, was estimated using family GTas02 
trait and mutation data and not from the population ascertainment correction dataset. As 
in previous analyses, age and sex were included in all models, and adjusted LOD scores 
and empiric p-values were calculated as described below. 
6.4.6 Empirical LOD adjustment 
Expected LOD scores and empiric locus-specific p-values were determined using the 
lod adjustment (iodadi ) command of SOLAR (Blangero et al. 2000; Blangero er al. 
2001). A total of 100,000 replicates were simulated to build up the distribution of LOD 
scores expected under the null hypothesis of no linkage, using a fully informative, 
unlinked marker. The observed LOD scores were then regressed on those expected for 
a multivariate normal trait, with the inverse slope of the regression line providing the 
LOD correction constant. Final LOD scores were multiplied by the correction constant 
only if the constant was less than 1. The LOD adjustment is used to account for 
possible errors introduced by any deviation from normal distribution, such as kurtosis 
(Blangero et al. 2000). Empiric locus-specific p-values were derived from the 
simulated LOD score distribution. 
6.4.7 Genome-wide p-values 
In order to control for the overall false positive rate in our linkage screens, we have 
converted the nominal p-values associated with our peak LOD scores to genome-wide 
p-values using an approach based on the work of Feingold et al. (1993) and 
implemented in Gauss 5.0.29 (Aptech Systems, Inc). This method takes into account 
the mean recombination rate in our study population and the marker density of the 
linkage map utilised in our genome scan. 
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6.5 Results 
6.5.1 Population ascertainment correction 
In the first population ascertainment correction dataset, an age based distribution of 
dichotomous POAG affection, prevalence rose from 0.08% in the initial 10-39 year age 
block to 9.2% at 90+ years. The prevalence of POAG in individuals >40 years of age 
was ascertained in 10 year age blocks. The average population prevalence was 3.2%. 
The distribution of this data is shown in Figure 6.2 and a summary of the data based on 
POAG affection status is given in Table 6.1. 
The fitted coefficients PAge (0.0267) and Psex (-0.0159) were obtained from the MVIP 
and BMES population data using SOLAR. A comparison between the ascertainment 
correction data for the dichotomous trait and family GTas02 is shown in Table 6.2. 
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Figure 6.2 - Population prevalence of POAG in Australia 
The population prevalence of POAG in Australia, derived from 5332 individuals from 
the Blue Mountains Eye Study (Mitchell et al. 1996) and Melbourne Visual Impairment 
Project (Wensor etal. 1998). 
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Population Number of individuals Mean age (years) SD age (years) 
Entire population 5332 59.5 24.0 
Unaffected individuals 5162 58.7 23.9 
Affected individuals 170 83.3 12.2 
Table 6.1 - Summary of POAG population prevalence data in the first 
ascertainment correction dataset 
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MVIP/BMES Family GTas02 
Age* (N) 5332 139 
Age (Mean) 59.5 53.1 
Age (SD) 24.0 14.4 
POAG prevalencet 3.2% 17.3% 
Table 6.2 - Age and trait distribution statistics from the population ascertainment 
correction datasets for the dichotomous trait and family GTas02 
MVIP: Melbourne Visual Impairment Project; BMES: Blue Mountains Eye Study; N: 
number of observations; SD: standard deviation. 
*Age in years. 
t Average prevalence. 
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The second population ascertainment correction dataset was used for the quantitative 
traits based on maximum recorded 10P and maximum vertical cup-to-disc ratio. The 
distribution of these traits in the population compared with family GTas02 is shown in 
Figure 6.3 and a summary of the population trait distributions is shown in Table 6.3. 
Although the kurtosis of maximum IOP in the general population appears high (Table 
6.3), the empirical LOD adjustment was used to determine whether any correction of 
the final LOD score was required, before any transformation of the data was considered. 
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Figure 6.3 - Population distribution of maximum 10P and vertical cup-to-disc ratio 
Panel A shows the MVIP population distribution of maximum recorded intraocular pressure compared with family GTas02. 
Panel B shows the MVIP population distribution of maximum vertical cup-to-disc ratio compared with family GTas02. 
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Mean SD Kurtosis Skew 
Age 59.42 11.61 -0.48 0.42 
Intraocular pressure 15.20 3.32 7.28 1.31 
Cup-to-disc ratio 0.43 0.21 -0.28 0.60 
Table 6.3 - Summary of age, maximum KW and cup-to-disc ratio distribution in 
the second ascertainment correction dataset 
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A comparison between the ascertainment correction data for the quantitative traits, 
maximum recorded MP and maximum vertical cup-to-disc ratio, and family GTas02 is 
shown in Table 6.4, including the fitted coefficients 3A ge and 13sex obtained from the 
MVIP population data. 
The mean age of the 139 subjects in the GTas02 sample (53.1 years, SD=14.4 years) 
was significantly lower (p<0.0001) than the mean age of the 5332 subjects in the 
ascertainment correction sample used for POAG as a dichotomous trait (59.5 years, 
SD=24.0 years). The mean age of the 139 GTas02 subjects was also significantly lower 
(p<0.0001) than the mean age of the 3892 subjects in the population ascertainment 
correction sample used for the quantitative traits maximum IOP and maximum cup-to-
disc ratio (59.4 years, SD= 11.6 years). The ascertainment correction datasets were not 
designed to be age matched, however the comparison of age and trait values between 
the two groups reveals the relative position of family GTas02 within the distributions of 
these populations. 
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Trait MVIP 
N 	Mean SD 
Family Gras02 
N 	Mean SD 
Fitted coefficients 
13Age 	f3Sex 
Age (years) 3892 59.4 11.6 139 53.1 14.4 
Max. Disc 2986 0.43 0.21 135 0.47 0.20 0.0016 -0.032 
Max. lOP (mmHg) 3221 15.2 3.32 137 17.9 4.15 0.0033 -0.211 
Table 6.4 - Age and trait distribution statistics from the population ascertainment correction datasets for the quantitative traits and family 
GTas02 
MVIP: Melbourne Visual Impairment Project; N: number of observations; SD: standard deviation; r3 Age : fitted coefficient for age; Os ex : fitted 
coefficient for sex; Max. Disc: maximum cup-to-disc ratio; Max. IOP: maximum intraocular pressure. 
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6.5.2 Analysis of the dichotomous trait based on POAG affection status 
Based on the population ascertainment correction dataset, the heritability for the 
dichotomous trait referring to POAG affection status, with covariate age, was 1. 
Heritabilities of I are often returned as incorrect results in the analysis of discrete traits, 
and this is most likely the result of having to fix parameters from the ascertainment 
correction model. However, although the heritabilities and resulting LOD score 
magnitudes may be incorrect, it is still possible to detect the approximate location of 
genetic loci using the multipoint analysis. 
The empirical LOD adjustment coefficient was 0.88 hence the multipoint LOD scores 
were adjusted down by this factor. The resulting linkage signal was weak, the strongest 
signals including two peaks on chromosome 10 (near marker D10S547 on 10p and 
D 10S537 on 10q), both with a LOD of 1.9 (p=0.004), and a third peak of LOD 1.8 
(p=0.005) on chromosome lq, near marker D1S249 and the myocilin locus (Figure 6.4). 
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6.5.3 Analysis of the quantitative trait based on maximum recorded IOP 
Maximum recorded IOP had a heritability of 0.55 for family GTas02. Covariates sex 
and age were statistically controlled for and included in the analysis, although in the 
ascertainment correction population neither showed effects that were significant 
(p=0.073 for sex, p=0.53 for age), and accounted for only 0.1% of the variance. The 
mean value for maximum recorded IOP in family GTas02 (17.9mmHg, SD=4.2mmHg) 
was significantly higher (p<0.0001) than the mean LOP in the general population 
(15.2mmHg, SD=3.3mmHg). The empirical LOD correction constant was greater than 
1(1.05), hence no adjustment was applied to the linkage results. The highest LOD 
score for .1013 in family GTas02 was 3.3 (locus-specific p=0.00015) near marker 
D10S537 (Figure 6.6), with the LOD-1 interval spanning approximately 20 cM on 
chromosome 10q22 (Figure 6.7). The genome-wide p-value for this result was 0.0165. 
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6.5.4 Analysis of the quantitative trait based on maximum cup-to-disc ratio 
Maximum vertical cup-to-disc ratio had a heritability of 0.39 for family GTas02. The 
effect of covariates sex (p=3.1x10 -5) and age (p=1.6x10-6) were highly significant in the 
ascertainment correction population, accounting for 1.4% of the variance; hence both 
were statistically controlled for and included in the analysis of family GTas02. After 
adjustment for age and sex, cup-to-disc ratios were significantly higher in family 
GTas02 than in the general population (t=2.59, p=0.01). The empirical LOD correction 
constant was greater than 1 (1.21), hence no adjustment was applied. The highest LOD 
score for maximum cup-to-disc ratio in family GTas02 was 2.3 (locus-specific 
p=0.00056) near markers D1S197 and D1S220 (Figure 6.8), with the LOD-1 interval 
spanning approximately 20 cM on chromosome 1p32 (Figure 6.9). The genome-wide 
p-value for this LOD score was determined to be 0.208. 
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Figure 6.8 - Genome-wide multipoint variance components linkage results for maximum vertical cup-to-disc ratio. 
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6.5.5 Inclusion of Q368X mutation status as a covariate 
The MYOC Q368X mutation was present in nine out of 24 (37.5%) individuals in 
family GTas02 with diagnosed POAG, and 10 individuals without a diagnosis of POAG 
at examination. SOLAR was used to compare the trait values of Q368X carriers and 
non-carriers, accounting for non-independence among relatives and age. MYOC Q368X 
mutation status was included as a covariate in the model used for the multipoint analysis 
of each trait (described in section 6.4.4). The polygenic command with covariate 
screening was used to estimate the Nyoc term (equal to the age-adjusted difference in 
trait means between Q368X carriers and non-carriers) and calculate a p-value for its 
significance. While the mean age of individuals carrying the Q368X mutation in family 
GTas02 was not significantly different from those without the mutation, mean 
maximum IOP and mean maximum cup-to-disc ratio were significantly higher in 
Q368X mutation carriers, regardless of POAG affection status (Table 6.5). 
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Trait 
Q368X mutation carriers 
N 	Mean 	SD 
Q368X mutation free 
N 	Mean 	SD p-value* 
Age 19 54.32 15.06 120 52.93 14.39 
Max. IOP 19 22.21 5.32 118 17.17 3.48 7.70x10 ." 
Max. Disc 19 0.64 0.23 116 0.44 0.18 2.26x104 
Table 6.5 — Age and quantitative trait comparison between myocilin Q368X 
mutation carriers and mutation-free individuals from family GTas02 
N: number of observations; SD: standard deviation (SD); Max. IOP: maximum 
intraocular pressure; Max. Disc: maximum cup-to-disc ratio. 
*p-value obtained by age-adjusted measured genotype analysis accounting for non-
independence among relatives. 
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The regression coefficient for MYOC Q368X mutation status used in the analysis of 
each trait (13my0c) was derived from family GTas02 trait and mutation data (as 
described above), and not from the population ascertainment correction dataset. The 
aim of this process was to use MYOC status as a covariate in an attempt to account for 
the presence of the mutation in family GTas02. The fitted coefficient for myocilin 
mutation status in the analysis of LOP was 5.065 while fimyoc for the analysis of 
maximum cup-to-disc ratio was 0.192. Myocilin mutation status was estimated to 
account for 16% of the genetic variance of maximum IOP (heritability reduced from 
0.55 to 0.46) and 49% of the genetic variance of maximum cup-to-disc ratio (heritability 
reduced from 0.39 to 0.20). Addition of MYOC Q368X mutation status as a covariate in 
the analysis of the quantitative traits resulted in the peak LOD score for maximum 
recorded 10P (near marker D 10S537 on chromosome 10q22) dropping from 3.3 to 1.9 
(Figure 6.7), while the peak LOD score for maximum cup-to-disc ratio (near markers 
D1S197 and D1S220 on chromosome 1p33) was reduced from 2.3 to 0.9 (Figure 6.9). 
6.5.6 Bivariate analysis of the quantitative traits 
The bivariate analysis of the quantitative traits maximum recorded IOP and maximum 
cup-to-disc ratio revealed no apparent genetic and/or environmental correlation 
between the traits. Both peaks of interest from the individual analyses were present, 
however the chromosome 1 p (cup-to-disc ratio) peak dropped to a LOD of 1.7 and the 
chromosome 10q (maximum IOP) peak dropped to a LOD of 2.4 (Figure 6.10). This 
reduction is most likely due to reduced power in the combined analysis. 
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6.6 Discussion 
The published sections of this chapter represent the one of the first linkage studies to 
investigate two individual phenotype components of POAG, maximum recorded IOP 
and maximum vertical cup-to-disc ratio, as quantitative traits using variance 
components analysis. Genome scan analyses of these traits in an extended pedigree 
revealed one region of significant or suggestive linkage for each trait. Multipoint 
linkage analysis of maximum recorded IOP identified a peak LOD of 3.3 (locus-specific 
p=0.00015) near marker D10S537 on chromosome 10q22; while analysis of maximum 
cup-to-disc ratio produced a peak LOD score of 2.3 (locus-specific p=0.00056) near 
markers D1S197 to D1S220 on chromosome 1p32. In comparison, analysis of the 
dichotomous trait based on POAG diagnosis was seriously underpowered and revealed 
no significant evidence of linkage. The bivariate analysis of the quantitative traits and 
analyses involving the inclusion of myocilin mutation status as a covariate suffered 
similar deficits in power. 
The putative trait locus for maximum recorded IOP produced a significant peak LOD of 
3.3 on chromosome 10q22 (Figure 6.7). The genome-wide significance level of this 
result (p=0.0165) strongly suggests that this region contains a gene that contributes to 
the variance of IOP. We did not see any overlap with the IOP linkage regions on 
chromosome 6q27 and 13q31 identified by Duggal et al. (2005). While our region of 
interest for IOP on chromosome 10q22 has not been reported previously for IOP, 
linkage to this region has also been found for systemic hypertension in a Japanese 
population (Wu et al. 2003). The association between systemic blood-pressure (systolic 
or diastolic) and IOP has been well documented (McLeod et al. 1990; Dielemans et al. 
1995; Tielsch et al. 1995b). It is possible that systemic hypertension and IOP share a 
- common QTL in this region on chromosome 10q. This region contains BMPRIA 
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(MIM:601299), a bone morphogenic protein receptor, of interest since Bmp4 has been 
implicated in increased IOP in mice (Chang et al. 2001). The peak region also contains 
RGR (MIIVI:600342), an opsin-related gene associated with retinitis pigmentosa (Bernal 
et al. 2003). The OPTN gene is located outside our 10p13 linkage peak, approximately 
60 cM upstream. 
Applanation tomometry measurements of IOP are known to be influenced by central 
corneal thickness (CCT) (Hansen and Ehlers 1971; Stodtmeister 1998). CCT has a 
positive and apparently linear correlation with 10P (Wolfs et al. 1997), and is strongly 
genetically determined with an extremely high heritability (Toh et al. 2005). There has 
been a report of familial thick corneas segregating in a family with apparent ocular 
hypertension (Dohadwala and Damji 2000), which leads to the suggestion that perhaps 
the variation in IOP in family GTas02 compared with the population is due to CCT. 
However, there are many individuals in family GTas02 with moderate to advanced 
visual field loss, which would support the elevated 10P being genuine rather than 
artefactual in nature. It is possible that measurement of CCT and subsequent adjustment 
of Goldmann applanation IOP readings for GTas02 may have the erect of strengthening 
the linkage at the IOP locus on chromosome 10q22, by providing a more accurate 
approximation of true IOP (as opposed to measured IOP). This approach is worthy of 
future investigation. However, CCT data is not currently available for this pedigree. 
This study identified a putative trait locus for maximum cup-to-disc ratio on 
chromosome 1p32 — the first reported locus for this trait — with a peak LOD score of 2.3 
(p=0.00056; Figure 6.9) and a genome-wide p=0.208. This corresponds to suggestive 
linkage, since there is a 20% chance of a LOD score of this size or greater occurring by 
chance in a genome-wide scan. The region covered by the linkage peak includes the 
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gene POMGnT1 (MIM:606822), mutant forms of which are responsible for muscle-eye-
brain disease (MEB; MIM:253280), a congenital muscular dystrophy based disorder 
with many additional features including early-onset glaucoma, optic nerve atrophy, 
severe congenital myopia and retinal hypoplasia. MEB is inherited as a loss-of-function 
of POMGnT1 (Manya et al. 2003), hence it is possible that more mild, heterozygous 
mutations of POMGnT1 may contribute to the optic nerve degeneration in POAG. The 
peak region also contains FOXE3 (MIM:601094), known to be associated with anterior 
segment ocular dysgenesis (Semina et al. 2001) and is approximately 25 cM distal to 
the primary congenital glaucoma locus GLC3B (MIM:600975), on chromosome 1p36 
(Akarsu et al. 1996). 
SOLAR 2.1.1 supports the analysis of a discrete trait that has two possible values, using 
a liability threshold model. However, the program's authors recommend the use of 
quantitative traits whenever possible as they provide more information than discrete 
traits, and the modelling of quantitative traits maximises more quickly and reliably 
(Williams et al. 1999a). The analysis of the discrete trait based on typical POAG 
affection status (clinical diagnosis) revealed no significant linkage information. There 
were a set of small peaks on chromosome lq, including a peak in the region of the 
myocilin gene (Figure 6.5), but no evidence of overlap with the chromosome 1 p locus 
for maximum cup-to-disc ratio identified in section 6.5.4. The dichotomous trait 
linkage analysis produced two broad peaks on chromosome 10 (Figure 6.5), one 
corresponding to the approximate location of OPTN and the other corresponding to the 
maximum IOP locus near marker DI0S537 identified in section 6.5.3. Several 
additional peaks (LOD>1) were identified on chromosomes 3, 4 and 9 (Figure 6.5). 
One of the peaks on chromosome 9 is of interest, since it overlaps the region on 9q22 
that was recently identified as a novel locus for JOAG (Wiggs et al. 2004). The peak 
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region of interest identified by Wiggs et al. (2004) lies between markers D9S287 and 
D9S1690 (see Figure 6.5 for chromosomal locations of these markers). One gene 
originally identified in JOAG (MYOC) had been clearly shown to influence POAG as a 
whole; hence it is plausible that, if identified, the gene at 9q22 may also be involved 
POAG pathogenesis. Although the regions are not necessarily the same, the standard of 
results (many small, somewhat 'noisy' peaks) are typical of other POAG analyses based 
on a dichotomy of affection (Wiggs et al. 2000; Nemesure et al. 2003) and are similar to 
results obtained by other researchers using nonparametric approaches to analyse the 
GTas02 genome-scan data (Dr Paul Baird 2003, personal communication; data not 
shown). 
The MYOC Q368X mutation is the most common mutation identified in POAG patients 
to date, found to account for approximately 1.6% of POAG (Fingert etal. 1999). In 
comparison to other MYOC mutations associated with JOAG, this mutation generally 
gives rise to a milder phenotype with late age of onset and raised IOP (Allingham et al. 
1998). Myocilin mutation status and related phenotypic modification effects within 
family GTas02 have been previously reported (Craig et al. 2001; Baird et al. 2003). 
The MYOC locus was not apparent in either of the linkage analyses for the two 
quantitative traits investigated in this study. This mutation is clearly unable to account 
for the presence of all cases of POAG in the entire family (Baird et al. 2003). Despite 
the absence of a linkage signal at MYOC, the Q368X mutation appeared to account for 
nearly half the genetic variance for the quantitative trait based on maximum cup-to-disc 
ratio, and nearly 20% of the genetic variance for maximum IOP. The differences 
between carrier and non-carrier trait values (shown in Table 6.5) were significant, which 
may indicate epistasis or some other form of interaction between MYOC and the 
putative trait loci for IOP and cup-to-disc ratio. The reduction in peak LOD scores for 
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both traits following the inclusion of the Q368X mutation as a covariate provides 
further evidence for the presence of an interaction. However, the sample size of family 
GTas02 does not provide sufficient power to determine the exact mechanism behind this 
interaction. Subsequent identification of the genes at these loci is anticipated to aid the 
investigation into the nature of this interaction. 
Baird et al. (2005) recently identified linkage of clinical POAG diagnosis to 
chromosome 3p21-p22 using MCMC based linkage analysis of family GTas02 and the 
same genome-wide scan data as this study. They generated a maximum two-point LOD 
score of 1.2 at marker D3S1300, and a minimum locus specific p-value of 0.003 with 
the Spairs and Smog  statistics at marker D3S1298 (Baird et al. 2005). We did not find any 
evidence of overlap with this region using the traits maximum 101 3 and cup-to-disc 
ratio, however we did identify a modest peak (LOD=1.7; p=0.0058) at the same locus 
(between markers D3S 1298 and D3S 1289) in the analysis of the dichotomous trait, 
which is equivalent to the classification of affection used by Baird et al. (2005). There 
are likely to be many genes contributing to the complex POAG phenotype, beyond 
those influencing maximum IOP and cup-to-disc ratio, and different analytical 
approaches will have varying power to detect certain loci. The gene at the 3p locus may 
contribute to a different POAG trait, such as progression from elevated 10P to optic 
nerve damage and subsequent clinical signs of visual field loss. Finally, as with any 
genome scan, one must also be mindful that some of these linkage results could 
represent chance events. 
The bivariate multipoint linkage analysis was used to take advantage of any additional 
information contained in the correlation pattern between two quantitative traits. 
However the results of the analysis provided no evidence of a common genetic locus 
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influencing both IOP and vertical cup-to-disc ratio. While both peaks of interest from 
the individual trait analyses were present, both were reduced in magnitude. This effect 
is suggestive of a reduction in power for the combined analysis. However, on 
considering the physiology of each trait, it may be unlikely that a single QTL 
influencing both intraocular pressure and cup-to-disc ratio exists, or has an influence at 
a level that could be detected given the power constraints of this study. 
The primary aim of this chapter was to explore the use of quantitative data, collected as 
a component of routine clinical examination for POAG, as the basis for the genetic 
linkage analysis, in an attempt to identify regions of linkage contributing to maximum 
recorded IOP and maximum cup-to-disc ratio. Applying this method to a pedigree 
enriched for POAG should improve the power to map genes related to POAG-correlated 
traits, since extreme values of lOP and cup-to-disc ratio are likely to be present within 
an extended POAG pedigree, as we found in family GTas02. When used in 
combination with population-based ascertainment correction (which provides a 
comparison between these extreme values and the distribution in the general 
population), this approach provides greater power to detect linkage to these POAG-
correlated traits. Trait selection for this study was based, not only on the data available 
and the relevance of the chosen trait values to the disease, but also on the quality of the 
available data. While maximum IOP is not an ideal measure, especially given the 
occurrence of pressure spikes and diurnal variation, mean IOP or any other measure is 
likely to be equally problematic, considering the likely inclusion of post-medication 
pressures. However, these biases in the chosen trait data are also present in the general 
population data used for the ascertainment correction. Utilising this method, this 
investigation was able to identify significant or near significant regions of linkage 
contributing to maximum recorded IOP and maximum cup-to-disc ratio. The discovery 
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of genes at loci that appear to influence components of the POAG phenotype is 
anticipated to provide significant insights into glaucoma pathophysiology as a whole. 
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Chapter 7— Discussion 
POAG is a complex and highly genetically heterogeneous disease. Three genes for 
adult onset POAG have been identified: MYOC (Stone et al. 1997), OPTN (Rezaie et al. 
2002) and WDR36 (Monemi et al. 2005), however mutations in these genes account for 
only a fraction of POAG cases. In addition to these genes, five other loci for adult-onset 
POAG have been mapped: GLCIB (Stoilova et al. 1996), GLC1C (Wirtz et al. 1997), 
GLC1D (Trifan et al. 1998), GLC I F (Wirtz et al. 1999) and GLC1I (Allingham et al. 
2005); however, only two of these loci have been replicated in published studies; 
GLC1B (Raymond et al. 1999 [abstract], Charlesworth et al. 2006) and GLC1C (Kitsos 
et al. 2001); one of these as a result of this dissertation (Charlesworth etal. 2006). 
Genome-wide scan results suggest several additional chromosomal regions may also be 
involved in POAG susceptibility (Wiggs et al. 2000; Nemesure et al. 2003; Wiggs et al. 
2004; Baird et al. 2005). 
This dissertation aimed to navigate the complexity of POAG and investigate genetic 
contributions to the disease in extended pedigrees from the Tasmanian population by 
applying different analysis methodologies to each of the two distinct datasets used in 
this investigation. The first investigation was comprised of a set of 10 extended 
pedigrees with information on disease status and genotypic data restricted to the six 
POAG loci known at the time, GLC1A-F. This dataset was analysed with exact and 
MCMC estimation based parametric and nonparametric linkage analyses, as described 
in Chapters 4 and 5. The second approach included 10 cM genome-wide scan data from 
a single extended pedigree and analyses of quantitative measures of phenotypic 
components or correlates of the POAG. For this dataset we were able to utilise 
multipoint variance components linkage analysis of both dichotomous and quantitative 
traits, as described in Chapter 6. 
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There are two common approaches to the exact linkage analysis of dichotomous traits, 
and these are based on either considering all loci simultaneously or all family members 
together. The first approach, implemented in programs such as LINKAGE, is based on 
the Elston-Stewart algorithm (Elston and Stewart 1971) and can be used with extended 
pedigrees, but with only a limited number of markers. The second, implemented in 
programs such as GeneHunter, is based on the Lander-Green algorithm (Lander and 
Green 1987) and can analyse many marker loci, but is restricted in terms of pedigree 
size. There is no exact likelihood-calculation method for linkage analysis that allows 
multipoint analysis of extended pedigrees with many markers. However, there are 
several approximation methods, such as the MCMC based estimation methods 
employed in SimWallc2, that can utilise extensive marker and genotypic data 
simultaneously. 
Given the size and complexity (the presence of marriage and inbreeding loops) of the 
pedigree dataset in Chapter 4, the available genetic data (3-5 markers per locus), the 
computational constraints (discussed in Chapter 4.6) and the available clinical data 
(dichotomous affection status based on POAG diagnosis), exact parametric analyses 
using FASTLINK were restricted to two-point analyses (unrestricted by pedigree size) 
while exact nonparametric analyses using GeneHunter were multipoint but involved 
trimming all but one of the pedigrees. In anticipation of these restraints, MCMC 
estimation based parametric and nonparametric linkage analyses (in this case using 
SimWallc2) were used as a first pass approach in the analysis of the data in Chapter 4. 
These methods were used to generate multipoint linkage results using all available 
family information. The lack of phase information from deceased relatives, especially 
spouses (see Figures 2.2-2.11), reduced our power to detect linkage, thus methods 
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employing information from all pedigree members, rather than affecteds only or 
trimmed pedigrees, were preferable. Using these MCMC based analyses as a first pass 
approach in Chapter 4 we identified two regions of interest that were followed-up in 
Chapter 5. The evidence for linkage at one of these regions (the GLC1B locus on 
chromosome 2 in family GTas15) was strengthened following fine mapping and follow-
up analysis. The empirical p-values calculated using SimWalla (p=0.01 or less) and 
exact GeneHunter p-value (p=0.005) at the distal end of the region of interest provide 
supportive evidence for the existence of a POAG susceptibility locus at 2cen-q13 
(Charlesworth et al. 2006). The success of this result supports the hypothesis that the 
MCMC estimation based parametric and nonparametric analysis conducted in Chapter 
4.5.3-4.5.4 was a suitable first pass approach to search for linkage given the available 
. pedigree and genotypic data. 
The results obtained by the initial MCMC based analyses described in Chapter 4.5.3 and 
4.5 4 and the duplicate exact analyses described in Chapter 4.5.7 and 4.5.8 are difficult 
to compare. The results of the two approaches employing nonparametric analyses were 
similar, supporting the utility of SimWalk2 for estimation based nonparametric linkage 
analysis. For example, the p-values for GTas11 and GTas121 at the GLC1C locus were 
similar in both the estimation based nonparametric linkage (NPL) analysis (0.04; 
Chapter 4.5.3) and the exact analysis (0.03; Chapter 4.5.7). The estimation based and 
exact parametric analyses are harder to compare, even though the same model 
constraints were used, because the estimation based analyses were multipoint while the 
exact were restricted to two-point. However, the results of the two approaches do not 
appear to compare favourably; for example the LOD of 1.08 at marker D3S1569 in 
family GTas121 in the estimation based analysis (Chapter 4.5.4) drops to 0.38 in the 
exact analysis (Chapter 4.5.8). While this may suggest an inherent weakness in the 
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SimWalla estimation based parametric analysis, or a failure of the two-point analysis, it 
most likely reflects the inability of parametric analyses to appropriately model complex 
diseases such as POAG. Investigations into the genetic contributions of POAG have 
traditionally employed some form of exact parametric analysis (Sheffield et al. 1993; 
Stoilova et al. 1996; Wirtz et al. 1997; Sarfarazi et al. 1998; Trifan et al. 1998; Wirtz et 
al. 1999; Wiggs et al. 2000; Nemesure et al. 2003). Parametric analysis is very 
powerful in situations where the disease model can be accurately described, including 
the heterogeneity, penetrance functions and disease gene frequency, however it may be 
less powerful in the case of complex disease where the disease model is not apparent, 
and where additional complications such as polygenic and epistatic effects may further 
confound the model. Given the apparent genetic complexity of this disease, the use of 
parametric models in POAG genetic studies may be a contributing factor to the 
difficulties of replicating the named POAG susceptibility loci, despite the fact that most 
of these loci were first reported more than six years ago. 
Many complex diseases have quantitative clinical correlates that may be directly related 
to disease risk. Parametric and nonparametric linkage analyses of complex disease have 
often involved the dichotomisation of information-rich quantitative phenotype 
components (Hams etal. 1996; Stoilova etal. 1996; Wiggs et al. 2000; Wiltshire etal. 
2001; Angius et al. 2002; Nemesure et al. 2003). The use of discretised versions of 
biologically continuous phenotypes for linkage analysis is often unnecessary and can 
result in marked reductions in power to detect and localise genes influencing these 
disease phenotypes (Duggirala et al. 1997; Wijsman and Amos 1997; Williams etal. 
1999a). When the observable phenotype is inherently continuous, methods of linkage 
analysis for quantitative traits are preferable (Duggirala et al. 1997). For common 
- diseases in particular, it may be more appropriate to examine the continuum of variation 
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than to limit analysis to a dichotomy of affected and unaffected individuals (Williams et 
al. 1999a). 
In the study by Duggirala et al. (1997), using data from the tenth Genetic Analysis 
Workshop (GAW10), a continuous phenotype was dichotomised using a liability 
threshold model and both the continuous and discrete traits analysed using variance 
components analysis in SOLAR. The dichotomisation clearly diminished the power to 
detect linkage when compared with the direct analysis of the continuous trait (Duggirala 
et al. 1997). The variance-component based method is less model-bound than 
parametric analyses and therefore more likely to avoid model misspecification 
problems. The authors of the variance components analysis program SOLAR (Almasy 
and Blangero 1998) recommend the use of quantitative over discrete traits whenever 
possible (Williams et al. 1999a). It is important to note that there are situations where 
the analysis of discrete traits may be unavoidable. For example, some phenotypes are 
classified clinically as qualitative traits (presence or absence of disorder), such as some 
psychiatric disorders, and even though there may be an underlying continuous 
phenotype or disease correlate that would be more useful for genetic analysis, such data 
may not be readily obtainable. 
Studies of POAG genetics have consistently used a dichotomous affection status 
derived from a combination of several clinical characteristics, most notably optic disc 
degeneration and characteristic visual field loss, and in some cases elevated intraocular 
pressure, by applying a threshold level to each (Sheffield et al. 1993; Stoilova etal. 
1996; Wirtz etal. 1997; Sarfarazi etal. 1998; Trifan etal. 1998; Wirtz etal. 1999; 
Wiggs etal. 2000; Nemesure etal. 2003; Allingham etal. 2005). There has been little 
standardisation of this process, which means that the definitions used for affection status 
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vary between studies (Kahn and Milton 1980; Wolfs et a/. 2000; Kroese and Burton 
2003). The high heterogeneity of the disease also suggests that the set of complex 
phenotypes that are combined into a clinical diagnosis of the disease may be controlled 
by a wide range of genetic and environmental factors. 
In light of the evidence supporting the likely superior power of quantitative traits over 
their dichotomous counterparts, we reconsidered the clinical data available from a 
typical linkage study of POAG and identified quantitative traits corresponding to 
components of the POAG phenotype. While there are many clinical measures available 
for this disease, not all are suitable traits for analysis. By selecting maximum recorded 
10P and maximum cup-to-disc ratio as quantitative traits for linkage analysis we were 
attempting to identify loci influencing these particular components of the POAG 
phenotype, in contrast to the classical approach of identifying `130AG genes' using 
clinical diagnosis as the affection status. Applying this method to an extended POAG 
pedigree should provide an enrichment of extreme values of these traits when compared 
with the general population, since the hypothesis is that variants at these loci influence 
traits involved in POAG pathogenesis or progression. The results of Chapter 6 suggest 
that this approach is appropriate, since one region of significant or suggestive linkage 
was identified for each trait. Multipoint linkage analysis of maximum recorded IOP 
(Chapter 6.5.3) identified a peak LOD of 3.3 (p=0.00015; genome-wide p=0.0165) near 
marker D 10S537 on chromosome 10q22; while analysis of maximum cup-to-disc ratio 
(Chapter 6.5.4) produced a peak LOD score of 2.3 (p=0.00056; genome-wide p=0.208) 
near markers D1S197 to D1S220 on chromosome 1p32 (Charlesworth etal. 2005). 
The quantitative trait analyses also appear to out-perform the variance components 
dichotomous trait analysis based on clinical diagnosis of POAG (equivalent to the 
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affection status used in previous studies of POAG genetics), both in terms of 
significance and clarity of the results. The analysis of the discrete trait based on typical 
clinical diagnosis revealed no significant linkage results (Chapter 6.5.2). However, we 
did identify a peak (LOD=1.7; p=0.0058) at 3p21-p22 (between markers D3S1298 and 
D3S1289), a locus also identified by Baird et al. (2005) using the same genome-wide 
scan and phenotype data as this study. The definition of our dichotomous trait was 
equivalent to the classification of affection used by Baird et al. (2005), and the results (a 
maximum two-point LOD score of 1.2 and a minimum locus specific p-value of 0.003 
with the S pairs and Smost  statistics) were similar to those obtained in our dichotomous trait 
analysis. Our 3p linkage result may have been more interesting than we initially 
thought, in view of the fact that Baird et al. identified this locus using the same dataset 
but a completely different analytical approach (MCMC based nonparametric linkage 
analysis as opposed to variance-components dichotomous trait linkage analysis). 
However, if multiple testing for linkage to POAG using the same dataset is taken into 
account, the significance of this finding is further reduced. 
Most traditional statistical genetic methods for the analysis of complex phenotypes are 
not designed to exploit the wealth of linkage information available in extended 
pedigrees. The results of the GAW10 revealed linkage methods using all available 
pedigree information were superior to nuclear pedigree approaches (Wijsman and Amos 
1997). The extended pedigrees were consistently more informative than their nuclear 
counterparts in terms of power and accuracy for linkage detection and parameter 
estimation. However, a surprise result, derived from a variety of contributions, was that 
more information could be extracted from 23 extended pedigrees analysed with a single, 
closely linked polymorphic marker than from multipoint analysis of 239 nuclear 
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pedigrees with as many as 25 equivalent, closely linked markers (Wijsman and Amos 
1997). 
The computational burden for exact multipoint (IBD) calculations is light in nuclear 
families but may be prohibitive in extended pedigrees (Almasy and Blangero 1998). 
Approximate IBD calculations for extended pedigrees can be performed by a range of 
statistical packages, including the MCMC based programs SimWalla (Sobel and Lange 
1996) and Loki (Heath 1997; Heath et al. 1997). SimWallc2 was utilised for the IBD 
calculations of the extended pedigree datasets in Chapters 4 and 5, due in part to the 
ease of use of this program in combination with the utility MEGA2 (Mukhopadhyay et 
al. 2005b), making it easy to perform parametric, nonparametric and haplotyping 
analyses on this data. Loki was used to calculate IBDs for Family GTas02 in Chapter 6 
from within SOLAR version 2.1. SimWallc2 could also have been used to generate the 
IBD probabilities for use with SOLAR, however Loki was selected due to reports of 
greater reliability of its mixing algorithm (Dr Thomas Dyer 2003, personal 
communication). 
POAG appears to be highly genetically heterogeneous. Three genes involved in POAG 
have been identified (Stone etal. 1997; Rezaie et al. 2002; Monemi et al. 2005), along 
with several named loci (Stoilova etal. 1996; Wirtz etal. 1997; Sarfarazi et al. 1998; 
Trifan et al. 1998; Wirtz etal. 1999; Allingham et al. 2005). Various other 
chromosomal regions have also been suggested (Wiggs et al. 2000; Nemesure et al. 
2003; Baird etal. 2005). As a result of this genetic heterogeneity, we did not expect to 
see multiple pedigrees from the GIST dataset analysed in Chapter 4 linked to the same 
chromosomal region. The ascertainment of the entire pedigree dataset from the same 
- source population, and from a population with demonstrated founder effects (Shepherd 
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1985; Pridmore 1990; Mackey and Howell 1992; Teh etal. 1995; Baird etal. 2003) was 
anticipated to reduce the genetic heterogeneity to some degree. Families GTas03 and 
GTas11 showed some evidence of linkage to the same region of chromosome 3 
(D3S3637 to D3S3694; Chapter 4.5.3), and although no common haplotype or shared 
alleles could be detected in this investigation, these results would be a worthy avenue 
for follow-up analyses in future projects of the GIST. 
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Conclusions 
This dissertation explored several different approaches to the analysis of extended 
POAG pedigrees in an attempt to dissect the genetic aetiology of this phenotypically 
and genetically heterogeneous disease. The study included two distinct datasets, both 
derived from the Glaucoma Inheritance Study in Tasmania. Different analysis 
methodologies were applied to each datasets, determined by the available data. 
In Chapter 4 we investigated linkage to markers within the regions of the known POAG 
loci GLC1A, GLC1B, GLC1C, GLC1D, GLC1E and GLC1F, in a set of 10 extended 
Tasmanian pedigrees. MCMC estimation based parametric and nonparametric analyses 
revealed two regions of possible interest. Family GTas15 produced p-values of 0.05- 
0.07 for three markers within the GLC1B region on chromosome 2 (D2S2264 to 
D2S1892) in the nonparametric analysis described in Chapter 4.5.3 and a maximum 
location score of 1.12 on chromosome 2 corresponding to marker D2S1892 in the 
parametric analysis described in Chapter 4.5.4. Similarly, family GTas35 produced p-
values of 0.05-0.06 for three markers within the GLC1E region on chromosome 10 
(D 1 0S1691 to D 1 0S1664) in the nonparametric analysis described in Chapter 4.5.3 and 
a peak location score of 1.43 at marker Dl 0S1664 in the parametric analysis in Chapter 
4.5.4. Fine-mapping and follow-up analysis of these two regions, described in Chapter 
5, revealed that the initial linkage signal in family GTas35 was most likely a false 
positive. However, fine-mapping and follow-up analysis of the GLC1B locus in family 
GTas15, as described in Chapter 5, strengthened the evidence for linkage. The 
empirical p-values calculated using SimWalk2 (p=0.01 or less) and exact GeneHunter 
p-value (p=0.005) at the distal end of the region of interest provided supportive 
evidence for the existence of a POAG susceptibility locus at 2cen-q13 (Charlesworth et 
al. 2006). 
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In Chapter 6 we utilised multipoint variance components linkage analysis of both 
dichotomous and quantitative traits using data from an extended POAG pedigree 
including comprehensive clinical information and genotyping data from a 10 cM 
genome-wide scan. In this investigation two individual phenotype components of 
POAG, maximum recorded IOP and maximum vertical cup-to-disc ratio, were analysed 
as quantitative traits using variance components analysis based on the hypothesis that 
these traits may have more simple genetic architectures than an overall diagnosis of 
POAG. Multipoint linkage analysis of maximum recorded 10P identified a peak LOD 
of 3.3 (locus-specific p=0.00015; genome-wide p=0.0165) near marker D10S537 on 
chromosome 10q22; while analysis of maximum cup-to-disc ratio produced a peak 
LOD score of 2.3 (locus-specific p=0.00056; genome-wide p=0.208) near markers 
D1S197 to D1S220 on chromosome 1p32 (Charlesworth et al. 2005). In comparison, 
however, the analysis of the dichotomous trait based on clinical diagnosis of POAG was 
underpowered and revealed no significant linkage information. The bivariate analysis 
of the quantitative traits and analyses involving the inclusion of myocilin mutation 
status as a covariate suffered similar deficits in power. 
The results of this dissertation suggest that the inclusion of quantitative correlates or 
components of disease in the genetic analysis of POAG may offer significant power to 
elucidate the genetic basis of glaucoma in the face of limited family and population 
datasets. The discovery of genes at the loci identified as contributing to the variance of 
maximum IOP and maximum cup-to-disc ratio in this study may provide significant 
insights into glaucoma pathophysiology as a whole. As an avenue for future 
investigation we would recommend that the loci identified in Chapter 6 of this 
dissertation be followed-up in the dataset of 10 extended POAG families used in 
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Chapter 4. In combination with the ascertainment correction model created as part of 
this dissertation, and given that these pedigrees come from the same source population 
as family GTas02, this dataset may provide significant power for the confirmation of the 
KW and cup-to-disc ratio loci. 
We would also recommend genotyping the 10 extended Tasmanian POAG pedigrees 
with either microsatellite markers at a density of at least 10 cM across the entire genome 
or at least a 10k SNP chip. The combination of the clinical information available from 
the GIST and comprehensive genome-wide scan data, these 10 POAG pedigrees would 
form a powerful dataset for the investigation of POAG phenotype components using the 
methods described in Chapter 6. 
Another avenue for additional investigation would be to include CCT as a covariate in 
the analysis of maximum IOP in family GTas02. CCT is a confounder of IOP 
measurement, with thick corneas causing artefactual ocular hypertension through 
measurement error; hence inclusion of CCT as a covariate may benefit the reanalysis of 
IOP as a quantitative trait by providing trait data that that more accurately models the 
biological variation. 
Another approach for follow-up investigations would be to analyse CCT as a 
quantitative trait in its own right, given suitable population data to provide the 
ascertainment correction. CCT is highly heritable (Toh et a/. 2005) and has been shown 
to influence the conversion from ocular hypertension to glaucoma (Brandt etal. 2001). 
As an important factor in glaucoma diagnosis and management, determining the genetic 
contributions to this trait would be of great interest to the wider study of POAG 
pathogenesis. 
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This dissertation has contributed to the genetic dissection of POAG through the 
confirmation of one genetic susceptibility locus (Charlesworth et al. 2006) and the 
identification of one significant and one suggestive quantitative trait locus for 
components or correlates of POAG (Charlesworth et al. 2005). This investigation has 
also prepared and refined a dataset of 10 extended POAG pedigrees from the Tasmania 
population that will provide considerable power for future investigations of the genetics 
of this complex disease. These pedigrees have so far been used for only minimal 
exploratory linkage analyses and, when combined with genome-wide coverage of a 
dense marker set, will be a powerful resource for future genetic analyses of POAG. 
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Appendix 1 - Clinical methodology and definition of POAG in the 
Glaucoma Inheritance Study in Tasmania 
Al.! Clinical Diagnosis of POAG 
Clinical examination and diagnosis of patients involved in the GIST is well documented 
(Coote et al. 1996). In brief, POAG was defined as an optic neuropathy which has 
present at least two of the following features: (1) optic nerve head excavation with 
thinning of the neuroretinal rim (generally measured by an enlarged vertical cup-to-disc 
ratio>0.7), often but not necessarily including significant focal or generalised loss of 
retinal nerve fibre layer, notching, pitting, or `Drance' type nerve fibre layer 
haemorrhages; (2) elevation of the IOP over a population-based normal range, or over 
the average of the unaffected individuals within a pedigree (generally IOP>21mmHg or 
2 standard deviations from the population mean); and (3) reproducible visual field 
defects consistent with the disc changes and with common descriptions of glaucomatous 
field loss (Coote et al. 1996). Glaucoma cases secondary to rubeosis, trauma or anterior 
segment dysgenesis were excluded. 
A1.2 Intraocular pressure measurement 
IOP measurements were taken using Goldman applanation tonometry and not 
standardised for the time of day. No corrections were made for corneal thickness since 
this information was not routinely collected at the time of patient ascertainment. 
Elevated IOP was generally defined as measured IOP greater than or equal to 22mmHg 
(two standard deviations above the mean) in either eye at the time of examination or as 
reported by a reliable third party prior to treatment. Pressure greater than 28mmHg (or 
four standard deviations from the mean) at the time of examination, or reported by a 
reliable third party such as a treating clinician, was considered 'extreme'. 
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A1.3 Optic disc analysis 
Optic disc appearance was independently classified by two clinicians at the time of 
examination using a slit-lamp biomicroscope with a 78D lens for binocular stereovision 
after pupil dilation. In addition, optic disc stereo photographs (Nidek, Japan) were 
taken for future reference in all cases. Where a discrepancy existed between the 2 
examiners, the stereo disc photos were independently assessed by a third glaucoma 
specialist. Attention was paid to similarity between eyes, particularly in relation to cup-
disc ratio disparity. A category called 'appearance precludes satisfactory assessment' 
(APSA) was used in situations where the appearance of the optic nerve was unable to be 
accurately assessed due to media opacity, or was subject to a condition making 
exclusion of glaucoma impossible. Discs were considered 'normal' if the appearance of 
both optics discs was normal or consistent with normal variation but not consistent with 
glaucoma. Optic nerve heads could be classified 'abnormal and consistent with 
glaucoma' based on observed features such as: a focal notch in the neuroretinal rim but 
not extending to the margin, a vertical cup-to-disc ratio of 0.7 or greater, or a 0.2 
difference in cup-to-disc ratios between two eyes. The appearance of optic discs highly 
consistent with glaucoma include: an acquired pit in the optic nerve, a notch in the 
neuroretinal rim extending to the margin or a vertical cup-to-disc ratio of 0.8 or greater. 
A1.4 Visual field analysis 
Visual field analysis was performed on a Humphrey perimeter using a 24-2 array, a size 
III target and the full-threshold test system. Both eyes were tested, with a short break 
between tests. Visual fields were categorised on a scale of A-D. Category A indicates 
normal field, where all points lie within the age corrected normal values on the pattern 
_deviation plot. Category B indicates a reliable field test with minor depression at one or 
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two points not consistent with glaucoma on the pattern deviation plot. Category C 
indicates a reliable test, significant and consistent with glaucoma, where there were 
'three or more adjacent or clustered points within a hemifield or within the nasal field 
with a significantly reduced threshold and a pattern deviation plot consistent with 
glaucoma' (Coote et al. 1996). Category D indicates the visual field was markedly 
degraded and highly consistent with glaucoma. Normal visual fields were consistent 
with categories A and B, whereas visual fields allocated to categories C and D were 
considered glaucomatous. In the case of unreliable performance based on fixation 
losses, or false positive or false negative rates exceeding 20%, visual fields were 
repeated on another occasion until reliable fields were obtained enabling definite 
classification. 
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Appendix 2 - Microsatellite marker primer information 
This appendix includes the primer sequence, pool number, fluorescent label and 
optimised PCR condition information for primers used in Chapter 4 (Table A2.1 and 
Table A2.2) and Chapter 5 (Table A2.3). 
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Primer Primer Sequence Heterogeneity Allele size (min) Allele size (max) Label Pool Temp °C Mg
2+ 
D I S2635-F TAGCAGATCCCCCGTC 0.87 142 160 FAM 2 58 1.5 
D1S2635-R TGAATCCTACCCCTAAGTAGAAT 
DIS2707-F CCCCITGGCATAGGGITCAAGA 0.82 137 159 FAM 1 58 1.5 
Dl S2707-R AGCCAGGCATCTGCACCTTC 
Dl S2675-F AGAGGCTGTTCTGAGGTACTGC 0.73 160 174 FAM 3 58 1.0 
D1S2675-R CATGATTGGCTCAAGTCCC 
D2S216I-F TGTTCACCCCTCAGGC 0.77 176 204 FAM 1 58 1.5 
D2S2161-R ATTACTCCTATTGTCCCTGTCTGC 
D2S I 13-F GCTTGITTCATCICACCCTG 0.77 206 230 FAM 3 58 1.5 
D2 S 1 13-R CTG1TG IT! rriAGGTGGGAG 
D2S2264-F CATCTCAAAGGGCATGTC 0.77 241 257 FAM 2 58 1.5 
D2S2264-R TCGAATGAACAGTGCCTC 
D2S 1897-F AGGAA1TTGCTGATACTCAACC 0.89 215 237 HEX 3 58 1.5 
D2 S1897-R AGGCATTGATATAAGGCMTCT 
D2 S I 892-F TCCTAACTCTGAAATGCTAAAGACA 0.80 211 251 HEX 2 58 1.5 
D2S1892-R AGCTCTGGCAGGGAGA 
D3 S3637-F TGGGAAGCCAGTCAGTCAAT 0.90 178 206 FAM 2 58 1.5 
D3 S3637-R TGGCCTGCACATAAAAGGAT 
D3S1301-F CATAAATATCACAGGGCCAA 0.77 187 197 HEX 2 58 1.5 
D3S1301-R TTCTTATCCGTTCTGCCA 
D3 S3694-F AGTGTCCATCAACATGGG 0.84 138 162 HEX 1 58 1.5 
D3 S3694-R TCGCACAAATAACAGGATTC 
D3S 1 569-F GCACCTTGGCTTACCITCTA 0.80 277 297 HEX 3 58 1.5 
D3 S1569-R GGACAGTTGAAAGGTTCTTAAAG 
D3S1608-F AGCAATCATGTGCCCC 0.61 184 206 HEX 4 55 1.0 
D3S1608-R CCCAATGGTAAGTGCAGG 
Table A2.1 — Details of the primers used in the initial investigation of the known POAG loci (Chapter 4) — Table 1 of 2 
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Primer Primer Sequence Heterogeneity Allele size (min) 
Allele size 
(max) Label Pool Temp °C Mg
2+ 
D8S1749-F ACACTTGTGTGCAAGCA 0.74 128 140 HEX 4 55 1.5 
D8S 1749-R AGCAATTTGGGCCTGT 
D8S556-F CTGGTGACTTCCTGCCATATAC 0.80 161 175 HEX 3 58 1.5 
D8S556-R CITGCTGTGAGGTAAGACGA 
D 8S 198-F AACCAGATTAGGGACAAAGA 0.83 155 173 HEX 2 58 1.5 
D 8S 198-R TAGGGACTACACATGATGGA 
DIOS1729-F AAGGACTGCATTG 111110 0.72 177 183 HEX 1 58 1.5 
D 1051729-R TCAGACACTMAGGATTACCIC 
Dl 0 S1713-F GACAGCAACTAACCTCCTGTAAG 0.60 245 255 FAM 4 55 1.5 
Dl OS1713 -R TGTGTTATTCAAGGGTCAGC 
DI OS 1691-F TCCITGCACGAAGGTAATGITCAG 0.67 247 277 HEX 4 55 1.5 
D10 S1691-R TGCCTGCTGAGAAACAGTGATG 
Dl OS 547-F CTFGAAAGGCGGAGGC 0.74 236 250 HEX 1 58 1.5 
D 1 0 S547-R CCCAATAGTCCACAGGGAG 
D10 51664-F AACCGTAATAACTTAGGTGCTC 0.75 164 198 FAM 4 55 1.5 
DlOS1664-R TGCTGAAGACAGGTAAAGAG 
D7 S2511-F CAGAGCAATACCATCAAAAC 0.79 243 265 F AM 3 58 1.0 
D7S251I-R GTACCATAAACTGGGTGGC 
D7S505-F ACTGGCCTGGCAGAGTCT 0.69 262 278 FAM 1 58 1.0 
D7S505-R CAGCCATTCGAGAGGTGT 
D7S2439-F CAGCAAAAGGTACAGCAATTTC 0.80 195 211 HEX 1 58 1.5 
D7S2439-R AAAGTCTACGCCGCATTC 
D7S2546-F GGAGGTTGAACAACTCTGAATAC 0.75 234 242 FAM 1 58 1.5 
D7S2546-R CACGCCAGGGTCTATC7T 
Table A2.2 — Details of the primers used in the initial investigation of the known POAG loci (Chapter 4) — Table 2 of 2 
220 
Primer Primer Sequence Heterogeneity Allele size (min) 
Allele size 
(max) Label Pool Temp °C Mg2+ 
D2 S2187-F GCTCCAAACCAGCCTC 0.63 149 159 TET 1 55 1.5 
D2 S2187-R GAAGCCTCACAATGCAAC 
D2S2364-F CTCCATGTACCAATTCAGGC 0.66 87 99 F AM 1 55 1.5 
D2S2364-R CCAGGCAGGATGTGTGAGTA 
D2S373-F ACAGACTTGGCCTGCC 0.74 218 238 FAM 1 55 1.5 
D2 S373-R TTGATGATAATGGTGATAGGAAT 
D2 S2269-F AGCCAAACCAAGTCAATGTC 0.88 252 280 FAM 1 55 1.5 
D2S2269-R TGAAAGCATGACACCAATC 
D2S1890-F TITCAGATCACCTAATGGGC 0.74 183 220 TET 1 55 1.5 	' 
D2S 1 890-R AACIUTCTGGICGGTCATTG 
D2 SI893-F AACAAGGTGAGGCFCTGTC 0.75 244 264 TEl 1 55 1.5 
D2S1893-R TCTAAAAATGAAGCAGGATACCA 
D 1 0S189-F CAAAAGTAACCATTGAGCCC 0.73 180 188 TEl 2 55 1.5 
DIOS189-R TTGATAGAAGAAGCGATAGATCG 
D I OS 1 649-F 0.84 120 150 TET 2 58 1.5 GCTCTTGAAGCATAC1 T1GG 
DIO S 1649-R CTTCTGCCCACTAAACAAAT 
DIOS I 653-F CCITTGGATAAAGCCTCCT 0.78 210 213 FAM 2 58 1.5 
D I 0 S1653-R TATCATTGTCTCATCCGGG 
Dl 0S585-F TG1TTCCAAAGATAAAGCCC 0.69 233 249 FAM 2 55 1.5 
DlOS585-R GTGATAATCCAGATGGTTTCCT 
D10 S570-F GCATTCATCCAACAAGCATA 0.81 287 305 FAM 2 55 1.5 
D10 S570-R AATTAGITCCATGGGCACAG 
D10S223-F AATTCTGAAGAGGCAAATCTAA 0.66 221 231 TET 2 58 1.5 
Dio S223 -R AGGAAAATATACACAACCCAAG 
D 1 0S1779-F TCTGTCTTCAGCACACCC 0.82 265 281 TET 2 55 1.5 
DlOS1779-R GCATATCTGTCCCACTCGATAC 
Table A2.3 - Details of the primers used in the follow-up investigation of GLC1B and GLC1E (Chapter 5) 
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Appendix 3 - Publication of material from Chapter 5 
The following article was published in Ophthalmologica. 
Charlesworth JC, Stankovich JM, Mackey DA, Craig JE, Haybittel M, Westmore RN 
and Sale MiM (2006). Confirmation of the adult-onset primary open angle glaucoma 
locus GLC I B at 2cen-q13 in an Australian family. Ophthalmologica 220(I): 23-30. 
- 
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Abstract 
Primary open-angle glaucoma (POAG) is genetically het-
erogeneous, with 6 named POAG loci GLC1A-F mapped 
and genes myocilin (MY0C)and optineurin (OPTN) iden-
tified at 2 of the loci. Using penetrance-model-free meth-
ods, we screened the POAG loci GLC1A-F in an extended 
Australian pedigree, using 3-5 markers within each lo-
cus. p values of less than 0.05 were obtained empirically 
using SimWalk2 and exactly using Genehunter for 2 
markers within the GLC1B region on chromosome 2. 
Fine mapping of this region produced p values of 0.01 or 
less at 5 markers flanked by D2S1897 and D2S2269. The 
9 cM haplotype of interest overlaps the original GLC1B 
region. These results provide supportive evidence for 
the GLC1B locus on chromosome 2cen-q13 and verify 
the existence of POAG susceptibility gene in this region, 
increasing the likelihood of gene identification. 
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Introduction 
Glaucoma is a term used to describe a heterogeneous 
group of eye disorders involving damage to the optic 
nerve and loss of vision, resulting in irreversible blindness 
if left untreated. Glaucoma is a major cause of visual im-
pairment and blindness in developed countries and is the 
second leading cause of blindness worldwide [1]. The 
most common form of glaucoma is adult-onset primary 
open-angle glaucoma (POAG). 
POAG has a strong genetic component, with family 
history of the disease being an acknowledged risk factor 
[2-4]. Relatives of POAG patients have been shown to 
have a ten-fold increase in risk of the disease [3], while 
studies on the underreporting of family history suggest 
the genetic component of POAG may be even greater 
than previously suggested [5]. 
There is no universally accepted definition of this phe-
notypically complex and subtle disease [6, 7]. The clinical 
diagnosis is based on a combination of several main char-
acteristics, including specific changes to the appearance 
of the optic nerve head, characteristic visual field loss 
with a slow and progression, and in many cases increased 
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intraocular pressure (I0P). The complexity of the pheno-
typic definition of POAG has contributed to the difficul-
ties in identifying genes involved in this disease. Other 
issues that have hindered mapping of POAG genes in-
clude the late age of onset in most cases, unclear mode of 
inheritance and penetrance in many families, the insidi-
ous progression that results in approximately half of cas-
es remaining undiagnosed, and the potential for intra-
pedigree genetic heterogeneity. 
Two genes for adult-onset POAG have been identified 
[8, 9]; however, mutations in these genes account for only 
a fraction of familial POAG. The first gene, myocilin 
(MYOC) at the GLC1A locus on chromosome 1q24.3, 
has been shown to account for approximately 3% of adult-
onset POAG [9-12]. The second gene, optineurin (OPTN) 
at the GLC1E locus on chromosome 10p15-14, was iden-
tified in a low-tension subset of POAG and shown by 
Rezaie et al. [8] to be involved in up to 17% of normal-
tension glaucoma pedigrees. Mutations in OPTN were 
recently shown to account for up to 1.6-14% of sporadic 
POAG including high-tension glaucoma, in Chinese sub-
jects [13]. However, recent studies involving Caucasian, 
African American and Japanese POAG patients and con-
trols have shown little to no association between the 4 
previously identified OPTNsequence variants and POAG 
[14, 15]. 
POAG is clearly genetically heterogeneous. In addi-
tion to the 2 genes described above, 4 other loci for POAG 
have been mapped: GLC1B [16], GLC1C [17], GLC1D 
[18] and GLC1F [19]; however, the genes at these loci 
remain to be identified. Although all 4 of these loci were 
originally mapped between 1996 and 1998, only one 
(GLC1C) has been replicated in a published study [20]. 
The results of 2 recent genome-wide scans suggest sev-
eral additional chromosomal regions may also be in-
volved in POAG susceptibility [21, 22]. 
Using model-free analysis methods, we screened all 6 
named POAG loci, including those containing the MYOC 
and OPTN genes, and found evidence for linkage to only 
the GLC1B locus. This result represents confirmation of 
the GLC1B locus. 
Eye and Ear Hospital, the Royal Hobart Hospital, and the Univer-
sity of Tasmania, and this study was conducted in accordance with 
the tenets of the Declaration of Helsinki. Written informed consent 
was obtained from all participants. 
Through the collaborative involvement of Tasmanian ophthal-
mologists, the GIST aims to identify all diagnosed glaucoma pa-
tients in Tasmania. The study represents almost complete popula-
tion ascertainment based on population prevalence predictions de-
rived from the Blue Mountains Eye Study [24]. The study identified 
adult-onset POAG families by first recruiting all diagnosed glau-
coma patients and then using genealogical data provided by par-
ticipants to determine familial relationships between patients. 
Once apparent pedigrees were identified, each pedigree was ex-
panded and all family members over 40 years of age invited to 
participate in the study. 
The focus of this paper is the GIST family GTas15 which con-
tains 32 individuals across 4 generations (fig. 1), of whom 15 living 
descendants consented to participate in the study. 
Definition of Glaucoma Status 
Clinical examination and diagnosis of patients involved in the 
GIST is documented elsewhere [25]. In brief, POAG was defined 
as an optic neuropathy which has present at least 2 of the following 
features: (1) optic nerve head excavation with thinning of the neu-
roretinal rim, often with `Drance' type nerve fiber layer hemor-
rhages, notching, pitting, significant focal loss or general loss of 
retinal fiber layer, (2) elevation of the IOP over a population-based 
normal or over the average of the unaffected individuals within a 
pedigree, and (3) visual field defects consistent with the disc 
changes and with common descriptions of glaucomatous field loss 
[25]. Glaucoma cases secondary to trauma or anterior segment dys-
genesis are excluded [25]. 
Family GTas15 contained seven individuals with clinically di-
agnosed POAG; individuals 15-01, 15-02, 15-03, 15-07, 15-11, 15- 
12 and 15-16. One individual (15-04) presented with characteristic 
visual field loss and could have been considered glaucoma suspect. 
However, for our model-free, affected-only approach it was not 
necessary to determine whether the remaining family members 
were glaucoma suspects or truly unaffected; this can be difficult 
given the late onset and subtleties of POAG. All other individuals 
were therefore classed as glaucoma status 'unknown' for the pur-
poses of the linkage analyses. Clinical features of GTas15 are indi-
cated in figure 1. 
Genotyping 
Whole blood was collected in 10-ml EDTA tubes from consent-
ing individuals. DNA was extracted using Nucleon BACC3 kits 
(Amersham Pharmacia Biotech). 
Microsatellite markers were selected from the Genome Data-
base (http://www.gdb.org/) based on location and heterozygosity. 
Genetic maps used for marker selection and linkage analyses were 
primarily based on the deCODE genetic map, with missing marker 
locations and distances estimated from the Marshfield genetic map, 
the Location DataBase [26, 27] integrated map, and the human 
genome sequence (Build 34). In the initial targeted screening of the 
known POAG loci, family GTas15 was genotyped with a total of 
25 microsatellite markers from GLC1A, B, C, D, E and F, at an 
average marker spacing of 4 cM in each region. The microsatellite 
markers used as well as their genetic distance in centimorgans rela-
tive to the deCODE framework map are shown in table 1. 
Methods 
The Glaucoma Inheritance Study in Tasmania 
This investigation was conducted as part of the Glaucoma In-
heritance Study in Tasmania [23] (GIST), a large population study 
of glaucoma genetics based in the island state of Tasmania, Austra-
lia. Ethics approval was obtained from the Human Research Ethics 
Committees of the Royal Children's Hospital, the Royal Victorian 
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affected for the linkage analysis while individuals with only one 
filled quadrant are glaucoma suspects and classified as unknown for 
linkage analyses. The haplotype of interest is marked by a vertical 
black bar. An unknown haplotype is denoted by an 'x'. Forward 
and backslashes between the haplotypes denote the direction of 
recombination. Although confirmed monozygotic twins 15-01 and 
15-02 are shown in the figure, individual 15-01 was removed for all 
linkage analyses. 
Fig. 1. GTasI5 pedigree structure, clinical features and haplotypes 
at GLC1B. ID numbers commencing with '15-' indicate individu-
als who participated in the study. Filled quadrants indicate the 
clinical characteristics of POAG [25]. A filled upper right quadrant 
indicates the presence of raised intra-ocular pressure; the bottom 
right quadrant indicates characteristic visual field loss. The left top 
and bottom quadrants indicate optic disc abnormalities character-
istic of POAG and are filled from bottom (mild) to top (severe). 
Individuals with 2 or more filled quadrants have been classified as 
PCR was carried out in a total volume of 10 I.L1 and contained 
10 mMTris-HCI, 50 mill KC1, 1.5 milf Mg2÷, 0.2 mill dNTP (Pro-
mega), 0.8 KM of each primer and 0.005 U/ILI Taq DNA Poly-
merase (Qiagen). Reactions underwent 25-35 cycles of 94°C for 
30s, 55°C for 30s and 72°C for 30s, followed by a final extension 
at 72°C for 15 mm. 
The forward PCR primer for each microsatellite marker was 
labeled at the 5' end with either 6-FAM, TET, or HEX (Sigma-Al-
drich). Fragments labeled with 6-FAM or TET underwent 25 am-
plification cycles, while those with HEX underwent 35 cycles. Sam-
ples were elect rophoresed using an ABI PRISM 310 Genetic Ana-
lyzer (Applied Biosystems) with POP4 polymer (Applied 
Biosystems). Data were analyzed with the Genescan version 3.7 
and Genotyper version 3.7 (Applied Biosystems). 
Linkage Analyses 
Genotyping errors were detected using Pedcheck [28] to iden-
tify Mendelian inconsistencies and SimWalk2 [29] to determine 
unlikely double recombinants [30]. Two of the affected individuals 
(15-01 and 15-02) were monozygotic twins, confirmed by genotyp-
ing at all 31 microsatellite markers. Individual 15-01 was therefore 
removed from the pedigree prior to all linkage analyses. 
Marker allele frequencies were derived from 100 chromosomes 
from elderly glaucoma-free individuals. SimWalk2 version 2.86b 
[29] was used to calculate empirical p values for the NPL-all statis-
tic [31], incorporating information from all pedigree members. 
Model-free linkage analysis was conducted using Genehunter [32] 
with a trimmed, 20-bit version of the pedigree that included all af-
fected individuals. A disease gene frequency of 0.0001 was used for 
all analyses. 
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Table 1. SimWalk2 empirical p values for the NPL-all statistics for Table 2. SimWalk2 empirical and GeneHunter exact p values for 
microsatellite markers used to evaluate linkage to known POAG the NPL-all statistics at the microsatellite markers used to evaluate 
loci GLCIA-F linkage to GLC I B 
The most likely haplotypes for the entire pedigree, including 
information from individuals classed as POAG status unknown, 
were estimated in SimWalk2 using a simulated annealing algo-
rithm. These haplotypes were displayed using Pedigree/Draw 5.1 
(Southwest Foundation for Biomedical Research http://www.pedi-
gree-draw.com/) . Running the algorithm 4 times with different se-
quences of random numbers produced identical haplotypes each 
time. For affected individuals, these haplotypes agreed with the 
most likely set of haplotypes derived using the exact calculations of 
Genehunter. 
Marker Distance from 
first marker, cM 
SimWalk2 empi- 
real p value for 
NPL-all 
GeneHunter 
exact p value 
for NPL-all 
D2S2161* 0.00 0.34 0.35 
D2SI 13* 3.00 0.06 0.06 
D2S2187 4.68 0.06 0.06 
D2S2264* 7.32 0.04 0.05 
D2S373 7.82 0.03 0.05 
D2S2364 9.97 0.02 0.03 
D2S1897* 10.97 0.009 0.005 
D2S1890 13.68 0.01 0.01 
D2S1893 14.68 0.01 0.01 
D2S1892* 16.57 0.01 0.01 
D2S2269 17.63 0.01 0.03 
* Markers used in the original screen of the POAG loci. Remain-
ing markers were added at the fine-mapping stage. 
04) presented with characteristic visual field loss. Raised 
LOP was not present in 3 of the 7 affected individuals, 
and 2 of the affected individuals (15-01 and 15-16) had 
equivocal optic disc appearances in the presence of vi-
sual field loss. The monozygotic twins 15-01 and 15-02 
differed clinically in the appearance of their optic discs; 
however, as they were genetically identical and both clas-
sified as 'affected', 15-0 I was not included in the genetic 
analyses. The mean age of diagnosis within the family was 
55 years, ranging from 47 to 60 years. Several individuals 
had their POAG diagnosed as a direct result of the fam-
ily study. 
Linkage Analyses of Known POAG Loci 
Empirical p values for the NPL-all statistic [31] using 
complete pedigree information are shown in table 1. A 
threshold of 0.05 was used to indicate interesting results 
for follow-up with fine mapping. As 2 markers at GLC1B, 
D2S2264 and D2S1897, produced p values less than 0.05 
(table 1), this locus was targeted for fine-mapping. There 
was no evidence of linkage of POAG to loci GLC1A, 
GLC1C, GLC I D, GLC1E, and GLC I F in pedigree 
GTas15 (p values between 0.20 and 0.80). 
Linkage Analyses of GLCIB 
An additional 6 microsatellite markers at approxi-
mately 1 cM spacing were selected from within the 
GLC1B region. The SimWalk2 p values at 5 markers, 
flanked by D2S1897 and D2S2269, were 0.01 or less (ta- 
POAG locus and 
approximate chro-
mosomal location 
Marker Distance from 
first marker, cM 
SimWalla, 
p value for 
NPL-all 
GLC1A 
1q21-3I 
D1S2635 
D I S2707 
D1S2675 
0.0 
1.8 
4.8 
0.20 
0.20 
0.26 
GLC IB D2S2161 0.0 0.34 
2cen-q13 D2S113 3.0 0.06 
D2S2264 7.3 0.04 
D2S1897 11.0 0.03 
D2S1892 16.6 0.08 
GLC IC D3S3637 0.0 0.42 
3q21-24 D3S1301 2.0 0.53 
D3S3694 4.0 0.58 
D3S1569 5.8 0.58 
D3S1608 8.0 0.59 
GLC ID D8S1749 0.0 0.50 
8q23 D8S556 6.0 0.52 
D8S198 15.0 0.51 
GLC1E DIOSI729 0.0 0.33 
10p15-14 DIOS1713 4.0 0.38 
DIOSI691 8.0 0.52 
D I 0S547 12.4 0.34 
DIOS1664 20.3 0.58 
GLC IF D7S25 1 1 0.0 0.80 
7q35-36 D7S505 4.0 0.71 
D7S2439 6.0 0.66 
D7S2546 14.0 0.42 
Results 
Clinical Features 
The clinical features of family GTas15 are indicated 
in figure 1. The POAG within family GTas15 appears to 
be transmitted in an autosomal dominant fashion. All af-
fected members of GTas15 and 1 glaucoma suspect (15- 
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Fig. 2. A comparison of the marker map 
and critical region of the original and cur-
rent investigations of the GLC1B locus. The 
ideogram shows the approximate cytoge-
netic location of the GLC I B locus. The 
marker map to the left of the expanded re-
gion indicates the marker location and hap-
lotype of interest from the original study by 
Stoilova et al. [16] in 1996. The marker map 
and region of interest from the current 
study is shown to the right. Numbers in ital-
ics indicate centimorgan distances between 
adjacent markers. 
15-14) while recombination events in another (15-08) 
have removed several alleles in the middle of the shared 
haplotype. Of these currently unaffected individuals, 15- 
08 and 15-10 were 43 and 45 years of age, respectively, 
at examination, well below the mean age of diagnosis 
within the family; however, 15-14 was aged 69, carries 
the full haplotype and showed no sign of glaucoma at the 
time of examination, indicating likely nonpenetrance at 
this stage. Individual 15-04 also carries the full haplotype 
and although this individual's optic disc ratios were with-
in normal limits, their clinical classification at age 79 
years was as a glaucoma suspect based on visual field 
changes. 
ble 2), indicating confirmation of linkage in this region. 
The lowest empirical p value produced by SimWalk2 was 
0.009 at marker D2S1897. GeneHunter produced an ex-
act p value of 0.005 at D2S1897, with p values of 0.01 at 
3 additional markers: D2S1890, D2S1893 and D2S1892 
(also shown in table 2). 
Haplotype Analysis 
Haplotype reconstruction using SimWalk2, shown in 
figure 2, revealed a shared haplotype of 8 markers (flanked 
by D2S2264 and D2S2269) in 6 of the 7 affected indi-
viduals (including the monozygotic twins), present in 
both arms of the pedigree. Two of the currently unaf-
fected individuals carry the entire haplotype (15-10 and 
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tribution. Four of the seven affected individuals had IOP 
measures over 22 mm Hg; however only I of these had 
peak LOP over 28 mm Hg. The remaining 3 affected in-
dividuals could be considered to have normal-tension 
glaucoma. These results suggest the susceptibility locus at 
GLC1B may be involved in POAG pathogenesis through 
pathways that do not involve IOP in all cases. 
The analyses of the unaffected meioses in the 6 fami-
lies originally linked to GLC1B revealed an example of 
incomplete penetrance: a healthy 86-year-old with no ev-
idence of glaucoma who had inherited the entire affected 
haplotype [16]. We similarly saw evidence for nonpene-
trance in at least 1 unaffected individual (15-14) aged 69 
and carrying the entire haplotype of interest with no clin-
ical sign of glaucoma. We also found evidence of a puta-
tive phenocopy, with I affected individual (15-12) who 
did not share the haplotype of interest. 
A candidate gene of interest located within the haplo-
type overlap is four-and-a-half lims domain 2 (FHL2: 
MIM# 602633), expressed in a wide range of tissues 
including optic nerve and eye anterior segment. The 
6-member interleulcin-1 receptor cluster [34] is also lo-
cated within the haplotype overlap and includes the in-
terleukin-1 receptors type land II (IL1R1:MIM# 147810 
and IL IR2: MIM# 147811) and also interleulcin-1 recep-
tor-like 1 (ILIRLI: MIM# 601203) expressed in the eye 
anterior segment. It has been suggested that the immune 
system, and in particular interleulcin-1, is involved in 
POAG pathogenesis [35, 36]. The interleulcin-1 gene clus-
ter [37] (including IL-1B) lies approximately 0.5 cM be-
yond the distal end of the GLC1B haplotype identified in 
this study. A polymorphism within IL-1B has recently 
been associated with sporadic POAG in the Chinese pop-
ulation [38], although investigation of this polymorphism 
showed no segregation with the POAG phenotype in ped-
igree GTas15 (data not shown). It is also interesting to 
note that mer tyrosine kinase protooncogene (MERTK: 
MIM# 604705), a gene associated with retinitis pigmen-
tosa [39] (a disease that also results in visual field loss) is 
located near marker D2S2269 at the distal end of the hap-
lotype of interest. 
The 6 smaller pedigrees originally linked to GLC1B 
[16] when combined with our replication study in an ex-
tended POAG pedigree provides support that the 2cen-
q13 region contains a POAG susceptibility gene, and in-
creases the likelihood of gene identification. Previous ex-
perience with positionally cloned POAG genes MYOC 
and OPTN suggests that once identified, this POAG sus-
ceptibility gene at GLC I B may also contribute to a sig-
nificant proportion of sporadic POAG cases. 
Discussion 
We have investigated all known POAG loci in an ex-
tended Australian pedigree using a model-free approach 
and found evidence for linkage to GLC1B. The empirical 
p values calculated using SimWalk2 (p = 0.01 or less) and 
exact Genehunter p value (p = 0.005) at the GLC1B locus 
provide supportive evidence for the existence of a POAG 
susceptibility locus at 2cen-q13. 
The POAG susceptibility locus GLC1B was originally 
identified in 1996 by Stoilova et al. [16] using 6 Caucasian 
families, predominantly from the United Kingdom, with 
3-7 affected individuals per family. Utilizing a penetrance 
model based approach, the maximum 2-point lod score 
was 6.48 at marker D2S113 (13 = 0). The lod score calcula-
tions were repeated for the affected meioses only, to elim-
inate the effect of potential incomplete penetrance, which 
shifted the peak lod distally to marker D2S373 (lod of 
3.40 at 0 = 0). Both these markers were used in our study; 
however the region of linkage in family GTas15 is located 
2.8 cM distally, with the most significant evidence for link-
age at marker D2S1897 (p = 0.005). An American Society 
of Human Genetics conference abstract of Raymond et al. 
[33] (1999) using a large French-Canadian family identi-
fied a peak lod of 2.97 at marker D2S388 (located between 
D2S2161 and D2S113), within the proximal portion of the 
GLC1B region; however, no other information relating to 
the location of their haplotype of interest was provided. 
Fine-mapping and haplotype analysis by Stoilova et 
al. [16] refined their smallest region of cosegregat ion to 
11.2 cM flanked by D2S2161 and D2S176; however, more 
recent genetic maps suggest a smaller distance of approxi-
mately 9.5 cM. A comparison of the maps and critical re-
gions from Stoilova et al. [16] and our study is shown in 
figure 2. The 8-marker shared haplotype from our study 
(flanked by D2S2264 and D2S2269) overlaps the lower 
portion of the original GLC1B region of interest and is of 
similar size (9.0 cM). The 8-marker haplotype commences 
within the critical region of Stoilova et al. [16] at marker 
D2S2264; however, the marker with the lowest p values in 
our study (D2SI897) lies outside the overlapping region. 
The smaller 2-marker haplotype (D2S373 and D2S2364) 
lies almost entirely within the 2.2 cM overlapping region. 
Key clinical features of the 6 families originally linked 
to GLC1B by Stoilova et al. [16] were mean age of diag-
nosis of 47 years and slightly elevated IOP, although half 
of the affected individuals had lOP within the normal 
range (<22 mm Hg). Family GTas15, used in the current 
study, had similar clinical features, with a slightly higher 
average age of diagnosis (55 years) and similar IOP dis- 
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PURPOSE. The purpose of this study was to identify genetic 
contributions to primary open-angle glaucoma (POAG) 
through investigations of two quantitative components of the 
POAG phenotype. 
METuous. Genome-wide multipoint variance- components link-
age analyses of maximum recorded intraocular pressure (LOP) 
and maximum vertical cup-to-disc ratio were conducted on 
data from a single, large Australian POAG pedigree that has 
been found to segregate the myocilin Q368X mutation in some 
individuals. 
Resurrs. Multipoint linkage analysis of maximum recorded 
TOP produced a peak LOD score of 3.3 (P = 0.00015) near 
marker D10S53 7 on 10q22, whereas the maximum cup-to-
disc ratio produced a peak LOD score of 2.3 (P = 0.00056) 
near markers D1S197 to DIS220 on 1p32. Inclusion of the 
myocilin Q368X mutation as a covariate provided evidence 
of an interaction between this mutation and the [OP and 
cup-to-disc ratio loci. 
CONCLUSIONS. Significant linkage has been identified for maxi-
mum [OP and suggestive linkage for vertical cup-to-disc ratio. 
Identification of genes contributing to the variance of these 
traits will enhance understanding of the pathophysiology of 
POAG as a whole. (Invest Opbtbalmol Vis Sci. 2005;46: 
3723-3729) D01:10.1167/iovs.05-0312 
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G laucoma is a major cause of visual impairment and the second leading cause of blindness worldwide.' The 
most common form is adult-onset primary open-angle glau-
coma (POAG), which has a strong genetic component, with 
family history of the disease an acknowledged risk factor. 2-4 
A 10-fold increase in risk of POAG has been documented in 
first-degree relatives of affected individuals, 3 whereas under-
reporting of family history suggests that the genetic compo-
nent of POAG may be even greater than is generally ac-
knowledged. 5 
The clinical diagnosis of glaucoma is based on a combina-
tion of several main features, including specific changes to the 
appearance of the optic nerve head constituting glaucomatous 
optic neuropathy, characteristic visual field loss with a slow 
and often asymptomatic progression, and, in most cases, in-
creased intraocular pressure (LOP). The complexity of the 
phenotypic definition of POAG6'7 has contributed to the diffi-
culties in identifying genes involved in this disease. 
Two genes have been identified for adult-onset POAG"; 
however, mutations in these genes account for only a fraction 
of POAG cases. Myocilin (MYOC) on 1q24.3 has been shown to 
account for approximately 3% of adult-onset POAG.9-12 Op-
tineurin (OPTN) on 10p15-p14 was shown by Rezaie et al. 8 to 
be involved in up to 17% of low-tension glaucoma pedigrees, 
although a recent study indicated a low prevalence of OPTN 
mutations (<0.1%) in unselected cases of both POAG and 
NTG. 13 The WD40-repeat 36 gene (WDR36) was recently iden-
tified at the GLC1G locus on 5q22.1, 14 although the impact of 
this gene on the wider POAG population is yet to be deter-
mined. In addition to these three genes, four other loci for 
POAG have been mapped: GLC1B, 15 GLCIC, GLCID," and 
GLC/F. 18 The results of three genome-wide scans suggest that 
several additional chromosomal regions may also be involved 
in susceptibility to POAG 19-21 ; however, only GLC/B22 and 
GLC/C23 have been replicated in published studies. 
Given the limited success so far in identifying genes 
conferring susceptibility to glaucoma, one approach that 
may have greater success is quantitative trait linkage analysis 
of precursors of glaucoma, such as raised 10P and increased 
cupping of the optic nerve. Such traits may have simpler 
genetic architecture than diagnosis of glaucoma, making it 
easier to map causative loci. 24-26 Furthermore, quantitative 
trait linkage analysis is inherently more powerful than di-
chotomous trait linkage analysis 27.28 and is particularly pow-
erful in large families. 29.30 
The heritabilities of LOP and vertical cup-to-disc ratio were 
estimated to be 0.36 and 0.48, respectively, in the Beaver Dam 
Eye Study, providing evidence for genetic determinants for 
these components. 31 Commingling analysis of 10P and glau-
coma by Viswanathan et al. 32 suggested the existence of a 
major gene accounting for 18% of the variance of 10P in the 
Blue Mountains Eye Study population.' Duggal et al.33 re-
cently conducted a complex segregation and linkage analysis 
3723 
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TABIE 1. Age and Trait Data Distribution Statistics from the MV1P Dataset and Family GTas02 
Fitted 
MVIP 
	
Family GTas02 	Coefficients 
Trait 	
• 	
Mean 
	
SD 	n 	Mean 	SD 
	PAg. 	f3Sex 
Age (y) 3892 59.4 11.6 139 33.1 14.4 
Maximum cup-to-disc ratio 2986 0.43 0.21 135 0.47 0.20 0.0016 -0.032 
Maximum IOP (mm Hg) 3221 15.2 3.32 137 17.9 4.15 0.0033 -0.21 
of LOP, identifying two potential regions of linkage on chro-
mosomes 6 and 13. 
The purpose of the present investigation was to identify 
regions of linkage that contribute to maximum LOP and maxi-
mum cup-to-disc ratio, using measures from an extended Aus-
tralian pedigree. This family already has been analyzed for 
linkage to glaucoma. 34 The discovery of genes contributing to 
the variance of maximum LOP and maximum cup-to-disc ratio 
is expected to provide significant insights into the pathophys-
iology of glaucoma. 
METHODS 
The Glaucoma Inheritance Study in Tasmania 
This investigation was conducted as part of the Glaucoma Inheritance 
Study in Tasmania 35 (GIST), a large population study of glaucoma-
affected families in Tasmania, Australia. Ethics approval was obtained 
from the Human Research Ethics Committees of the Royal Children's 
Hospital, the Royal Victorian Eye and Ear Hospital, the Royal Hobart 
Hospital, and the University of Tasmania, and the study was conducted 
in accordance with the tenets of the Declaration of Helsinki. Written 
informed consent was obtained from all participants. 
GTas02, the family of interest in this investigation, is one of the 
largest pedigrees identified as part of the GIST. It consists of more than 
1350 members, and ancestry can be traced back to a founder couple 
six generations ago. The "core" pedigree containing the POAG cases 
consists of 246 individuals when deceased linking members are in-
cluded. One hundred thirty-nine family members consented to clinical 
examination and blood collection for genotyping and mutation analy-
sis. The structure, clinical diagnosis, and MYOC mutation status of this 
family have been published. 36 
Clinical Examination 
Clinical examination and diagnosis of patients involved in the GIST are 
documented elsewhere. 37 In brief, POAG was clinically defined as an 
optic neuropathy that had at least two of the following features: (1) 
optic nerve head excavation with thinning of the neuroretinal rim, 
often with Drance-type nerve fiber layer hemorrhages, notching, pit-
ting, significant focal loss or general loss of the retinal nerve fiber layer 
(generally measured by an enlarged vertical cup-to-disc ratio 0.7); (2) 
elevated 10P above a population-based normal range or above the 
average of the unaffected individuals within a pedigree (generally IOP 
>21 mm Hg or two standard deviations from the population mean); 
and (3) visual field defects consistent with the disc changes and with 
common descriptions of glaucomatous field loss. 37 Glaucoma cases 
secondary to trauma or anterior segment dysgenesis were excluded. Of 
the 139 individuals available for examination, 24 had a diagnosis of 
POAG. The details of the clinical diagnoses for this family have been 
extensively reported. 36 
10P was measured with a calibrated Goldmann applanation tonom-
eter. Multiple 10P measures were available for each individual; hence, 
maximum 10P was selected, to reduce any bias introduced by using 
postmedication pressure values. No corrections were made for corneal 
thickness, because this information was not routinely collected at the 
time of patient ascertainment. Optic disc appearance was classified by  
two clinicians at the time of examination, with a slit lainp biomicro-
scope after pupil dilation. In addition, optic disc stereo photographs 
(Nidek, Gamagori, Japan) were obtained for future reference in all 
cases. When there was a discrepancy between the two examiners, the 
stereo disc photographs were independently assessed by a glaucoma 
specialist. The highest vertical cup-to-disc ratio in either eye at any 
clinical examination was used as the trait measure. 
Quantitative measures collected as part of the clinical examination 
of patients with POAG and their relatives included maximum recorded 
intraocular pressure (10P) without medication and maximum vertical 
cup-to-disc ratio from the highest-scoring eye. 36 
Myocilin mutation detection in this family has been reported. 36 •38 
Of the 139 individuals from GTas02 screened for mutations in the 
MYOC gene, 19 were known to carry the Q368X mutation. 
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FIGURE 1. Genome-wide multipoint variance components linkage re-
sults for maximum recorded LOP. 
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FIGURE 2. Multipoint variance-compo-
nents linkage results for maximum 
recorded LOP for chromosome 10 
(solid line) and linkage signal after 
the inclusion of Q368X status as a 
covariate (dashed line). Covariates 
are indicated on the plots. The loca-
lion of the optineurin (OPTN)gene is 
indicated. 
Genotyping 
A 10-cM genome-wide scan was conducted with 401 microsatellite 
markers from fluorescence marker sets (vers. 1 and 2; Applied Biosys-
tents, Inc. [ABM Foster City, CA), run on sequencers (model 377; ABI) 
and analyzed (GeneScan and GenoTyper software; ABI). 34 Inconsisten-
cies in Mendelian inheritance of genotypes were detected with Ped-
check.39 Marker allele frequencies were estimated from 72 elderly 
glaucoma-free control individuals drawn from the same population. 4° 
Multipoint identity by descent (BD) files were created with the 
Markov chain Monte Carlo (MCMC)- based program Loki (ver. 
2.4.7)41 .42 from within SOLAR (Sequential Oligogenic Linkage Analysis 
Routines, ver. 2.1.1; http//:www.sfbr.org/ provided in the public do-
main by the Southwest Foundation for Biomedical Research, San An-
tonio, Tx).25 
Ascertainment Correction 
The population ascertainment correction data set was taken from the 
Melbourne Visual Impairment Project (MVIP) and included 3905 indi-
viduals from the general population with data on age, sex, maximum 
recorded 10P, and maximum cup-to-disc ratio. 43 The MAU clinical data 
were collected by the same methods as were used in the GIST. A 
comparison between the MV1P and family GTas02 data is shown in 
Table 1. Mean age and trait variables in family GTas02 and the ascer-
tainment correction sample were compared by two-tailed t-tests. The 
ascertainment correction dataset was not intended to be age matched; 
however, comparison of age and trait between the two groups re-
vealed the relative position of family GTas02 within the distribution of 
the general population. 
The ascertainment correction was conducted with SOLAR (ver. 
2.1.1)25 and the population-based ascertainment correction dataset. 
The mean effects for each trait were estimated from this dataset, 
including the regression coefficients gAw and (3s,_ which were used to 
adjust the trait mean for the effect of the covariates age and sex. The 
resultant mean, SD, /3,w, and (3 obtained from the population-based 
dataset were-then used in-the model to analyze the pedigree data. By 
constraining these mean effects and the total variance to that of the  
general population, trait values for individuals in family GTas02 were 
given the appropriate weight. 
Variance Components Analysis 
Heritability for each trait was estimated with genetic variance compo-
nent modeling as implemented in SOLAR (ver. 2.1.1).25 The covariates 
were selected among age, sex, age-sex interaction; however, age-sex 
interaction was not significant in any dataset and was thus removed. 
Variance component linkage analysis was performed to detect and 
localize quantitative trait loci (QTLs) influencing variation in maximum 
10P and maximum cup-to-disc ratio, by using SOLAR. 25 
The variance-component linkage method is based on specifying the 
expected genetic covariances between arbitrary relatives as a function 
of IBD relationships at a given marker locus. 25 The method involves 
partitioning the total trait phenotypic variance (02 ) into components 
attributable to covariate effects, effects of a specific Q"I'L (QTL (cr2q), 
and residual additive genetic effects (u2h2,). The test for linkage com-
pares the likelihood of this model with the likelihood of a null model 
(no linkage), where the QTL effect size cr, 42 is fixed to be zero. The 
difference between the two log ic, likelihoods produces a LOD score 
that can be interpreted in a fashion similar to that of the classic LOD 
scores of parametric linkage analysis. 44 The variance component quan-
titative genetic approach enables penetrance model-free multipoint 
linkage analysis of complex quantitative traits in pedigrees of arbitrary 
size and complexity25' 28.45-47 and has been used successfully to local-
ize QTLs that influence many important disease-related traits, including 
risk of alcoholism, 47 serum leptin levels, 48.49 and resting heart rate." 
Expected LOD scores and empiric locus-specific probabilities were 
determined with the "lodadj" command of SOLAR. 44'5° A total of 
100,000 replicates were simulated to build up the distribution of LOD 
scores expected under the null hypothesis of no linkage, using a fully 
informative, unlinked marker. The observed LOD scores were then 
regressed on those expected for a multivariate normal trait, with the 
inverse slope of the regression line providing the LOD correction 
constant. Final WD scores were multiplied by the correction constant 
only if the constant was <1. 
3726 Charlesworth et aL 
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FIGURE 3. Genome-wide multipoint variance components linkage re-
sults for maximum vertical cup-to-disc ratio. 
To test the impact of the lIfY0C Q368X mutation on the linkage 
results, Q368X status was included as a covariate in a second round of 
analyses for each trait. The regression coefficient for Q368X mutation 
status (Emy0,), used in the analysis of each trait, was estimated from 
the family GTas02 trait and mutation data and not from the population 
ascertainment correction dataset. As in previous analyses, age and sex 
were included in all models, and adjusted LOD scores and empiric 
probabilities were calculated as described earlier. The fitted coefficient 
for MYOC mutation status Omyoc) in the analysis of 10P was 5.065, 
whereas 8,,,,,y0c for the analysis of maximum cup-to-disc ratio was 
0.192. 
To control for the overall false-positive rate in our linkage screens, 
we converted the nominal probabilities associated with our peak LOD 
scores to genome-wide probabilities, using an approach developed by 
Feingold et al. 5 ' This method takes into account the mean recombina-
tion rate in our study population and the marker density of the linkage 
map used in our genome scan. 
RESULTS 
Maximum recorded !OP had a heritability of 0.55 for family 
GTas02. The covariates sex and age were statistically con-
trolled for and included in the analysis, although in the ascer-
tainment correction population, neither showed effects that 
were substantial (P = 0.073 for sex, P = 0.53 for age), and 
accounted for only 0.1% of the variance. The mean value for 
maximum recorded TOP in family GTas02 (17.9 ± 4.2 man Hg 
[SD]) was significantly higher (P < 0.0001) than the mean IOP 
in the general population (15.2 ± 3.3 mm Hg). The empiric 
LOD correction constant was greater than 1; hence, no adjust-
ment was applied to the linkage results. The highest LOD score 
for TOP in family GTas02 was 3.3 (locus-specific P = 0.00015) 
near marker DI0S537 (Fig. 1), with the LOD-1 interval span-
ning approximately 20 cM on 10q22 (Fig. 2). The genome-wide 
probability for this result was 0.0165. 
Maximum cup-to-disc ratio had a heritability of 0.39 for 
family GTas02. The effect of the covariates sex (P = 3.1 x 
10-5) and age (P = 1.6 X 10 -6) were highly significant in the 
ascertainment correction population, accounting for 1.4% of 
the variance; hence, both were statistically controlled for and 
included in the analysis of family GTas02. The mean ± SD 
cup-to-disc ratio in family GTas02 (0.47 ± 0.20) was not sig-
nificantly different (P> 0.05) from the mean cup-to-disc ratio 
in the general population (0.43 ± 0.21). The empiric LOD 
correction constant was greater than 1; hence, no adjustment 
was applied. The highest LOD score for maximum cup-to-disc 
ratio in family GTas02 was 2.3 (locus-specific P = 0.00,056) 
near markers D1S197 and D1S220 (Fig. 3), with the LOD-1 
interval spanning approximately 20 cM on 1p32 (Fig. 4). The 
genome-wide probability for this LOD score was determined to 
be 0.208. 
The MYOCQ368X mutation was present in 9(37.5%) of 24 
individuals in family GTas02 with diagnosed POAG and in 10 
individuals without a diagnosis of POAG at examination. 
Whereas the mean age of individuals with the Q368X mutation 
in family GTas02 was not significantly different from those 
without the mutation, mean maximum LOP and mean maxi-
mum cup-to-disc ratio were significantly higher in Q368X mu-
tation carriers, regardless of POAG affection status (Fable 2). 
MYOC Q368X mutation status (flmycw) accounted for 16% of 
the genetic variance of the maximum IOP (heritability reduced 
from 0.55 to 0.46) and 49% of the genetic variance of the 
maximum cup-to-disc ratio (heritability reduced from 0.39 to 
0.20). Addition of MYOC Q368X mutation status as a covariate 
in the analysis of the quantitative traits resulted in the peak 
LOD score for maximum recorded LOP (near marker D10S537 
on 10q22) decreasing from 3.3 to 1.9 (Fig. 2), and the peak 
LOD score for maximum cup-to-disc ratio (near markers 
D1S197 and D1S220 on 1p32) was reduced from 2.3 to 0.9 
(Fig. 4). 
DISCUSSION 
In this study, we investigated two individual disease compo-
nents of POAG-maximum recorded lOP and maximum verti-
cal cup-to-disc ratio-as quantitative traits using variance com-
ponents linkage analysis. Genome scan analyses of these traits 
in an extended pedigree revealed one region of significant or 
suggestive linkage for each trait. Multipoint linkage analysis of 
maximum recorded 10P identified a peak LOD of 3.3 (locus-
specific P = 0.00015) near marker D10S537 on 10q22, 
whereas analysis of the maximum cup-to-disc ratio produced a 
peak LOD score of 2.3 (locus-specific P = 0.00056) near 
markers D1S197 to D1S220 on 1p32. 
The putative trait locus for maximum recorded 1013 pro-
duced a significant peak LOD of 3.3 on 10q22. The genome-
wide significance level of this result (P = 0.0165) strongly 
suggests that this region contains a gene that contributes to the 
variance of LOP. We did not see any overlap with the LOP 
linkage regions identified by Duggal et al.33 Although our 
region of interest for 10P on 10q22 has not been reported 
previously for 10P, linkage to this region has also been found 
for systemic hypertension in a Japanese population. 52 The 
association between systemic blood-pressure (systolic or dia-
stolic) and LOP has been well documented. 53-55 It is possible 
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FIGURE 4. Multipoint variance com-
ponents linkage results for maximum 
vertical cup-to-disc ratio for chromo-
some 1 (solid line), and linkage sig-
nal after the inclusion of Q368X sta-
tus as a covariate (dashed line). 
Covariates are indicated on the plots. 
The location of the myocilin (MYOC) 
gene is indicated. 
that systemic hypertension and LOP share a common QTL in 
this region on the long arm of chromosome 10. The region 
contains BMPRIA (MIM: 601299), a bone morphogenic pro-
tein receptor—interesting because Bmp4 has been implicated 
in increased 10P in inice. 36 The peak region also contains RGR 
(MIM: 600342), an opsin-related gene associated with retinitis 
pigmentosa." The °YIN gene is located outside our 10p13 
linkage peak, approximately 60 cM upstream. 
Applanation tonometry measurements of IOP are known to 
be influenced by central corneal thickness (CC1). 38•39 CCT has 
a positive and apparently linear correlation with 10P6° and is 
strongly genetically determined (Toh TY, et al. /OVS 2005;46: 
ARVO E-Abstract 1093). There has been a report of thick 
corneas segregating in a family with apparent ocular hyperten-
sion,61 which leads to the suggestion that perhaps the variation 
in LOP in family GTas02 compared with the population is due 
to CCT. However, there are many individuals in family GTas02 
with moderate to advanced visual field loss, which would 
support the elevated IOP's being genuine rather than artifac-
tual in nature. It is possible that measurement of ccr and 
subsequent adjustment of Goldmann applanation IOP readings 
for GTas02 may have the effect of strengthening the linkage at 
the 10P locus on 10q22 by providing a more accurate approx-
imation of true LOP (as opposed to measured 10P). This ap-
proach is worthy of future investigation. 
This study identified a putative trait locus for maximum 
cup-to-disc ratio on 1p32—the first reported locus for this 
trait—with a peak LOD score of 2.3. This corresponds to 
suggestive linkage, because there is a 20% chance of a LOD 
score of this size or greater occurring by chance in a genome-
wide scan. The region covered by the linkage peak includes 
the gene POMGnT1 (MIM: 606822), mutant forms of which are 
responsible for muscle-eye-brain disease (MEB; MIM: 253280), 
a congenital muscular dystrophy- based disorder with many 
additional features, including early-onset glaucoma, optic nerve 
atrophy, severe congenital myopia and retinal hypoplasia. MEB 
is inherited as a loss of function of POMGnTI.62 The peak 
region also contains FOXE3 (MLM: 601094), known to be 
associated with anterior segment ocular dysgenesis 63 and is 
approximately 25 cM distal to the primary congenital glaucoma 
locus GLC3B (MIM: 600975), on 1p36. 64 
The MYOC Q368X mutation is the most common mutation 
identified in patients with POAG to date, found to account for 
approximately 1.6% of POAG. I ` In comparison to other MYOC 
mutations associated with the juvenile-onset form of POAG 
(JOAG), this mutation generally gives rise to a milder pheno-
type with late age of onset and increased 10P.63 Myocilin 
mutation status and related phenotype modification effects 
within family GTas02 have been reported. 36 '38 The MYOC 
locus was not apparent in either of the linkage analyses for the 
TABIE 2. Comparison between Myocilin Q368X Mutation Carriers and Mutation-Free Individuals from 
Family GTas02 
Q368X Mutation 
Carriers 
 
Q368X Mutation Free 
   
Trait 	 Mean 	SD 	n 	Mean 	SD 
Maximum 10P 19 22.21 5.32 118 17.17 3.48 7.70 X 10-8 
Maximum cup-to-disc ratio 19 0.64 0.23 116 0.44 0.18 2.26 X 10 -4 
• Obtained by age-adjusted measured genotype analysis accounting for nonindependence among 
relatives. 
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two quantitative traits investigated in this study. Because only 
9 of the 19 Q368X mutation carriers in this family were clini-
cally diagnosed with POAG, this mutation is unable to account 
for the presence of all cases of POAG in the entire family. 38 
Despite the absence of a linkage signal at MYOC, the Q368X 
mutation appeared to account for nearly half the genetic vari-
ance for the quantitative trait based on maximum cup-to-disc 
ratio, and nearly 20% of the genetic variance for maximum LOP. 
The differences between carrier and non- carrier-trait values 
(shown in Table 2) were significant, which may indicate ep-
istasis or some other form of interaction between MYOC and 
the putative trait loci for 10P and cup-to-disc ratio. The reduc-
tion in peak LOD scores for both traits after the inclusion of the 
Q368X mutation as a covariate provides further evidence for 
the presence of an interaction. However, the sample size of 
family GTas02 does not provide sufficient power to determine 
the exact mechanism behind this interaction. Subsequent iden-
tification of the genes at these loci is anticipated to aid inves-
tigation into the nature of this interaction. 
Baird et al." recently identified linkage of clinical POAG 
diagnosis to 3p21-p22 in this family, using MCMC-based linkage 
analysis. We did not find any evidence of overlap with this 
region using the traits maximum IOP and cup-to-disc ratio. 
There are likely to be many genes contributing to the complex 
POAG phenotype, and different analytical approaches will 
have variable power to detect certain loci. It is also possible 
that the gene at the 3p locus may contribute to a different 
POAG trait, such as progression from elevated 10P to optic 
nerve damage and subsequent clinical signs of visual field loss. 
Although we are unaware of any systemic biases in pedigree or 
family member ascertainment, genotyping methodology, or 
trait measurements, if any such biases exist they would impact 
both linkage studies and any subsequent analyses of this data-
set. Finally, as with any genome scan, one must also be mindful 
that some of these linkage results could represent chance 
events. 
The loci identified in this study are believed to contribute to 
the variance of LOP and cup-to-disc ratio in the general popu-
lation. However, since more extreme values are present in a 
POAG pedigree, when combined with population-based ascer-
tainment correction, the approach used in this investigation is 
expected to provide greater power to map genes for these 
traits. Maximum LOP and maximum vertical cup-to-disc ratio 
may not be ideal measures, given the influence of pressure 
spikes and diurnal variation on 10P, for example, however 
other traits such as mean 10P are likely to be equally problem-
atic considering the probable inclusion of postmedication lev-
els. In addition, any measurement error in LOP and cup-to-disc 
ratio would also be present in the population data used for 
ascertainment correction. 
In this investigation, we were able to identify regions of 
linkage contributing to maximum recorded LOP and maximum 
cup-to-disc ratio, quantitative clinical contributors to POAG 
diagnosis that are collected as a routine part of clinical prac-
tice. The discovery of the genes involved in these components 
of POAG at these loci is anticipated to provide significant 
insights into glaucoma pathophysiology as a whole. 
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Appendix 5 - Complete list of individuals genotyped in family GTas02 
Individual ID Individual ID Individual ID Individual ID Individual ID 
1 35 66 99 , 634 
2 36 67 100 636 
3 37 68 101 637 
4 38 69 102 638 
6 39 70 103 640 
7 40 71 104 641 
8 41 72 105 642 
9 42 76 106 647 
10 44 77 107 648 
14 46 78 108 649 
15 47 79 109 650 
16 48 80 110 654 
17 49 81 111 655 
18 50 82 112 657 
19 51 83 113 659 
20 52 84 114 660 
21 53 85 115 670 
23 54 86 116 671 
, 	24 55 87 117 672 
25 56 88 271 673 
26 57 89 273 675 
27 58 90 416 676 
28 59 91 457 2081 
29 60 92 463 
30 61 93 464 
31 62 95 629 
32 63 96 631 
33 64 97 632 
34 65 98 633 
Table A5.1 - A complete list of the individuals genotyped in family GTas02 
Numbers listed are individual ID numbers. Data from these individuals, including the 
10 cM genome-wide scan, clinical information and mutation analysis, were used in 
Chapter 6. 
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